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Andrographolide (Andro) is one of the major active components in Andrographis 
paniculata, a traditional herbal medicine which has been widely used in treatment of 
various disorders including respiratory infection, bacterial dysentery, diarrhea, and 
fever. Andro, a bicyclic diterpenoid lactone, has been shown to possess potent anti-
inflammatory effect, which is executed by inhibiting NF-κB pathway and regulating 
expression of various cytokines. Recently, Andro was proposed to be able to induce 
apoptosis in cancer cells, suggesting the anticancer potential of this compound. 
However, the molecular mechanisms are largely unknown. Therefore, in order to 
systematically investigate the anticancer properties of Andro, the following 
investigations have been conducted in this study: (i) identification of the molecular 
mechanisms involved in Andro-induced apoptosis; (ii) evaluation of the anti-tumor 
potential of Andro by investigating its sensitization ability on TRAIL-induced 
apoptosis; (iii) investigation of the combined effect of Andro with an established 
cancer theratpeutic agent doxorubicin in cancer cells. 
First, I found that Andro could induce caspase-dependent apoptosis in various 
human cancer cells. To elucidate the mechanisms of Andro-induced apoptosis, a series 
of experiments were conducted to demonstrate the critical role of pro-apoptotic Bcl-2 
proteins (Bid and Bax) in relaying the cell death signaling initiated by Andro from 
caspase-8 to mitochondria, leading to the release of cytochrome c and activation of 
caspase cascade, and eventually resulting in apoptotic cell death in cancer cells.  
Next I investigated the anticancer potential by evaluating the synergistic effect of 
Andro on TRAIL-induced apoptosis. Andro significantly sensitized various cancer 
cells in response to TRAIL-mediated apoptosis. Such sensitization was achieved 
 x
through the up-regulation of DR4. Furthermore, p53 protein which was stabilized and 
activated by ROS-mediated JNK phosphorylation, was found to be responsible for the 
DR4 up-regulation and Andro-sensitized apoptosis in cancer cells.  
In addition to the sensitization effect of Andro and TRAIL, I also investigated the 
synergistic effect of Andro on the anticancer activities of doxorubicin, a potent 
chemotherapeutic agent that has been widely used in cancer therapy. Our data 
demonstrated that the sensitization effect was due to Andro-mediated inhibition on 
STAT3 activity. As a result, Andro caused the suppression of STAT3-mediated 
transcription of anti-apoptotic genes (Bcl-2 and Mcl-1), which contributed to the 
enhanced sensitivity of cancer cells in response to doxorubicin.  
In conclusion, the present study provides a new insight of the anticancer property 
of Andro. Andro could be used alone as an anticancer agent through inducing 
apoptosis in various cancer cells. More importantly, this study provides convincing 
evidence showing that Andro is capable of sensitizing cancer cells to TRAIL and 
doxorubicin-induced apoptosis. Such findings support the potential application of 
Andro as a potent apoptosis inducer and chemo-sensitizer in cancer therapy. 
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1.1 Andrographolide (Andro)  
1.1.1 Andrographis paniculata and Andro 
Andrographis paniculata (Chuan Xin Lian in Chinese) is a traditional medicinal 
herb which grows widely in many regions of Asia, including China, Thailand, India 
and Sri Lanka. This herb is also known as “king of bitters” due to its bitterness, and is 
prescribed for the treatment of numerous ailments and diseases, including bacterial 
dysentery, diarrhea, and fever (Iruretagoyena et al., 2005; Poolsup et al., 2004). Its 
fresh and dried leaves as well as the juice of the whole plant are used in various Asian 
traditional medicines, often in herbal combinations (Bright et al., 2001; Thamlikitkul 
et al., 1991).  
Extensive research in the last few decades had revealed that the plant extract of 
Andrographis paniculata contains diterpenes, flavonoids and stigmasterols (Dai et al., 
2006). The predominant and well-studied active component of Andrographis 
paniculata is found to be diterpenoid lactone, such as andrographolide (Andro), 14-
deoxyandrographolide, 14-deoxy-11,12-dide-hydro-andrographolide, and neo- 
andrographolide (Matsuda et al., 1994). Importantly, Andro and its derivatives are 
considered to be the main bioactive compounds with immunostimulant (Puri et al., 
1993), antipyretic, anti-inflammatory (Iruretagoyena et al., 2005) and anti-diarrhea 
properties in Andrographis paniculata (Singha et al., 2003).  
1.1.2 Chemical structure and metabolism of Andro 
The major bioactive constituent extracted from the aerial parts of Andrographis 
paniculata is Andro, a bicyclic diterpenoid lactone that constitutes 1% of the herb’s 
dry weight. Andro contains an α-alkylidene γ-butyrolactone moiety, two olefin bonds 
Δ 8(17) and Δ 12(13), and three hydroxyls at C-3, C-19 and C-14 which are responsible 





Fig. 1.1 Andrographis paniculata and chemical structure of Andro 
 
The pharmacokinetics and oral bioavailability of Andro have been recently 
investigated in rats and human (Panossian et al., 2000). Pharmacokinetics of Andro in 
human was found to fit into an open two-compartment model. After oral 
administration of Andro tablets named as Kan Jang (equal to 20 mg Andro) to humans, 
393 ng/ml (1.12 μM) equivalents of Andro reached the maximum plasma values after 
1.5 - 2 h. Terminal half life and mean residence times in blood was about 6.6 and 10.0 
h, respectively. It was also found that after multiple doses (1 mg Andro /kg body 
weight /day) the calculated steady state plasma concentration of Andro could reach to 
600 ng/ml (1.90 μM) while maximum plasma concentration to 1342 ng/ml (3.8 μM). 
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In rats, 55% Andro was bound to plasma proteins (Cui et al., 2004; He et al., 2003). 
The identification of Andro metabolites is important in reflecting the in vivo metabolic 
fate and disposition of Andro in human. Most absorbed Andro was found to be 
intensively metabolized in vivo, mainly as sulfonic acid adducts and sulfate 
compounds. These formations may increase the polarity of the mother compound and 
in turn help its excretion in urine and feces. In addition, glucuronide conjugates of 
Andro could also be detected in human urine (Cui et al., 2005).  
1.1.3 Pharmacological properties of Andro 
As the main component of Andrographis paniculata, Andro is responsible for 
most bioactive properties of the herbal plant. Accumulating data have shown that 
Andro is potent in multiple pharmacological effects, including anti-inflammatory, 
anti-microbial (Amaryan et al., 2003; Caceres et al., 1999; Gabrielian et al., 2002), 
hepatoprotective (Choudhury et al., 1987; Handa and Sharma, 1990b; Visen et al., 
1993), anti-platelet aggregation (Amroyan et al., 1999; Thisoda et al., 2006) and anti-
human immunodeficiency virus (HIV) effects (Calabrese et al., 2000; Chang et al., 
1991; Reddy et al., 2005). In this section, these major pharmacological effects of 
Andro will be discussed in detail.  
1.1.3.1 Inhibitory effects on inflammation  
Inflammation is an important biological process contributing to pathological 
responses to infection and wound healing. A complicated network of immuno-factors 
involved in inflammatory response has been evolved (Coussens and Werb, 2002). 
Anti-inflammatory activity is one of the most prominent bioactivities of Andro. 
The mother plant Andrographis paniculata has been traditionally used for the 
treatment of fever and common cold for thousands of year in herbal medicine. 
Recently, the prevention and treatment of common cold and acute upper respiratory 
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tract infections, have been extensively studied by three randomized double blind 
clinical trials in Chile (Amaryan et al., 2003; Caceres et al., 1999; Gabrielian et al., 
2002). All these reports indicated that Andrographis paniculata extract or drugs 
containing Andro were effective in the treatment of acute upper respiratory tract 
infections and the improvement of the common cold symptoms, such as headache and 
nasal and throat symptoms, and in the improvement of the inflammatory symptoms of 
sinusitis. It is worth noting that no adverse effects were reported in these studies. 
Several mechanism studies implied that the anti-inflammation effect of Andro 
possibly resulted from its inhibition of nuclear factor-kappaB (NF-κB), suppression of 
the activation of immunocompetent cells and repression of production of key pro-
inflammatory cytokines, such as TNF-α, IL-1, IL-6, IL-12. It has been suggested that 
the interference of DNA binding activity of NF-κB by Andro was responsible for its 
anti-inflammatory action (Hidalgo et al., 2005; Iruretagoyena et al., 2006; Xia et al., 
2004). Therefore, Andro inhibited NF-κB-induced gene transcriptions, which are 
critical in thrombosis and inflammation (Wang et al., 2007). Xia and colleagues found 
that Andro may form a covalent adduct with NF-κB p50 subunit through reduced 
cysteine 62 (Xia et al., 2004). This formation did not affect p50 nuclear translocation, 
but instead block binding of NF-κB to nuclear proteins. It was also found that IκB 
degradation, the main NF-κB activating mechanism, was not affected by Andro (Xia 
et al., 2004). Thus, Andro, being a specific inhibitors of p50, may be therapeutically 
valuable for preventing and treating thrombotic arterial diseases, including neointimal 
hyperplasia in arterial restenosis (Wang et al., 2007).  
Inhibition of ERK (extracellular regulatory kinase) pathway was suggested to be 
the second mechanism of Andro mediating the decreased cytokine production in 
inflammation process (Qin et al., 2006). In murine peritoneal macrophages, Andro 
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decreased production of TNF-α and IL-12 by deactivating ERK (Qin et al., 2006). It 
is noteworthy that in this mode NF-κB and other MAPK molecules (p38 and JNK) 
were not affected.  
1.1.3.2 Immuno-regulatory effects 
The immuno-regulatory effects of Andro not only present as an inhibitor of 
immuno-related cytokines, Andro treatment also could act as immunostimulant in 
response to infection. In the last decade, the immunity-modulatory effect of Andro has 
been extensively studied.  
Accumulating data favors the idea that Andro acts as an immunostimulant agent in 
response to microbial infection and tumor. It has been found that Andro treatment can 
enhance the activity of natural killer cell and cytotoxic T lymphocyte and production 
of interleukin-2 (IL-2) and interferon-γ (IFN-γ) (Kumar et al., 2004; Peng et al., 2002; 
Sheeja and Kuttan, 2007a, b). Increased generation of IL-2, IFN-γ and others 
cytokines may mediate the antimicrobial, immunoregulatory, and anti-tumor 
properties of Andro. In addition, Andro may also induce production of antibody, 
which accounts for specific immune response against foreign antigens (Puri et al., 
1993; Xu et al., 2007). 
Andro was reported to be capable of protecting immune cells (thymocytes) or 
endothelial cells against apoptosis (Burgos et al., 2005; Chen et al., 2004). It was 
shown that Andro could protect human umbilical vein endothelial cells from 
mitochondrial-mediated apoptosis induced by growth factor deprivation (Chen et al., 
2004). It was proposed to be mediated through activation of AKT pathway and 
phosphorylation of its downstream molecule BAD by Andro. Another studies showed 
that Andro could reduce apoptosis in thymocytes induced by hydrocortisone and PMA 
(Burgos et al., 2005).  
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It is noteworthy that both immuno-stimulatory and immuno-inhibitory effects may 
occur simultaneously upon Andro treatment. For example, cyclophosphamide 
intoxication could induce urothelial inflammatory damages through increased 
production of proinflammmatory cytokines (such as TNF-α) and repressed expression 
of IL-2 and IFN-γ (Sheeja and Kuttan, 2006). It was suggested that Andro could 
reverse these two actions by inhibiting TNF-α production and stimulating the 
production of IL-2 and IFN-γ. Similarily, the dual effects of Andro in 
immunomodulation could also be found in cancer cells. Decreased generation of IL-1, 
IL-6 and TNF-α but enhanced production of IL-2 were also found to be involved in 
Andro-suppressed capillary formation of B16F-10 melanoma cell line in C57BL/6 
mice (Sheeja et al., 2007).  
1.1.3.3 Anti-HIV effects 
Although not much experimential work have been done on the anti-HIV (human 
immunodeficiency virus) effect of Andro, a phase I dose-escalating clinical trial of 
Andro was conducted in 13 HIV positive patients and five healthy volunteers 
(Calabrese et al., 2000). The objectives of this clinical trial were primarily to assess 
the safety and tolerability of Andro and secondarily to assess effects of Andro on 
plasma virion HIV-1 RNA levels and CD4+ lymphocyte levels. A significant rise in 
the mean CD4+ lymphocyte level of HIV subjects occurred after administration of 10 
mg/kg Andro, but no statistically significant changes in mean plasma HIV-1 RNA 
levels throughout the trial. Immune system, especially the restoration of CD4+ cell 
population in the early stages of this disease is vital to permit the development of 
more appropriate therapies for AIDS. Results from the above work suggested that 
Andro may inhibit HIV-induced cell cycle dysregulation, leading to a rise CD4+ in 
lymphocyte levels in HIV-1 infected individuals. 
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1.1.3.4 Hepatoprotective effects 
The hepatoprotective property of Andro has been well established by several in 
vivo studies using rat models (Choudhury et al., 1987; Handa and Sharma, 1990b; 
Visen et al., 1993). It was shown that Andro pretreatment could efficiently prevent 
hepatic damages induced by galactosamine, paracetamol (Handa and Sharma, 1990a), 
carbontetrachloride, tert-butylhydroperoxide, or ethanol (Kapil et al., 1993). This 
protective effect of Andro was comparable to that of silymarin, a standard 
hepatoprotective agent (Singha et al., 2007). Kapil and colleagues suggested that the 
hepatoprotective effect of Andro might be resulted from its antioxidant property, but 
they did not further explore the regulation of Andro on hepatocellular antioxidant 
defense system (Kapil et al., 1993). Recently, Trivedi and coworkers also indicated 
that Andro is a hepatoprotective and hepastimulative agent (Trivedi et al., 2007). They 
suggested that long exposure of liver to hexachlorocyclohexane (BNC) resulted in 
many-fold increase of γ-GTP, which would induce hepatoma in rats. However, Andro-
supplemented animals showed the adaptive nature of GSH/GST system against severe 
hepatic damage by BHC, indicating the antioxidant effects of Andro, and this property 
of Andro due to its ability to activate antioxidant enzymes including catalase, 
superoxide dismutase, glutathione reductase, and glutathione peroxidase (Trivedi et 
al., 2007).  
1.1.3.5 Cardiovascular protective effect 
Andro was found to be effective in preventing human blood platelet aggregation, a 
crucial pathological step in thrombosis. This action of Andro was revealed by in vitro 
studies that Andro could inhibit platelet-activating factor or thrombin induced platelet 
aggregation (Amroyan et al., 1999; Thisoda et al., 2006). Furthermore, Andro 
inhibited nitrite synthesis by suppressing protein expression of inductible nitric oxide 
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synthase (iNOS) in vitro (Chiou et al., 1998). This inhibition of iNOS synthesis may 
contribute to the beneficial haemodynamic effects of Andro in endotoxic shock. It has 
been recently reported that pretreatment with Andro, but not with any other extracts of 
Andrographis paniculata protected cardiomyocytes against hypoxia/reoxygenation 
injury (Woo et al., 2008). The cardioprotective action of Andro was found to coincide 
in a time-dependent manner with the up-regulation of reduced glutathione and 
antioxidant enzyme activities.  
1.1.3.6 Anti-diabetes effects 
Diabetes is a chronic disease that occurs when the pancreas does not produce 
enough insulin, or alternatively, when the body cannot effectively use the insulin to 
regulate blood sugar (Pearl and Kanat, 1988). Hyperglycaemia, or raised blood sugar, 
is a common consequence of uncontrolled diabetes and over time hyperglycaemia 
leads to serious damage to many systems in the body, especially the nerves and blood 
vessels. Chinese herbal medicines have showed certain effectiveness in promoting the 
living qualities of diabetes patients and reducing the mortality (Zhao et al., 2006). 
Oral administration of Andro decreased the plasma glucose concentration in a 
dose-dependent manner in streptozotocin (STZ)-induced diabetic rats (Yu et al., 2003). 
A follow-up study by the same research group (Yu et al., 2007a) disclosed the 
involved mechanism of the glucose-decreasing action of Andro in this diabetic mice 
model. It was found that Andro could increase α1-adrenoceptors-mediated secretion 
of β-endorphin, an important cytokine responsible for activating opioid μ-receptors to 
reduce hepatic gluconeogenesis and to enhance the glucose uptake in soleus muscle 
and finally to reduce plasma glucose in STZ-diabetic rats (Yu et al., 2007a). It is 
noteworthy that the activation of α1-adrenoceptors by Andro may be mediated by the 
phospholipase C/protein kinase C (PLC/PKC) signalling cascade (Hsu et al., 2004). 
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Thus, the above findings suggested that Andro could lower plasma glucose by 
enhanced glucose utilization in diabetic rats lacking insulin.  
1.1.3.7 Anticancer potential of Andro  
Besides its well-known activities such as anti-inflammation and hepatoprotective 
effect, recently Andro aroused increasing interest in its anticancer effect. To date, 
Andro has exhibited potent cytotoxicity in various cancer cell lines. This action is 
possibly mediated by two different mechanisms: induction of cell cycle arrest and 
apoptotic cell death. Some studies have been carried out to demonstrate the potent 
anticancer activities of Andro and the possible molecular mechanisms. In the 
following sections, these findings will be summarized accordingly. 
1.1.3.7.1 Inhibition of cancer cell proliferation and induction of cell cycle arrest 
The effect of Andro on cell proliferation and viability are less reported. The 
anticancer property of Andro was first reported by Rajagopal and his colleagues 
(Rajagopal et al., 2003). In their study, Andro treatment inhibited the in vitro 
proliferation of different tumor cell lines, as well as the tumor growth in vivo in 
B16F0 melanoma and HT-29 xenograft models. In another study, Kumar et al 
demonstrated that Andro exhibited higher cytotoxicity against a variety of cancer cells, 
when compared with its analogue deoxyandrographolide, neoandrographolide, 14-
Deoxyandrographolide and 14-Deoxy-11,12-didehydroandrographolide, (Kumar et al., 
2004), suggesting the unique cytotoxicity of Andro, among the extracts from 
Andrographis paniculata.  
Meanwhile, the possible mechanisms which may be responsible for the inhibitory 
effect of Andro on tumor growth have been partially revealed. Dys-regulated cancer 
growth could be reverted by regulation on key checkpoint proteins or other cell cycle 
related factors, as part of the important approaches for cancer chemotherapy. The 
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property of Andro on G1/S cell cycle arrest has been demonstrated in several tumor 
cells, including human colon carcinoma HT29 (Rajagopal et al., 2003) and human 
acute myeloid leukemic HL60 cells (Cheung et al., 2005). Furthermore, this action of 
Andro on G1/S cell cycle arrest has been proposed to be mediated by up-regulation of 
CDK2 inhibitor p27 and down-regulation of CDK4 (Rajagopal et al., 2003).  
1.1.3.7.2 Induction of apoptotic cell death 
Andro may have dual effects on apoptosis: in cancer cells Andro could stimulate 
apoptosis while in normal epithelial and immune cells Andro prevents apoptosis 
induction. The latter effect has been discussed in Chapter 1.1.3.2. The induction of 
apoptotic death in cancer cells has been revealed by two recent studies. In the first 
study, Kim and coworkers (Kim et al., 2005) described typical apoptotic 
morphological changes in Andro-treated human prostate cancer PC-3 cells: membrane 
blebbing, chromosome fragmentation and formation of apoptotic bodies. The author 
further suggested that the activation of caspase-8 and caspase-3 was involved in 
Andro-induced apoptosis. Another group (Cheung et al., 2005) explored the 
apoptosis-inducing effect of Andro in human leukemic HL-60 cells and indicated the 
Andro-induced chromosome fragmentation (observed by confocal microscopy and gel 
electrophoresis) was accompanied by disappearance of mitochondrial cytochrome c 
and increased expression of Bax but decreased expression of Bcl-2 proteins, 
suggesting that Andro induced the intrinsic mitochondria-dependent pathway of 
apoptosis. Both studies pointed out that, Andro could inhibit cell growth by inducing 
apoptosis in cancer cells. However, the detailed molecular mechanisms of Andro-
induced apoptosis are still largely unknown. As apoptosis-inducing ability of Andro is 
directly related to its potential of anticancer property, it is important to further 
investigate the mechanisms of Andro-induced apoptosis and the molecular targets of 
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this compound.  
On the other hand, the proapoptotic effect of Andro in cancer cells seems 
contradictory to the anti-apoptotic effect found in normal epithelial and immune cells 
(Chapter 1.1.3.2). But it may reflect that in different circumstances and molecular 
scenario Andro may exhibit different properties either towards or against apoptosis. 
1.1.3.7.3 Anti-angiogenesis, anti-adhesion and other effects   
It was recently found that Andro could inhibit capillary formation induced by 
B16F-10 melanoma cells in C57BL/6 mice (Sheeja et al., 2007). Decreased 
production of proinflammatory cytokines such as TNF-α and potent angiogenic factor 
VEGF, as well increased anti-angiogenic factors such as TIMP-1 and IL-2 may 
account for its inhibitory effect. Since angiogenesis is important for solid tumor 
formation and metastasis, this effect discloses a novel anticancer property of Andro.  
Although no related work has been carried our in clarifying the possible effect of 
Andro on cancer cell adhesion and invasion, its anti-inflammatory property may 
suggest its potential role in cancer metastasis. It was found that neutrophil adhesion 
(Shen et al., 2002) and macrophage migration (Tsai et al., 2004) could be efficiently 
blocked by treatment of Andro. Whether this action of Andro also applies to cancer 
cells is still to be determined.  
1.1.4 Molecular mechanisms involved in the biological effects of Andro 
1.1.4.1 Effect on NF-κB signaling pathway 
NF-κB is an important transcription factor in inflammation and cancer. 
Modulation of its activity has been suggested to be one of the crucial approaches in 
the treatment of inflammation and cancer (Karin, 1999; Mercurio and Manning, 1999). 
The NF-κB family is composed of five proteins: RelA (p65), RelB, c-Rel, NF-κB1 
(p50), and NF-κB2 (p52), each of which may form homo- or heterodimers (Ghosh et 
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al., 1995). NF-κB can be activated by many types of stimuli including TNF-α, UV 
radiation, free radicals, etc (Karin, 1999; Mercurio and Manning, 1999).  
There are two signaling pathways leading to the activation of NF-κB known as the 
canonical pathway (or classical) and the non-canonical pathway (or alternative 
pathway) (Ghosh et al., 1995; Karin, 1999). In the canonical NF-κB activation 
pathway, NF-κB dimers are sequestered in the cytoplasm through tight association 
with inhibitor IκBα. Usually upon a stimulatory ligand-receptor binding (e.g. tumor 
necrosis factor (TNF) and TNF-receptor (TNF-R)), adaptor proteins (e.g. TRAFs and 
RIP) recruit IKK complex (containing α and β catalytic subunits and two molecules 
of regulatory scaffold NEMO proteins) onto the cytoplasmic domain of the receptors. 
This clustering activates IKK complex, leading to IκBα phosphorylation at two serine 
residues by IKK and IκBα degradation by the 26S proteasome. This process allows 
NF-κB (p50-RelA) to become free and is able to translocate into the nucleus for 
binding to NF-κB-specific DNA-binding sites and, in turn, regulating the transcription 
of target genes (Ghosh et al., 1995; Karin, 1999). NF-κB activation also leads to the 
expression of the IκBα gene, which consequently sequesters NF-κB subunits and 
terminates transcriptional activity unless a persistent activation signal is present. 
 The non-canonical pathway is responsible for the activation of p100/RelB 
complexes and occurs during the development of lymphoid organs responsible for the 
generation of B and T lymphocytes. In the non-canonical pathway, p52-RelB complex 
is activated through a series of processes: receptor binding, recruiting and activation 
of NF-κB-inducing kinase (NIK), phosphorylation and activation of an IKK complex 
(containing two α subunits but not NEMO) by NIK, phosphorylation of precursor 
p100 by IKK and its partial proteolysis into p52 and liberation of the p52-RelB 
complex (Gilmore, 2006; Hayden and Ghosh, 2004)  
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The activity of NF-κB has been found to be repressed by Andro in several studies 
(Hidalgo et al., 2005; Iruretagoyena et al., 2006; Xia et al., 2004). Unexpectedly, the 
main NF-κB activation mechanism, IκB degradation was not affected by Andro 
treatment (Hidalgo et al., 2005; Xia et al., 2004). Instead, Andro form a covalent with 
reduced cysteine (62) of p50, which subsequently prevented its binding with nuclear 
proteins (Xia et al., 2004). Later on, Hidalgo et al. reported that Andro exerted its 
anti-inflammatory effect by inhibiting NF-κB binding to DNA and reducing the 
expression of proinflammatory proteins, such as COX-2 (Hidalgo et al., 2005), which 
is consistent with the conclusion from Xia et al. At present, the possible effects of 
Andro on the upstream of NF-κB have not been studied. 
1.1.4.2 Effects on Mitogen-activated protein kinase (MAPK) pathway  
The MAPKs is one of the most thoroughly studied signaling transduction system 
and have been shown to play a central role in regulating cell proliferation, apoptosis 
and migration (Pearson et al., 2001). They are typically organized in a three-kinase 
cascade consisting of MAP kinase, MAP kinase activator (MEK, MKK, or MAP2K) 
and MEK activator (MEKK, or MAP3K). In the classical model, transmission of 
signals is achieved by sequential phosphorylation and activation of MAP3K and 
MAP2K, which then activates MAP kinase through phosphorylation on the serine and 
tyrosine residues of MAP kinase. This cascade is evolutionarily conserved in all 
eukaryotes, and activation of MAPK is a transient and rapid event that is tightly 
regulated by both kinases and phosphatases (Chang and Karin, 2001; Lewis et al., 
1998). 
MAPK members consist of three major classes: the c-jun N-terminal kinases 
(JNKs), the extracellular signal regulated proteins kinase (ERKs) and p38. Among 
them, JNK and p38 mainly play a pro-apoptotic function in response to various 
 15
cellular stresses, while ERK subgroup is primarily involved in mitogen-activated 
proliferative responses (Chang and Karin, 2001; Kyriakis and Avruch, 2001; Lewis et 
al., 1998; Shen and Liu, 2006). 
There are a few studies suggesting that Andro could inhibit ERK phosphorylation 
(Burgos et al., 2005; Qin et al., 2006; Thisoda et al., 2006; Tsai et al., 2004). Andro 
attenuated complement 5a induced phosphorylation of ERK and its upstream kinase 
MEK (Tsai et al., 2004). This action has been proposed to account for the decreased 
macrophage cell migration. In murine peritoneal macrophages (Qin et al., 2006) and 
murine T-cells (Burgos et al., 2005), Andro repressed production of TNF-α and IL-12, 
as accompanied by the decreased phosphorylation of ERK. Thus it was proposed that 
ERK inhibition may be responsible for the anti-inflammatory effect of Andro, since 
both NF-κB and other MAPK molecules (e.g. p38 and JNK) were not affected in their 
studies (Burgos et al., 2005; Qin et al., 2006). But some contradicting data suggested 
that Andro could not block ERK phosphorylation in human umbilical vein endothelial 
cells (Chen et al., 2004) and HL-60-derived neutrophilic cells (Hidalgo et al., 2005), 
suggesting that the effect of Andro on the ERK signaling pathway is stimulus- or cell 
text-dependent. At present, the knowledge about the potential effects of Andro on 
MAPKs other family members, including JNK and p38, are rather limited. The exact 
role of MAPK pathway in the bioactivities of Andro remains to be further investigated. 
1.1.4.3 Effects on AKT/PKB survival pathways 
The serine/threonine protein kinase Akt, also known as protein kinase B (PKB) 
plays an important role in mammalian cellular signaling. Three Akt family members 
have been identified in mammals, designated as Akt1/PKB, Akt2/PKB and Akt3/PKB 
(Testa and Bellacosa, 2001).  
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This protein kinase can be activated by insulin and various growth and survival 
factors in a phosphatidylinositol 3-kinase (PI3K)-dependent manner (Franke et al., 
1995). Akt activation is a multistep process including its membrane translocation, and 
the phosphorylation (Testa and Bellacosa, 2001). Akt possesses a protein domain 
known as PH domain, which has high affinity to bind with either PIP3 or PIP2, and 
thereby initiate the membrane translocation of Akt. Upon membrane translocation, 
Akt is phosphorylated at Thr308 in the kinase activation loop and Ser473 in the 
carboxyl-terminal tail, and the phosphorylation of both sites is required to generate a 
high level of Akt activition (Brazil et al., 2002; Datta et al., 1999). On the other hand, 
the activity of Akt can be negatively regulated by tumor suppressor PTEN, which is 
frequently mutated in human malignancy. PTEN acts as a phosphatase to 
dephosphorylate PtdIns(3,4,5)P3 and PtdIns(3,4)P2, thereby restraining PI3-kinase-
dependent Akt activation (Blanco-Aparicio et al., 2007; Li et al., 1997).  
Akt is involved in cellular survival pathways via inhibiting apoptosis and 
promoting proliferation (Testa and Bellacosa, 2001). This kinase could phosphorylate 
BAD on Ser136, which results in the release of Bcl-2/Bcl-xL from association with 
BAD Akt could also activate NF-κB via regulating IκB kinase (IKK), thus result in 
transcription of pro-survival genes (Ozes et al., 1999). Furthermore, Akt is known to 
play a role in the cell cycle regulation by preventing GSK-3β mediated 
phosphorylation and degradation of cyclin D1 and by negatively regulating the cyclin 
dependent kinase inhibitors p27 Kip and p21 Waf1/CIP1 (Diehl et al., 1998; Gesbert 
et al., 2000; Zhou et al., 2001). Therefore, this pathway plays a major part in cell 
survival and the resistance of tumor cells to conventional cytotoxic and targeted 
anticancer therapies. Blocking the PI3K/Akt pathway could therefore simultaneously 
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inhibit the proliferation and growth of tumor cells and sensitize them toward 
programmed cell death. 
The mechanism of how Andro affects cell proliferation and viability through Akt 
pathway are less reported. But the effects of Andro on this survival pathway are 
controversial. In human umbilical vein endothelial cells, growth factor deprivation 
induced apoptotic cell death, which could be protected by pretreatment of Andro. 
Andro-induced activation of Akt pathway and phosphorylation of its downstream 
molecule BAD were proposed to account for its protective effect (Chen et al., 2004). 
On the contrary, another groups suggested that Andro could strongly abolish 
complement 5a-stimulated Akt and ERK phosphorylation, and in turn inhibited the 
RAW264.7 macrophage migration in response to C5a (Tsai et al., 2004). Thus, the 
effect of Andro on AKT pathway could be stimulus- or cell text-dependent. 
 
1.2  Apoptosis and Apoptosis Regulation 
1.2.1 General introduction about apoptosis 
Apoptosis, a Greek word that means “dropping off” or “falling off” as in leaves 
from a tree, is a description of a tightly regulated and conserved programed cell death 
in eukaryotic cells which is morphologically and biochemically distinct from necrotic 
cell death. Apoptosis research has received much attention because of its wide-
ranging implications in many human diseases, such as cancer (Kaufmann and 
Earnshaw, 2000).  
Apoptotic cell death is marked by a well-defined sequence of morphological 
changes: plasma membrane blebbing, nuclear chromatin condensation and then 
fragmentation, formation of small membrane-bound apoptotic bodies, which 
eventually are phagocytosed by other cells. Simultaneously, apoptotic cells undergo a 
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chain reaction of biochemical changes, including activation of caspases, dysfunction 
of the mitochondrial and non-specific cleavage of DNA around histone octamers 
(Hengartner, 2000; Kaufmann and Hengartner, 2001). These highly stereotyped 
changes suggest that apoptotic cell death is under the control of a strict cellular 
regulation. In cells undergoing apoptosis, which is different from necrotic cell death, 
the intracellular constituents are not released into the extracellular milieu where they 
might have deleterious effects on neighboring cells. Thus, apoptotic cell death does 
not trigger any inflammatory response in vivo. 
There are generally three phases in apoptosis process: initiation phase, execution 
phase and degradation phase. In the initiation phase, the cell death signals, which 
might be either intrinsic or extrinsic, trigger the initiation of apoptotic cascade. As 
shown in Fig.1.2, two apoptotic pathways leading to caspase activation have been 
described (Budihardjo et al., 1999; Youle and Strasser, 2008). The extrinsic pathway 
starts with ligation of cell surface receptors termed “death receptor” (DRs). Members 
of the DR family include Fas/CD95, tumor necrosis factor-α (TNF-α) receptor 1, and 
another two receptors, DR4 and DR5 (or named as TRAILR1 and TRAILR2), which 
bind to TNF-α related apoptosis-inducing ligand (TRAIL) (Ashkenazi and Dixit, 
1999). The ligation of receptors with their respective ligands leads to recruitment of 
the adaptor molecules (such as FADD) and formation of death-inducing signaling 
complex (DISC), which results in the cleavage and activation of initiator caspases 
(mainly caspase-8) (Wang and El-Deiry, 2003). At this point, DR-initiated signaling 
diverges in different cells. In type I cells, DR ligation leads to vigorous activation of 
caspase-8, which then directly cleaves and activates procaspase-3. While in type II 
cells, DR ligation-induced caspase-8 activation is insufficient to directly activate 
procaspase-3. Instead, caspase-8 cleaves one of its substrates Bid, leading to the 
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translocation of truncated Bid (tBid) to mitochondria and thus transduction of 
apoptotic signals from cytoplasmic membrane to mitochondria (Li et al., 1998). The 
intrinsic mitochondrial pathway of caspase activation involves the loss of 
mitochondrial membrane potential and cytochrome c release, which in turn activates 
caspase-9, subsequently the activation of effector caspases (e.g. caspase-3) 
(Kaufmann and Hengartner, 2001) (Fig.1.2). It is believed that once the cell enters the 
execution phase, the cell death process becomes irreversible, since activated effector 
caspases will cleave a number of substrates, including DNase II, caspase-activated 
deoxyribonuclease (CAD) and cytoskeletal proteins which responsible for the distinct 









































Fig. 1.2 Scheme depicting intrinsic and extrinsic pathways of apoptosis 
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1.2.2 Caspases 
Caspases are cysteinyl aspartate proteinases (cysteine proteases that cleave their 
substrates following an Asp residue) (Miller, 1997). Currently, 11 human caspases 
have been identified (Degterev et al., 2003). All caspases are synthesized as inactive 
zymogens containing a prodomain followed by p20 large and p17 small subunits 
(Kumar, 2007; Strasser et al., 2000). According to their structures and functions, these 
caspases can be classified into two groups, initiator caspases and effector caspases. 
Initiator caspases possess long prodomains containing one of two characteristic 
protein–protein interaction motifs: the death effector domain (DED) (caspase-8 and -
10) and the caspase activation and recruitment domain (CARD) (caspase-1, -2, -4, -5, 
-9, -11 and -12), providing the basis for interaction with upstream adaptor molecules. 
On the other hand, the downstream effector caspases form an “executioner” class 
(caspase-3, -6 and -7) and are characterized by the presence of a short prodomain. 
Effector caspases, which perform the downstream execution process of apoptosis by 
cleaving multiple cellular substrates are activated by upstream caspases at Asp 
position between large and small subunits (Degterev et al., 2003; Earnshaw et al., 
1999; Kumar, 2007). Interestingly, initiator caspases also serve as the substrates of 
active effector caspases. For example, active caspase-3 can cleave and activate 
procaspase-8. Therefore, the apoptosis process can be accelerated by this positive 
feedback loop (Shi, 2002). Activation of caspases appears to be a common feature of 
most, if not all, apoptotic cell death. Caspases have specific intracellular targets, and 
the cleavage of their substrates leads to the demise of a cell.  
Activation of caspases is negatively regulated by a group of the inhibitors of 
apoptosis (IAPs). The mammalian IAP-like proteins, e.g. XIAP, c-IAP-1 and c-IAP-2, 
can physically interact with caspases and inhibit caspase-3, -7 and -9 (Vaux and Silke, 
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2005). Elevated levels of IAPs are often associated with the resistance to apoptosis in 
human cancer cells and suppressed IAPs is known to be able to sensitize cells to 
cytotoxic agents (Schimmer et al., 2006). Another potent anti-apoptotic protein is 
FLICE-inhibitory proteins (c-FLIP), which is a key regulator of extrinsic apoptotic 
pathway of caspase-8 activation. c-FLIP exists as a long (c-FLIPL) and a short (c-
FLIPS) splice variants, both of which are capable of protecting cells from death 
receptor-induced apoptosis through replacing caspase-8 to form the death-inducing 
signal complex (DISC) (Irmler et al., 1997; Kumar, 2007).  
Knowledge of these apoptosis regulators provides the basis for novel therapeutic 
strategies aiming at promoting tumor cells to death directly or enhancing their 
susceptibility to apoptotic inducers. 
1.2.3 Bcl-2 protein family and mitochondria 
1.2.3.1 Bcl-2 protein family 
Although the caspase family represents a central point in apoptosis, their 
activation is tightly regulated by a variety of other factors. Among these, Bcl-2 family 
plays a pivotal role in caspases activation, and their functions are known to be 
achieved mainly at the mitochondria level. Currently, Bcl-2 proteins have been well 
established as the main regulators in controlling the release of cytochrome c and other 
apoptosis promoting proteins from mitochondria (Adams and Cory, 1998; Gross et al., 
1999; Hengartner, 2000; Youle and Strasser, 2008). In mammals, Bcl-2 family has 
more than 20 members, all of them are characterized by containing at least one of four 
conserved Bcl-2 homology (BH) domains, designated BH1-BH4, which correspond to 
α–helical segments (Adams and Cory, 1998). Based on their cellular function and 
structural properties, they can be classified into two groups: anti-apoptotic proteins 
and pro-apoptotic proteins (Table 1.1). 
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Anti-apoptotic Bcl-2 proteins which specifically contain BH4 domain, include 
Bcl-2, Bcl-xL, Bcl-w and Mcl-1 (Adams and Cory, 1998). Their hydropholic carboxy-
terminal domain facilitates the attachment of these proteins to the cytoplasmic face of 
three intracellular membranes: the outer mitochondrial membrane, the endoplasmic 
reticulum (ER) and the nuclear envelope (Nguyen et al., 1993). Bcl-2 possesses 
protective effect against apoptosis mainly through its mitochondrial localization, and 
it has been proved to be unique among oncogenes in blocking apoptosis rather than 
promoting proliferation (Hockenbery et al., 1990; Korsmeyer, 1992).  
On the other hand, the pro-apoptotic proteins include Bax and Bak which contain 
an essential pro-apoptotic BH3 domain but lack of BH4 domain (Gross et al., 1999). 
Bax and Bak are thought to function mainly at the mitochondrion as well. Briefly, Bax 
was discovered as an inhibitory binding partner for Bcl-2 (Oltvai et al., 1993). In 
addition, there is a subgroup of pro-apoptotic proteins which contains a single BH3 
domain, such as Bid, Bad and Bim (Table 1.1). These BH3 only proteins are 
maintained in inactive forms in resting condition but could trigger apoptosis in 
response to various cytotoxic signals (Huang and Strasser, 2000; Willis and Adams, 
2005). It was demonstrated that Bid could relay the cell death signaling from caspase-
8 to mitochondria and then to downstream caspases, providing a connection between 
receptor and mitochondria (Li et al., 1998; Luo et al., 1998). Therefore, the ratio 
between the antiapoptotic and proapoptotic Bcl-2 members helps determine the 
susceptibility of cells to a death signal (Oltvai et al., 1993). 
Multiple lines of evidence have implied that the principal mechanism by which 
Bcl-2 proteins regulate apoptosis is probably by controlling mitochondria membrane 
integrity, regardless of these Bcl-2 proteins displaying either anti-apoptotic or pro-
apoptotic function. Therefore, in order to explore the regulation of Bcl-2 proteins on 
 24
mitochondrial apoptotic pathway, the pivotal function of mitochondria in coordinating 
caspase activation and its interaction with Bcl-2 proteins will be discussed in the 
following sections. 
 
Table 1.1 Bcl-2 family members (Strasser, 2005)  
 
1.2.3.2 The central role of mitochondria in apoptosis process 
The mitochondrion is well recognized as a central organelle responsible for energy 
generation in mammalian cells (Kerr et al., 1972). However, reviews in past decades 
revealed the key role of mitochondria in controlling cell fate by releasing cytochrome 
c and Smac/DIABLO into the cytosol, thereby activating caspases (Green and Reed, 
1998; Gross et al., 1999; Shi, 2001). Furthermore, apoptosis-activating factor (Apaf-1) 
has been confirmed to be able to induce apoptosis through its translocation from 
mitochondria to cytosol, and this effect is caspase-independent (Cande et al., 2002).  
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The mechanisms regulating the mitochondrial release of pro-apoptotic proteins are 
still largely unclear. To date, one possible mechanism through which mitochondrial 
outer membranes become permeabilized is dependent on the permeability transition 
(PT) pore protein complex. The structure of PT pore is still elusive, however, it is 
generally believed that the PT pore mainly consists of the complexes including 
cyclophilin D and the adenine nucleotide translocator (ANT) protein in the inner 
membrane, associated with voltage-dependent anion channel (VDAC) and the 
peripheral benzodiazepine receptor in the outer membrane (Zamzami and Kroemer, 
2001). In physiological condition, periodic reversible opening of the PT pore allows 
the release of Ca2+ from the mitochondrial matrix, thereby participating in Ca2+ 
homeostasis, and the ANT/VDAC couple also participate in regulating ATP/ADP 
transport and synthesis (Zamzami and Kroemer, 2001). However, under death 
signaling stimuli, the non-specific opening of PT pore results in an immediate 
dissipation of H+ gradient across the inner mitochondrial membrane, which 
contributes to the dissipation of the inner membrane potential (△Ψm). This ionic 
redistribution may cause a progressive osmotic swelling of the mitochondrial matrix, 
leading to the rupture of outer mitochondrial membrane and the release of pro-
apoptotic proteins to cytosol (Green and Reed, 1998; Zamzami and Kroemer, 2001). 
However, several research groups were curious about the importance of PT in the 
mitochondrial apoptosis, because in the absence of the hallmarks of PT, including the 
loss of the inner membrane potential and the rupture of the outer membrane, the 
release of mitochondrial proteins still could occur (Bossy-Wetzel et al., 1998; Eskes et 
al., 1998; Yang et al., 1997). Instead, these groups suggested some other regulatory 
mechanisms which might depend on the participation of Bcl-2 proteins. 
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1.2.3.3 Mechanisms of Bcl-2 proteins regulating apoptosis at mitochondrial level 
As discussed above, Bcl-2 family members are known to be critical regulators for 
the permeability of the mitochondrial outer membrane, and most effects of the Bcl-2 
family proteins seem to be conditional on their mitochondrial localization. In the 
absence of death stimuli, pro- and anti-apoptotic Bcl-2 proteins are localized to 
distinct intracellular compartments (Zhu et al., 1996). Bcl-2 and the related anti-
apoptotic proteins are present in mitochondrial membranes. On the contrary, pro-
apoptotic Bcl-2 proteins (Bax, Bak, Bid, Bim and Bad) appear in the cytosol in 
normal condition. But following the death signal, these pro-apoptotic proteins 
undergo conformational change that enable them to integrate into mitochondria outer 
membrane and trigger the release of cytochrome c (Adams and Cory, 2007; Gross et 
al., 1999; Youle and Strasser, 2008). Although cellular functions for these proteins are 
well established, the precise molecular mechanism by which Bcl-2 proteins regulate 
the apoptosis is controversial and subject to further investigation.  
To date, three mechanism models have been proposed to account for the 
apoptosis-regulating function of Bcl-2 proteins, in which post-transcriptional 
modification (dimerization, cleavage and phosphorylation) of Bcl-2 are involved. . 
(i) Dimerization. An important feature of the members of Bcl-2 family is their 
ability to form homo- as well as hetero-dimers, suggesting these proteins are able to 
function either individually or together in group. Sato et al explored the interactions 
of the Bcl-2 protein with itself and other Bcl-2 members with a yeast two-hybrid 
system (Sato et al., 1994). This experiment demonstrated the evidence for the 
homodimerization of Bcl-2 proteins and the heterodimerization among Bcl-2, Bcl-XL, 
Mcl-1 and Bax. Bax is a cytosolic monomer in normal physiological conditions, but it 
experiences conformation change in response to death stimuli, and translocates to 
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mitochondrial membrane. The translocated Bax is oligomerized into homodimer and 
inserts into mitochondrial outer membranes to form a pore allowing pro-apoptotic 
proteins to be released into cytosol (Eskes et al., 1998; Gross et al., 1999). Bak is an 
oligomeric integral mitochondrial membrane protein in healthy cells, but in the 
presence of Bid, it also can change conformation and form larger aggregates (Wei et 
al., 2000).  
Regarding the regulation on Bax and Bak, roles of both anti-apoptotic Bcl-2 
proteins and BH3-only pro-apoptotic molecules have been proposed. Apoptotic 
process can be prevented by the Bcl-2 and Bcl-xL by forming inhibitory heterodimers 
with Bax or Bak. Over-expression of Bcl-2 or Bcl-xL could effectively block Bax 
mitochondrial translocation and cytochrome c release (Anto et al., 2002; Murphy et 
al., 2000). In addition, the BH3-only proteins more likely act upstream of Bax and 
Bak, because they could not induce apoptosis in the absence of both Bax and Bak 
(Cheng et al., 2001). There are two distinct models which could explain how BH3-
only proteins activate Bax and Bak (Kuwana et al., 2005). In the direct activation 
model, Bim and t-Bid can bind directly to Bax /Bak and promote their activation 
(Certo et al., 2006; Kuwana et al., 2005). In the indirect activation model, on the 
contrary, Bim and t-Bid bind to anti-apoptotic Bcl-2 proteins and block their 
inhibitory effect on the activation of Bax and Bak (Chen et al., 2005; Willis et al., 
2007).  
(ii) Cleavage. When apoptosis is initiated by cell surface death receptors, Bid is 
cleaved into a p15 C-terminal fragment by the activated caspase-8 (Li et al., 1998; 
Luo et al., 1998). The truncated Bid (tBid) then translocates to mitochondria and 
induces cytochrome c release by either t-Bid direct insertion (Luo et al., 1998) or 
cooperation with Bax/Bak (Korsmeyer et al., 2000), or suppression on anti-apoptotic 
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Bcl-2 proteins (Chen et al., 2005). 
(iii) Phosphorylation. The BH3-only protein, Bad can bind and regulate the anti-
apoptotic Bcl-2 proteins to promote apoptosis. Bad is regulated primarily by 
phosphorylation which modulates its protein-protein interactions and subcellular 
localization, in response to growth-factor deprivation (Condorelli et al., 2001). In the 
presence of survival signals, Bad is phosphorylated on three serine sites (Ser112, 
Ser136 and Ser155) and sequestered by 14-3-3 molecule in the cytosol (Zha et al., 
1996). Following the death signals, Bad is de-phosphorylated and de-associated from 
14-3-3 and then translocates to mitochondria, subsequently liberates pro-apoptotic 
Bcl-2 proteins by neutralizing pro-survival members, such as Bcl-2, Bcl-xL and Bcl-w 
(Chen et al., 2005). Besides to Bad, the phosphorylation sites of Bcl-2 (Ser70, Ser87 
and Thr69) also have been studied (Haldar et al., 1998; Yamamoto et al., 1999), and 
Bcl-2 phosphorylation has been correlated with its inactivation in some cell types 
(Yamamoto et al., 1999). 
Bcl-2 proteins are regulated primarily in post-translational level, however, the 
transcriptional regulation of Bcl-2 proteins also seems to play an important role. For 
instance, Bcl-xL and Mcl-1 could be transcriptionally regulated in response to death 
stimuli (Gross et al., 1999). Pro-apoptotic Bcl-2 members are transcriptionally silent 
in healthy cells, but they could also be transcriptionally regulated in response to 
selected death stimuli. For example, evidences exist that Bax is subject to the 
transcriptional regulation of p53 in response to cellular stress (Miyashita and Reed, 
1995).  
Recently, a number of studies have highlighted the endoplasmic reticulum (ER) as 
a key upstream signaling organelle for the regulation of apoptosis. Bcl-2 members, in 
addition to their role at the mitochondria, also could affect Ca2+ dynamics at the ER, 
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allowing an alternative pathway leading to apoptosis (Annis et al., 2004; Danial, 
2007). Scorrano et al utilized Bax/Bak double knockout MEF cells and found the 
critical roles of Bax and Bak in increasing the releasing of ER Ca2+ (Scorrano et al., 
2003). On the contrary, Bcl-2 also could reduce the amount of releasable Ca2+ from 
the ER (Foyouzi-Youssefi et al., 2000; Pinton et al., 2000), suggesting that the Bcl-2 
proteins regulate cell death not only through the mitochondrion but also the ER. But it 
is still largely unknown how the pro- and anti-apoptotic Bcl-2 family members 
antagonizes each other on the ER Ca2+ handling machinery, and it is still not clear if 
BH3 only proteins play a role in this pathway. 
1.2.4 p53  
The p53 gene is the most commonly mutated tumor suppressor gene in human 
cancers and loss of p53 function promotes malignant transformation which is required 
for cancer progression (Hainaut and Hollstein, 2000). In normal cells, p53 remains at 
low expression level in the absence of stresses. In response to stress signals, however, 
p53 becomes functionally active and triggers either cell cycle arrest or apoptotic cell 
death (Vogelstein et al., 2000). Recent studies in the p53 knock-in mice which 
replaced with common p53 cancer mutation sequence indicated that the common 
mutated p53 abolish the wild-type p53-dependent tumor suppression activities in vivo 
(Lang et al., 2004; Olive et al., 2004; Song et al., 2007). 
1.2.4.1 Regulation of p53 expression and function in apoptosis 
The amount of p53 protein in cells is determined mainly by the rate at which it is 
degraded rather than the rate at which it is synthesized (Vogelstein et al., 2000). It is 
well accepted that the ubiquitin-proteasome pathway plays a major part in the p53 
regulation. Mouse double-minute 2 protein (Mdm2) plays a pivotal role in down-
regulating p53 expression (Brooks and Gu, 2006). Mdm2 gene is one of p53 
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transcriptional targets encoding an E3 ubiquitin ligase, which interacts with p53 and 
mediated its ubiquitination, resulting in p53 proteasomal degradation (Michael and 
Oren, 2003; Momand et al., 1992). The negative feedback regulatory loop between 
Mdm2 and p53 allow the appropriate response to cellular stresses (Brooks and Gu, 
2006).  
However, the expression level of cellular p53 is not sufficient to represent its 
activation. In addition to ubquitination, phosphorylation remains to be another major 
posttranslational modification for p53 activity (Brooks and Gu, 2006). The regulation 
of p53 function by phosphorylation and dephosphorylation could occur through many 
sites. At present, more than a dozen phosphorylation sites have been mapped on p53, 
such as Ser6, Ser9, Ser15, Ser20, Ser37, Ser46, Thr18 and Thr81, but only a few have 
been characterized with respect to the phosphorylating kinase and the relevance to p53 
activities (Bode and Dong, 2004; Olsson et al., 2007; Shieh et al., 1997). Most 
residues are phosphorylated by different kinases, and distinct protein kinases could 
phosphorylate several sites on p53 in response to different stresses, indicating 
significant redundancies in the regulation of p53 (Bode and Dong, 2004). Following 
DNA damage, ATM (ataxia telangiectasia mutated) and ATR (ATM- and Rad3-related) 
could phosphorylate p53 at Ser15 or/and Ser37 either directly or indirectly through 
intermediators such as Chk1 and Chk2 kinases (Shieh et al., 1997; Taylor and Stark, 
2001). Furthermore, the regulatory effects of mitogen-activated protein kinases 
(MAPKs) on p53 phosphorylation also have been discovered. Phosphorylation by p38 
kinase on Ser33 and Ser46 has been shown to be required for UV-induced p53-
mediated apoptosis (Bulavin et al., 1999). It is noteworthy that MEKK1/JNK 
signaling plays an important role in p53 stability and transcriptional activities (Fuchs 
et al., 1998). Activation of JNK has been linked with p53 Thr81 phosphorylation in 
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response to DNA damage and stress-inducing agents, and Thr81 phosphorylation 
confers p53 transcriptional activities and the ability to elicit apoptosis (Buschmann et 
al., 2001; Wu, 2004). Whereas Ser376 and Thr55 are dephosphorylated in cells 
exposed to ionizing radiation, indicating that dephosphorylation might also contribute 
to the activation of p53 (Li et al., 2007a; Waterman et al., 1998). 
Even though the posttranslational modifications of p53 have been studied 
extensively, the specific functional consequence and exact temporal sequence of each 
specific modification event remain to be further explored.  
1.2.4.2 Role of p53 in apoptosis  
One important role of p53 as a tumor suppressor is its function in apoptosis. p53 
activates caspase cascade and apoptosis predominantly via the mitochondrial death 
pathway (Johnstone et al., 2002). The striking pro-apoptotic activity of p53 includes 
its transcription-dependent and -independent functions. 
The main function of p53 protein is to act as a transcription factor. p53 mediates 
the transcription of a very broad spectrum of pro-apoptotic proteins, including Bax 
(Miyashita and Reed, 1995), Bid (Sax et al., 2002), Noxa (Oda et al., 2000), PUMA 
(Nakano and Vousden, 2001), DR4 (Liu et al., 2004), DR5 (Sheikh et al., 1998; Wu et 
al., 1997) and CD95 (Fukazawa et al., 1999). Recently, several groups employed 
bioinformatics and microarray approaches to detect the transcription patterns of p53-
responsive genes in the presence of different cellular stresses (e. g., DNA damage, 
oncogene activation and hypoxia), and they found that the type, strength and kinetics 
of the target gene profiles depend on the levels of p53 in the cell, the type of inducing 
agent, and the cell type investigated (Wang et al., 2001; Zhao et al., 2000). This 
phenomenon indicated that in a given stimuli only certain genes will be chosen from 
the broad spectrum of potential p53-responsive targets to mediate a specific event. 
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In addition to the primary function of p53 as a transcriptional factor, accumulating 
evidences have implicated that p53 could exert its pro-apoptotic effect though 
transcriptional-independent manner. In some cell types, p53-dependent apoptosis 
occurs in a p53 transcription-independent manner. Transcription-incapable p53, such 
as p53 dl214 lacking DNA-binding domain and p53 carrying mutations in residues 22 
and 23, still could be a potent inducer of apoptosis in tumor cells (Haupt et al., 1995; 
Kokontis et al., 2001). In this decade, several studies linked the transcription-
independent apoptotic activity of p53 to the intrinsic mitochondrial apoptotic pathway. 
More importantly, two detailed mechanisms have been described according to specific 
location of p53 protein, either in the cytosol or at the mitochondria, both of which 
involves permeabilization of the outer mitochondrial membrane via the participation 
of Bcl-2 proteins (Moll et al., 2005). In the presence of cellular stimuli, p53 rapidly 
translocates to mitochondria, where p53 interacts with the anti-apoptotic Bcl-2 
porteins Bcl-xL and Bcl-2 and antagonizes their anti-apoptotic stabilization of the 
outer mitochondrial membrane, resulting in Bak oligomerization, the permeabilization 
of outer mitochondrial membrane (OMM) and rapid induction of cytochrome c 
release (Marchenko et al., 2000; Mihara et al., 2003). Furthermore, an in vivo study 
demonstrated that mitochondrial p53 accumulation occurred rapidly in sensitive 
organs in response to death stimuli, triggering a rapid first wave of apoptosis that is 
transcription-independent and might precede a second induction of apoptosis which is 
transcription-dependent (Erster et al., 2004). On the other hand, the transcription-
independent effect of p53 on the permeabilization of the OMM could depend on the 
activation of Bax. Unlike Bak, Bax locates mainly in the cytosol in non-stressed cells 
(Gross et al., 1999). Upon cellular death stress, cytosolic p53 can directly activate 
Bax translocation and thereby initiate the mitochondria-dependent apoptotic pathway 
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(Chipuk et al., 2004; Chipuk et al., 2003; Speidel et al., 2006). 
The complexity of the p53 pro-apoptotic network raises some questions 
concerning how p53 coordinates its transcriptional and non-transcriptional functions 
in response to cellular stresses. It seems plausible that the p53 pathways are 
differently regulated under different stress conditions and in different cellular 
environments (Rahman-Roblick et al., 2007; Zhao et al., 2000). 
1.2.5 Reactive Oxygen Species (ROS) 
1.2.5.1 ROS and ROS-activated molecules 
Reactive oxygen species (ROS) is a collective term that describes the chemical 
species that are formed upon incomplete reduction of oxygen. ROS mainly include 
superoxide anion (O2·), hydrogen peroxide (H2O2), and the highly reactive by-
product of H2O2, hydroxyl radical (OH·). The intracellular generation of ROS and its 
removal by scavenging antioxidants have been well reviewed (Inoue et al., 2003; 
Vignais, 2002). Low level of ROS regulates cellular signaling and serves as an 
important signaling molecule in normal cell proliferation (Burdon, 1995). More 
importantly , the imbalance of excessive ROS generation and/or decreased antioxidant 
activities results in oxidative stress, which is believed to contribute to the 
development of several diseases including cancer (Sawa and Ohshima, 2006; Vaquero 
et al., 2004), cardiovascular diseases (Sabuncu et al., 2001), diabetes (Bitar et al., 
2005; Chowienczyk et al., 2000), Alzheimer and other neurodegenerative diseases 
(Butterfield, 2002; Halliwell, 2001), as well as to the aging process (Sohal et al., 
2002). 
Cellular responses to the increases in superoxide, hydrogen peroxide, or other 
related ROS also involve the activation of numerous intracellular signaling pathways. 
These cytosolic pathways can, in turn, regulate a series of transcriptional changes that 
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allow the cell to respond appropriately to oxidative stress (Kamata and Hirata, 1999; 
Liu et al., 2005). How ROS exert its cellular effect might better be investigated by 
identifying its intracellular targets. It has been demonstrated that ROS can act as a 
second messenger for the regulation on its target molecules, including kinases, 
phosphatases and redox sensitive transcription factors, which are responsible for 
various biological responses, including apoptosis, necrosis, senescence, or cell 
survival (Davis, 2000; Gupta et al., 1999; Ozben, 2007).  
One of the important downstream signal cascades involved in ROS-mediated 
signaling pathways is the MAPK signaling pathway, including ERK, JNK and p38 
(Garcia-Fernandez et al., 2002; McCubrey et al., 2006; Usatyuk et al., 2003). 
Particularly, JNK is appreciated as one of the oxidative-sensitive molecules playing a 
role in apoptotic cell death (Garcia-Fernandez et al., 2002; Kaneto et al., 2007; Lu et 
al., 2007; Shen and Liu, 2006)  
PKC contain multiple cysteine residues that can be oxidized and activated by ROS 
for a variety of cellular effects. On the contrary, PKC activation is required for ROS 
generation in several systems including diabetic complication and cell migration 
(Inoguchi et al., 2003; Lin and Takemoto, 2005). Also, PKC may play critical role for 
ROS-mediated ERK activation leading to cell migration of hepatoma cell HepG2, 
providing a hypothetic model of ROS-PKC-MAPK cascade (Wu et al., 2006).  
ROS also regulates the protein-DNA binding of transcription factors and then 
affects gene transcription. It has been suggested that the signaling pathways to AP-1 
and NF-κB could be modulated by redox regulation system. NF-κB itself is a redox-
regulated transcription factor whose DNA binding could be abolished by oxidation 
(Hayashi et al., 1993; Toledano and Leonard, 1991). The conserved cysteine residue is 
required for optimal DNA-protein interactions and is regulated by redox changes. 
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Cys62 is located in a region known as the Rel-homology domain (RHD). The 
replacement of Cys62 with serine results in decreased levels of DNA-binding activity 
(Kumar et al., 1992). Similar redox regulation has been observed in the signaling to 
AP-1. AP-1 is the redox-sensitive transcription factor whose activity is dependent on 
its cysteine residues being reduced (Abate et al., 1990; Okuno et al., 1993). On the 
other hand, oxidant-induced activation of the upstream MAP kinase cascade could 
result in AP-1 stimulation (Meyer et al., 1993). 
p53 is a zinc-binding protein containing several reactive cysteines, and its key 
biochemical property, sequence-specific DNA binding is dependent upon metal and 
redox regulation in vitro (Hainaut and Mann, 2001). For example, in response to H2O2, 
p53 could be phosphorylated at serine 15, and this effect might due to the platelet-
derived growth factor-β receptor-mediated ATM kinase activation (Chen et al., 2003a). 
Moreover, an earlier report indicated that oxidative stress is responsible for the 
ultraviolet light activation of the p53 pathway (Renzing et al., 1996). Pretreatment of 
cells with N-acetylcysteine could attenuate the cellular p53 response to ultraviolet 
light. Hainaut hypothesized p53 lying at the center of a network of complex redox 
interactions, in this network, p53 can control the timely production of reactive oxygen 
intermediates, but this activity is under the control of changes in cellular redox status 
(Hainaut and Hollstein, 2000; Hainaut and Mann, 2001). This redox sensitivity may 
be one of the biochemical mechanisms by which p53 acts as a "sensor" of multiple 
forms of stress.  
Studies of these pathways have provided the fundamental molecular principles of 
ROS-based redox regulation. It is worthy of noting that these molecular targets 
demonstrated to be regulated by ROS have close relationship with each other, 
suggesting cells process cross-talk between different signaling systems at the cellular 
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redox state. Presently, the gene regulation by means of oxidants, antioxidants and the 
redox state, remains as a promising therapeutic approach.  
1.2.5.2 Involvement of ROS in apoptosis 
Increased cellular oxidative stress or incubating cells with exogenous oxidants 
have been shown to trigger apoptosis. Many agents that induce apoptosis are either 
oxidants or stimulators of cellular oxidative metabolism (Carmody and Cotter, 2001; 
Haddad, 2004).  
Generally, ROS are involved in both intrinsic and extrinsic apoptosis. On the one 
hand, ROS may be essential for the extrinsic apoptotic pathway (Lu et al., 2007). 
Saitoh et al. suggested that TNF-α-induced activation of the apoptosis signal-
regulating kinase 1 (ASK1) is highly dependent on the redox status (Saitoh et al., 
1998). Conversely, ligation of TNF-α or other death signals to the death receptor is 
capable of inducing ROS production through the mitochondria, while scavenging 
ROS (by addition of pharmacological antioxidants or genetic over-expression of SOD 
and thioredoxin) is able to abolish caspase activation and apoptosis (Devadas et al., 
2003; Goossens et al., 1999; Kasahara et al., 1997). The molecular mechanism 
linking death receptors to ROS production from the mitochondrial source is yet 
unclear. A recent study comparing JNK knockout cells with wild-type cells suggested 
that TNF-α-induced JNK activation may account for the mitochondrial-derived ROS 
production (Ventura et al., 2004). Furthermore, the generated ROS may promote 
death receptor-mediated apoptosis through increased expression of death receptors on 
cell surface (Jung et al., 2005; Kim et al., 2006; Minana et al., 2002).  
On the other hand, ROS may directly activate the mitochondria-mediated intrinsic 
apoptotic pathway (Fruehauf and Meyskens, 2007; Kroemer and Reed, 2000). This 
effect is primarily mediated through opening of the mitochondrial permeability 
 37
transition pore complex in the process of MOMP. The pore complex consists of an 
inner membrane segment, adenine nucleotide translocase (ANT), and an outer 
membrane segment VDAC, as well as cyclophilin D and intermembrane creatine 
kinase. VDAC functions in regulating superoxide flux from the mitochondria to the 
cytosol, making itself vulnerable to superoxide-mediated MOMP (Buchsbaum et al., 
2003; Shoshan-Barmatz et al., 2006). It has been well recognized that upon oxidative 
stress, pore-opening proteins (such as Bax and Bak, together with tBid, and Bim) are 
up-regulated and target VDAC to destabilize it (Scorrano et al., 2003). VDAC 
destabilization in turn promotes ion influx, and ultimately induction of MOMP and 
the release of proteins normally sequestered in the mitochondrial inter-membrane 
space. While in terms of ANT, its three cysteinyl residues (Cys 57, 160, and 257) are 
redox-sensitive and ready to be oxidized to form intramolecular Cys cross-linking 
upon oxidative stress (Bauer et al., 1999; Costantini et al., 2000; Faustin et al., 2004). 
ANT with such oxidative modifications alters its structural conformation and becomes 
incapable of binding nucleotide and allowing calcium entry, which finally induces 
MOMP and pore opening. This biochemical chain of MOMP, especially ANT 
oxidation, could be blocked by mitochondrial antioxidant, such as GSH and 
thioredoxin (Certo et al., 2006; Wudarczyk et al., 1996).  
However, direct treatment with redox radicals, such as hydrogen peroxide and 
redox-active quinones, can initiate either apoptosis when given in lower doses or 
necrosis when given in higher doses (Hampton and Orrenius, 1997). Thus, the dose of 
the redox signal is an important factor in the modulation of cell function. In addition 
to the intensity and duration of the oxidative stress, the extent of these different 
cellular responses also depend on the cellular genetic background, the types of the 
specific ROS involved (Pelicano et al., 2004). Moreover, the switch from apoptotic to 
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necrotic cell death in the increasing level of oxidative stress has been proposed to be a 
result of the oxidative deactivation of caspases (such as thiol oxidation (Nobel et al., 
1997; Samali et al., 1999) and S-nitrosylation (Melino et al., 1997)) and/or dys-
regulated ATP depletion (Leist et al., 1999).  
1.2.6 STATs signaling pathway  
1.2.6.1 STAT family members and their functional domains 
Signal transducers and activators of transcription (STATs) are both signal 
transducers and transcriptional factors, which were first identified as a unique family 
of DNA-binding proteins in 1992 (Shuai et al., 1992). Since then, STATs have drawn 
considerable attention because of their diverse biological effects from inflammation to 
cell survival.  
STAT proteins have been reported to play important roles in proliferation, 
development, differentiation, inflammation, and apoptosis (Darnell, 1997; Schindler 
and Darnell, 1995). There are seven mammalian STAT proteins have been identified, 
STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, and STAT6. Structurally, STAT 
proteins have the following distinct domains: the N-terminal, coiled-coil, DNA-
binding domain, the Linker, Src-homology 2 (SH2) and C-terminal transactivation 
domains. Each of these domains has a distinct function. The DNA binding domain 
forms complexes between STAT proteins and DNA; the N-terminal domain is 
important in STAT dimmer-dimer interactions; the C-terminal is considered as the 
transcriptional activation domain; the SH2 domain is required for STAT dimerization, 
and the SH2 domain is critical for the recruitment of STATs to activated receptor 
complexes, for example, it is required for the interaction with the Janus protein-
tyrosine kinases (JAKs), which phosphorylate the STATs (Darnell, 1997; Schindler 
and Darnell, 1995) 
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1.2.6.2 Activation of STATs signaling 
STAT proteins play a central role in transmitting cytokine signals from cell surface 
to nucleus (Darnell, 1997; Hirano et al., 2000). The STAT proteins are latent in the 
cytoplasm until they are activated by extracellular ligands, including cytokines (e.g., 
IL-6), growth factors (e.g., EGF), and hormones in response to cellular stimuli. 
Cytokines and growth factors exert their effects through their specific receptors on the 
cell surface, which initiates the phosphorylation of STATs. Upon the binding of 
growth factors or cytokines to their cognate receptors on the cell surface, STATs are 
recruited to the cytoplasmic portions of the receptors, where they become 
phosphorylated on a critical tyrosyl residue (Y) in the C-terminus by receptor Tyr 
kinases (RTKs) (Schindler and Darnell, 1995). On the other hand, STATs also can be 
phosphorylated by non-receptor Tyr kinases (NRTKs), such as JAKs, Src or Abelson 
(Abl) kinase. NRTKs can directly phosphorylate STATs in the absence of ligand-
binding to receptors (Darnell, 1997; Ihle, 1996). Tyrosine-phosphorylated STATs then 
form homodimers or heterodimers and translocates into the nucleus, where regulate 
the transcription of a specific set of genes responsible for their physiological functions 
(Fig. 1.3) (Darnell, 1997; Ihle, 1996; Zhong et al., 1994).  
Besides regulation by tyrosine phosphorylation, the duration and degree of gene 
activation by STATs can be regulated by serine-phosphorylation. In the transactivation 
domain of some STAT proteins is a serine residue (S), the phosphorylation of this 
residue greatly augments the transcriptional competence of these proteins, by binding 
to transcriptional coactivators, or by modulation of the rate of nuclear export which is 
required for renewing the non-phosphorylated pool of STATs available for 




Fig. 1.3 STAT3 signaling regulation (Yu et al., 2007b) 
 
1.2.6.3 Negative regulation of STAT signaling 
The ultimate biochemical effect of activated STATs lies in their ability to increase 
the transcriptional activity of genes. Once STATs reach the nucleus, different STAT 
proteins activate different genes. Under physiological condition, both activation and 
inactivation of STATs are crucial to their biological actions. There were several types 
of negative regulators for STAT signaling pathways.  
Protein-tyrosine phosphatases (PTPs), playing positive as well as negative roles in 
signal transduction, among the numerous PTPs identified so far, two mammalian SH2 
domain-containing PTPs, namely SHP-1 and SHP-2 have been extensively studied. 
SHP-1 has been suggested to suppress interferon-α/β-stimulated activation of STATs 
by dephosphorylating JAK1 and JAK2 (David et al., 1995; Klingmuller et al., 1995). 
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In the presence of IL-2 stimulation, SHP-1 is recruited to the activated receptor and 
decreases tyrosine phosphorylation of IL-2R β and the kinase activity of JAK1 and 
JAK3 (Migone et al., 1998). In contrast to SHP-1, SHP-2 has been shown to function 
as a positive regulator in interferon-α/β-stimulated activation of STATs. Transient 
expression of a phosphatase-inactive mutant caused the dominant negative effect on 
interferon-α/β-induced gene expression (David et al., 1996). 
The suppressor of cytokine signaling (SOCS family), also referred to as Janus 
kinase binding protein (JAB), consists of eight proteins: CIS and SOCS1-SOCS7. The 
most well-characterized SOCS-family members, CIS, SOCS1, SOCS2 and SOCS3 
seem to act in a classical negative-feedback loop to inhibit cytokine signal 
transduction (Alexander, 2002; Naka et al., 1997). The expression of SOCS proteins 
are induced by cytokine or growth factors stimulation, resulting in the attenuation of 
JAKs activity by means of an interaction between the SOCS1 and the JAKs activation 
loop (Yoshikawa et al., 2001). CIS does not interact with the JAKs, but uses its SH2 
domain to bind to phosphorylated tyrosine residues on activated cytokines receptors, 
which are used to recruit and activate STATs, subsequently inhibits the cytokine 
signaling mediated by STATs (Matsumoto et al., 1999). Meanwhile, SOCS3 has been 
implicated in the modulation of both STAT3 and STAT5 activity. The mechanism of 
SOCS3-mediated inhibition seems to involve interaction with both cytokine receptors 
and JAKs (Cohney et al., 1999; Sasaki et al., 2000).  
The protein inhibitors of activated STAT (PIAS) act by interacting with the STAT 
dimmer and blocking its transcriptional activity in nuclei. PIAS-1 and PIAS-3 were 
first shown in cultured mammalian cells to interact with tyrosine-phosphorylated 
STAT1 and STAT3, respectively, and to inhibit their binding to DNA (Chung et al., 
1997a; Liu et al., 1998).  
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1.2.6.4 STAT3 as an oncogene in cancer therapy 
Under normal biological conditions, the signaling by STATs is under tightly 
regulation so that the signal is rapid and transient. In contrast, in many cancerous cell 
lines, with existing frequent growth factor dysregulation, the STAT proteins (in 
particular STAT1, 3 and 5) are persistently active. Accumulating data strongly 
demonstrate that aberrant activation of certain STAT proteins would lead to 
uncontrolled cell proliferation and the suppression of host immune surveillance.  
Of great interest is constitutively active STAT3, which is known to occur in a wide 
variety of human cancer cells, including multiple myeloma, leukemia, lymphoma and 
solid tumors (Bharti et al., 2003; Buettner et al., 2002; Hirano et al., 2000; Hodge et 
al., 2005; Mora et al., 2002), implicating aberrant STAT3 signaling as an important 
process in malignant progression. 
 
Table. 1.2 Activated STAT transcription factors in tumor types (Hodge et al., 2005) 
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STAT3 has been demonstrated to directly contribute to oncogenesis by preventing 
apoptosis and stimulating proliferation of tumor cells (Bowman et al., 2000; 
Bromberg et al., 1999; Hirano et al., 2000). These effects are primarily fulfilled 
through its transcriptional regulation on a range of target genes. Bcl-xL was the first 
anti-apoptotic factor shown to be regulated by STAT3. In myeloma tumor cells, 
inhibition of STAT3 activation inhibited Bcl-xL expression and induced apoptosis, 
demonstrating that STAT3 signaling is important for the Bcl-xL regulation and cell 
survival (Catlett-Falcone et al., 1999). Bcl-xL is an antiapoptotic protein within the 
Bcl-2 family that inhibits apoptosis by binding proapoptotic proteins and preventing 
cytochrome c release (as reviewed in above section). High levels of Bcl-xL expression 
were associated with advanced disease and poor prognosis in several tumor systems 
(Cory and Adams, 2002). myeloid cell leukaemia sequence 1 (Mcl-1) also represents a 
survival factor for human cancer cells (Zhou et al., 1997). STAT3 activation 
contributed to the increased Mcl-1 protein levels in large granular lymphocyte 
leukemia, in which cells display high levels of activated STAT3 (Epling-Burnette et 
al., 2001). Suppression of the expression of Bcl-xL and Mcl-1 proved to be useful in 
cancer therapy by inducing cell apoptosis. Many other proteins that are crucial for cell 
cycle regulation also have been found to be regulated by STAT3, including survivin 
(Niu et al., 2002), cyclinD1 and MYC (Bowman et al., 2001; Sinibaldi et al., 2000), 
suggesting that STAT3 plays a crucial role in the regulation of cell proliferation and 
survival in cancer. 
On the other hand, cell culture and animal models, these experimental methods 
have established the STAT3 pathways as valid molecular targets for therapeutic 
intervention in a variety of human cancers (Deng et al., 2007). Cells bearing the 
constitutive active mutant form of STAT3 acquire the transformed phenotype, and this 
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kind of STAT3 mutant has been found in cells transformed in culture by known 
oncogenes or in cell lines started from human tumors, and constitutively active STAT3 
displays cell-transforming activity and tumor formation ability in nude mice 
(Bromberg et al., 1999). Meanwhile, disrupting STAT3 signaling causes growth 
inhibition. When a dominant-negative form of STAT3 was introduced into cancer 
cells, IL-6-induced JAK-STAT signal transduction could be blocked resulting in 
increased apoptosis (Kaptein et al., 1996; Niu et al., 1999). 
Constitutively active STAT3 presents an attractive target for drug discovery with 
the potential of inducing cell death or inhibiting the growth of human cancer cells. 
Pharmacological interventions on STAT3 transcriptional activity have been explored 
in various aspects. For example, inhibitors of the upstream of STAT3, including 
inhibitors of JAK kinases and Src kinase, could effectively block STAT3 activation 
and survival of human myeloma cells and breast cancer cells (Catlett-Falcone et al., 
1999; Garcia et al., 2001); In addition to the development of tyrosine kinase inhibitors, 
the more specific inhibitors, including STAT3 antisense oligonucleotides, decoy 
oligonucleotides and dominant negative STAT proteins, also have been proven to be 
of great value in suppressing cancer cell growth in vitro and in vivo (Mora et al., 2002; 
Niu et al., 1999). Furthermore, the negative regulators of STAT3 and the interaction 
between STATs also provide targets for drug development. 
1.2.7 Dys-regulated apoptosis in cancer 
Cancer is a general term for the diseases in which unscheduled and uncontrolled 
expansion of somatic cells occur. Cancer cells have defects in regulatory circuits that 
govern normal cell proliferation and homeostasis (Evan and Vousden, 2001). The 
ability of malignant cells to evade apoptosis is a hallmark of cancer, and their 
resistance to apoptosis constitutes an important clinical problem.  
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A growing understanding of the mechanisms that control apoptosis has led to the 
development of promising strategies that directly target the apoptotic machinery to 
restore apoptosis in cancer cells. The therapeutic approaches could be grouped within 
the following categories: (i) restoration of caspase expression by gene transfer or 
demethylation (Fulda et al., 2001), and introduction of recombinant TRAIL (rTRAIL) 
and agonistic DR4 and DR5 mAbs (Cretney et al., 2006); (ii) small molecule for the 
activation of p53 (Yu, 2006); (iii) different strategies aiming to antagonize apoptosis 
inhibitor proteins; such as a range of XIAP antagonists including inducers of mRNA 
degradation, inhibitors of translation, disruptors of caspase binding  (Cheung et al., 
2006; Danson et al., 2007); (iv) therapeutic inhibition of pro-survival Bcl-2 proteins: 
small molecule Bcl-2 and Bcl-xL inhibitors, and BH3 mimetics (Adams and Cory, 
2007); (v) inhibition of pro-survival function of growth factors (NF-κB, STAT3 and 
PI3k/Akt etc.) (Garcia-Echeverria and Sellers, 2008). 
The success of repairing the apoptotic response in tumor cells depends on the 
extent to which anticancer therapies confine death to the cancer cells, and allow the 
survival of normal ones. However, a fundamental problem is that therapy is not 
specific enough to enable the delivery of highly toxic agents to tumor cells but spare 
normal cells. On the other hand, unlike the normal cells, cancer cells often evolve 
resistance to the drugs against them. Moreover, cancer cells vary widely in their 
response to radiation and to the cytotoxic drugs. Because of their unpredictable side 
effects and drug efficiency, combined therapies have been explored in clinical trials, 
and are definitely more effective to overcome chemo-resistance than single 
administration. 
 
1.2.8 TRAIL and TRAIL-induced apoptosis  
1.2.8.1 Introduction 
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 Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a 
member of the TNF subfamily. Unlike other TNF family members, TRAIL is a 
promising anticancer agent for its ability to selectively induce apoptosis in tumor cells 
but not in normal cells. TRAIL elicits its function by binding to its receptors on the 
cell surface. To date, four types of receptors have been identified. Death receptor 4 
(DR4) and death receptor 5 (DR5), also named as TRAIL-R1 and TRAIL-R2, have 
both an extracellular domain that binds to TRAIL, and intercellular domains with 
death domains (DDs) that trigger caspase cascade. However, another two receptors, 
death decoy receptors 1 (DcR1) and death decoy receptors 2 (DcR2), lack the 
functional intercellular domains. Therefore, DcR1 and DR2 could competitively bind 
to TRAIL but do not trigger caspase cascade and cell death (Wang and El-Deiry, 
2003). 
TRAIL induces apoptosis through recognizing and binding to its cognate death 
receptors, DR4 and DR5 on the cell surface (LeBlanc and Ashkenazi, 2003; Takeda et 
al., 2007; Wang and El-Deiry, 2003). This ligand binding initiates receptor 
conformational changes and formation of a death-inducing signaling complex (DISC) 
by further recruiting an adaptor molecule Fas-associated death domain (FADD) and 
caspase-8/10, which consequently results in the auto-activation of caspase-8/10 or 
cleavage of Bid, which then cross-talks with mitochondria to trigger the caspase-9 and 
caspase-3 and eventually leads to apoptosis (Ashkenazi, 2002; Wang and El-Deiry, 
2003). 
1.2.8.2 Regulation of TRAIL-induced cell death 
To date, effective apoptosis induction by recombinant TRAIL and anti-DR4/DR5 
mAb have been reported in human melanoma, leukemia, breast, prostate and colon 
cancer in single treatments and combination therapy with chemotherapeutic agents 
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(Buchsbaum et al., 2003; Bucur et al., 2006; Kaufmann and Steensma, 2005; 
Merchant et al., 2004; van Geelen et al., 2003; Voelkel-Johnson, 2003). However, the 
anticancer application of TRAIL is unfortunately shadowed by the fact that some 
types of cancer cells are resistant to TRAIL-induced cell death (Duiker et al., 2006; 
Dyer et al., 2007).  The resistance of cancer cells to TRAIL has been studied 
extensively. It is generally conferred by a few molecular changes in a variety of ways:  
(i) Deficient expression of cell surface death receptors, and/or excessive 
expression of decoy receptors DcR1/DcR2 (LeBlanc and Ashkenazi, 2003; Takeda et 
al., 2007; Wang and El-Deiry, 2003). A number of chemotherapeutic agents which 
induce tumor cell apoptosis through p53 activation have been reported to exert 
synergistic effect for rTRAIL treatment, due to the transcriptional regulation of p53 on 
the expression of both DR4 and DR5 (El-Deiry, 2001; Guan et al., 2001; Liu et al., 
2004). Thus, a combination of other cytotoxic drugs with TRAIL might be a more 
effective approach. 
(ii) Elevated expression of FLIP and the inhibitor of apoptosis proteins (XIAP, c-
IAP-1 and c-IAP-2), Bcl-2, Bcl-xL and Mcl-1 in cancer cells. Some tumor cells over-
express FLIP, which interferes with the caspase-8 recruitment into the DISC, and 
IAPs could directly attenuate caspase activities (Suh et al., 2003; Suliman et al., 
2001). Some tumor cells are deficient in Bax/Bak or over-express Bcl-2 and Bcl-xL 
(Cheng et al., 2001; Murphy et al., 2000; Suliman et al., 2001), which lead to the 
suppression of intrinsic pathway. Re-establishment of TRAIL-induced cell death in 
TRAIL-resistant cells is usually conveyed by the down-regulation of these anti-
apoptotic molecules. 
(iii) Constitutively activion of Akt or NF-κB in cancer cells. Several cancer cell 
lines are resistant to TRAIL due to high constitutively active Akt (Chen et al., 2001). 
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Constitutively active Akt could up-regulate FLIP (Nam et al., 2003) or block Bid 
cleavage (Chen et al., 2001; Nesterov et al., 2001), and subsequently neutralize the 
sensitivity of cancer cells to TRAIL. On the other hand, TRAIL has been reported to 
activate NF-κB in certain cancer cell lines (Oya et al., 2001; Ravi et al., 2001). NF-κB 
enhances the expression level of anti-apoptotic proteins, including Bcl-xL 
(Schoemaker et al., 2002), c-IAP-1 and c-IAP-2 (Schoemaker et al., 2002), to confer 
protection against TRAIL-induced apoptosis. However, the constitutively active NF-
κB does not always protect cells from TRAIL-induced apoptosis. NF-κB was reported 
to promote the expression of death receptors and thereby sensitize tumor cells to 
TRAIL (Ravi et al., 2001), The dual function of NF-κB may depend on cell-type 
where relative levels of RelA and c-Rel subunits determine the cell survival or death 
(Chen et al., 2003b). 
One effective strategy to overcome the resistance to TRAIL is to combine TRAIL 
with other anticancer agents, thus, identification of sensitizing agents capable of 
overcoming such resistance and establishment of TRAIL-based combination regimens 
may facilitate an improved treatment of TRAIL-resistant cancers, and there are 
already quite a number of agents that have been demonstrated to potentiate TRAIL 
cytotoxicity in cancer cells (Wang, 2008; Zhang and Fang, 2005). TRAIL-induced 
apoptosis can be enhanced via combination with various chemotherapies, which could 
up-regulate death receptor (DR4 or DR5) (Galligan et al., 2005; Jin et al., 2004), or 
with NF-κB inhibitors (Festa et al., 2009; Romagnoli et al., 2007) or with Akt 
inhibitors (Chen et al., 2009; Tazzari et al., 2008), or suppressors of anti-apoptotic 
proteins such as FLIP, XIAP and IAPs (Ricci et al., 2007; Shi et al., 2005; Zhang et 
al., 2005). Adjustments of these TRAIL signaling regulators by various agents have 
been reported to be synergistic with TRAIL-mediated apoptosis in certain tumor cells.  
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Collectively, TRAIL has been proved to be a promising anticancer agent in 
various cancer cells, either alone or in combination with conventional approaches 
such as chemotherapy or radiation therapy.  
 
1.3 Objectives of the study 
Andro is the principle active component of traditional anti-inflammatory herbal 
medicine Andrographis paniculata. At present, numerous studies have been done to 
investigate different bioactivities of Andro, including the anti-inflammatory and 
hepatoprotective functions. On the other hand, emerging evidences in recent years 
have suggested its anticancer potential. However, the underlying molecular 
mechanisms are largely unknown and no systematic study has been carried out on the 
anticancer potential of Andro. Thus, the main objective of this study is to further 
investigate the anticancer effect of Andro and the underlying mechanisms involved. 
To achieve these goals, this study sought to determine the following specific 
objectives: 
1. To elucidate the mechanisms of Andro-induced apoptosis by focusing on the 
effect of Andro on both the extrinsic death receptor and the mitochondria-
mediated apoptosis pathway. 
2. To investigate the anticancer potential of Andro by studying its sensitization 
effects on cancer cells in response to cell death stimuli such as TNF-related 
apoptosis-inducing ligand (TRAIL).  
3. To elucidate the effect of Andro on STAT3 signaling pahtway, in addition, to 
evaluate the potential synergistic effect of Andro with known therapeutic agent 
(doxorubicin). 
This study will help in understanding the anti-tumor properties of Andro, and 
provide experimental evidence to support the potential effects of this compound on 
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cancer prevention and therapy. Furthermore, the study of combined effects of Andro 
with other cancer therapeutic agents could provide useful insight on the synergistic 
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Andrographis paniculata is a traditional medicinal herb which has been widely 
prescribed for the treatments of various diseases, such as respiratory infection, fever, 
bacterial dysentery and diarrhea (Coon and Ernst, 2004; Iruretagoyena et al., 2005; 
Poolsup et al., 2004). The major bioactive constituent extracted from the aerial parts 
of the plant is Andrographolide (Andro), a bicyclic diterpenoid lactone. As shown in 
Fig. 1.1 (Chapter 1), it contains an α-alkylidene γ-butyrolactone moiety and three 
hydroxyls at C-3, C-19 and C-14 which are responsible for the bioactivities of Andro 
(Nanduri et al., 2004). In the last decade, various bioactivities of Andro have been 
described, including anti-inflammatory (Panossian et al., 2002; Xia et al., 2004), anti-
viral, and anti-hypertensive activities (Jain et al., 2000; Kumar et al., 2004). The 
underlying molecular mechanisms have also been investigated. For instance, nuclear 
transcription factor kappaB (NF-κB) is the molecular target for the anti-inflammatory 
activity of Andro (Hidalgo et al., 2005; Xia et al., 2004). Andro effectively inhibited 
the nuclear activation of NF-κB by covalent modification of reduced cysteine 62 of 
p50, to exert its potent anti-inflammatory activity (Xia et al., 2004). 
Andro’s potent anti-inflammatory property implies the anticancer potential of this 
natural product, and such a notion is supported by a number of recent studies. For 
instance, Andro has been shown to inhibit cancer cell growth and its IC50 ranges from 
10 to 28 µM, depending on the type of cancer cell tested (Kumar et al., 2004). Andro 
was also found to cause G0/G1 cell-cycle arrest through induction of p27 and 
decreased expression of cyclin-dependent kinase (CDK) 4 in some human cancer cells 
(Rajagopal et al., 2003; Satyanarayana et al., 2004). The anticancer activity of this 
compound is further substantiated by findings using in vivo B16F0 melanoma 
syngenic and HT-29 xenograft models (Rajagopal et al., 2003). The effect of Andro 
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on apoptosis is controversial. Andro is capable of protecting immune cells 
(thymocytes) or endothelial cells against apoptosis under growth factor deprivation 
(Burgos et al., 2005; Chen et al., 2004). On the other hand, a couple of very recent 
reports showed that Andro at relatively high concentrations (from 40 to 100 μM) 
could induce apoptosis in human prostatic adenocarcinoma PC-3 cells (Kim and 
Milner, 2005) or human leukemic HL60 cells (Cheung et al., 2005). In both studies, 
Andro was shown to activate the caspase cascade; however, the detailed molecular 
mechanisms of Andro-induced apoptosis are still largely unknown. This discrepancy 
of apoptosis-protecting or –inducing effect in Andro may be due to the differences on 
cell types (primary normal cells vs. cancer cell lines) and apoptotic stimulus.  
Apoptosis is a cell death process that plays a critical role in development, tissue 
homeostasis and development of various human diseases (Kaufmann and Earnshaw, 
2000; Kaufmann and Hengartner, 2001). Lack of apoptotic induction and 
inappropriate-controlled apoptosis process have been implicated in tumor 
development and progression as well as chemoresistance (Evan and Vousden, 2001). 
Two major apoptotic pathways have been identified, namely the extrinsic and the 
intrinsic apoptotic pathway. The extrinsic pathway is initiated via death receptors on 
cell membrane, leading to sequential activation of initiator caspases (caspase-8 or -2, 
12) and effector caspases (caspase-3 and -7) (Budihardjo et al., 1999). In certain cell 
types (type I), activation of caspase-8 is sufficient for activation of caspase-3, but in 
great majority of cells (type II), the effector caspases activation need the amplification 
through mitochondria which is initiated by the cleavage of Bid by caspase-8 
(Budihardjo et al., 1999; Li et al., 1998). Among many apoptotic regulatory proteins, 
the Bcl-2 family, including both anti-apoptotic (Bcl-2, Bcl-xL, Mcl-1) and pro-
apoptotic members (Bid, Bax, Bad), is particularly important (Li et al., 1998; Oltvai et 
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al., 1993). Moreover, it has been well established that there is a cross-talk between the 
death inducing signaling complex (DISC) and mitochondria via Bid, an important 
member of the Bcl-2 family proteins (Danial and Korsmeyer, 2004). In this chapter, 
the mechanisms involved in Andro-induced apoptosis by focusing on the functional 
role of the Bcl-2 family members will be elucidated. Results from the present study 
demonstrate a critical role of some pro-apoptotic Bcl-2 proteins, especially Bid and 
Bax in Andro-induced apoptosis. Understanding of the mechanisms of Andro-induced 
apoptosis could provide valuable knowledge for further development this compound 
into a potential anticancer agent. 
2.2 Materials and Methods 
2.2.1 Chemicals and reagents 
Andro, 4'-6-Diamidino-2-phenylindole (DAPI) and anti-Bax 6A7 antibodies were 
purchased from Sigma (St Louis, MO, USA). Propidium iodide (PI) was from 
Molecular Probe (Eugene, OR, USA). Antibodies against PARP, MnSOD, caspase-8, 
caspase-3 and cytochrome c were obtained from BD Pharmingen (San Diego, CA, 
USA). Anti-Bid antibody was purchased from Cell Signaling (Beverly, MA, USA) 
and anti-caspase-9 and anti-Bax antibodies were acquired from Chemicon (Temecula, 
CA, USA). Anti-tubulin antibody was obtained from Santa Cruz (Santa Cruz, CA, 
USA). pDsRed-N1 was purchased from Clontech (Palo Alto, CA, USA). The 
following reagents were all from BioMol (Plymouth meeting, PA, USA): pan caspase 
inhibitor Z-VAD-FMK, caspase-3 inhibitor Z-DEVD-CHO, caspase-8 inhibitor Z-
IETD-FMK and caspase-9 inhibitor Z-LEHD-CHO.  
2.2.2 Cell culture and treatments 
Human cervical cancer cell line HeLa, human hepatoma cell line HepG2 and 
human breast cancer cell line MDA-MB-231 were obtained from ATCC. All cells 
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were maintained in DMEM medium (Sigma) with 10 % FBS (Hyclone). Equal 
numbers of cells were seeded in full medium and switched to DMEM medium 
supplemented with 1% FBS for treatment. Same dose of DMSO was applied to 
control cells. All the inhibitors were added into the wells 1 h before Andro treatment. 
2.2.3 Detection of apoptosis 
The cells undergoing apoptosis were evaluated by two methods. First, DAPI 
staining was chosen to examine chromatin condensation, which is characteristic for 
apoptosis (Shi et al., 2005). Briefly, after designated treatments, medium was 
removed and cells were washed and fixed with 70% ethanol at room temperature for 
10 min. After staining with 0.3 μg/mL DAPI (in PBS) at room temperature for 10 min, 
cell nucleus were visualized under an inverted fluorescence microscope and 
photographed (Nikon ECLIPSE TE2000-S, Nikon Instruments, Tokyo, Japan). 
Second, apoptotic cells were quantified using DNA content analysis to determine 
percentage of sub-G1 cells (Darzynkiewicz et al., 1992). At the end of designated 
treatments, cells were collected and washed with PBS twice, then fixed and 
permeabilized in 70% ice-cold ethanol for 2 h. Fixed cells were incubated with PI 
staining buffer (0.1% TritonX-100, 200 μg/mL RNase A and 20 μg/mL PI in PBS) for 
15 min at 37°C followed by flow cytometry analysis. 
2.2.4 Caspase-3/7 activity assay 
Caspase-3/7 activity was examined using Apo-One™ Caspase-3/7 Assay Kit 
(Promega). Experiment was conducted following manufacturer’s instruction. Briefly, 
cells were subcultured into 96-well plate in the medium containing 1% FBS for 12 h 
before Andro treatment. At the end of designated treatment, z-DEVD-rhodamine 110 
substrate was added into the wells directly. After 4 h incubation at room temperature, 
the fluorescence intensity was measured by a plate reader (Tecan Spectra Flour Plus) 
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at excitation 492 nm and emission 535 nm. 
2.2.5 Cell subfractionation  
Cell subfractionation was performed as described previously (Zhang et al., 2004). 
Cells were first collected and washed with cold PBS once, then resuspended in 
isotonic homogenization buffer (250 mM sucrose, 10 mM KCl, 1.5 mM MgCl2, 1 
mM Na – EDTA, 1 mM DTT, 0.1 mM PMSF, 10 mM Tris-HCl, pH 7.4) containing 
protease inhibitor cocktail (Roche). Cells were incubated on ice for 10 min and then 
passed through gauge #27 needle for 20 times to break the cell membrane. The cell 
homogenates were applied to a series of centrifugation at 50 g for 10 min, 500 g for 
20 min and 15,000 g for 20 min to fractionate unbroken cells, heavy nuclear fraction 
and mitochondria fraction, respectively. After the final centrifugation at 100,000 g for 
30 min, the supernatant was collected as the cytosol fraction. Equal amount of 
mitochondrial and cytosol proteins were subjected to western blot. 
2.2.6 Immunoprecipitation and western blot 
For immunoprecipitation, cells were lysed in CHAPS lysis buffer (10 mM Hepes, 
pH 7.4, 150 mM NaCl, 1% CHAPS) containing protease inhibitors (Yamaguchi et al., 
2002). The cell lysates were normalized for protein content and 500 μg of total protein 
were incubated with 2 μg of anti-Bax 6A7 monoclonal antibody in 500 μl of CHAPS 
lysis buffer overnight at 4°C. Then, 25 μl of protein G-agarose were added into the 
reactions and incubated at 4°C for additional 3 h. After three washings in CHAPS 
lysis buffer, beads were boiled in loading buffer containing 5% β-mercaptoethanol 
and the conformational changed Bax proteins in the immunoprecipitates were 
subjected to western blot analysis with anti-Bax polyclonal antibody.  
For western blot, cells were first lysated in cell lysis buffer (50 mM Tris-HCl pH 
8.0, 150 mM EDTA, 1% TritonX-100, 0.5% SDS and protease inhibitor cocktail) and 
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equal amount of proteins were fractionated on SDS-PAGE gel in the Mini-PROTEAN 
II system (Bio-RAD) and blotted onto PVDF membrane (Millipore). After blocked 
with 5% nonfat milk in TBST (10 mM Tris-HCl, pH 7.5, 100 mM NaCl and 0.1% 
Tween 20), the membrane was probed with various antibodies and developed with 
enhanced chemiluminescence (Pierce) using a Kodak Image Station 440CF (Kodak). 
The density of the various bands in western blot was quantified using the Kodak 
Image Station 440CF software (Kodak). 
2.2.7 Transient transfection and siRNA-mediated protein knock-down 
HeLa cells were seeded in 12-well plate overnight before transfection. Cells were 
co-transfected with pcDNA3.1 control vector, Bcl-2 or CrmA expression vector (a 
kind gift from Dr ZG Liu, NCI, USA) together with the pDsRed-N1 vector (Clontech) 
using Lipofectamine™ 2000 (Invitrogen) according to the manufacture’s 
recommendations. For siRNA experiments, negative control siRNA, validated siRNA 
duplex targeting human Bid and Lamin A/C were purchased from QIAGEN. HeLa 
cells were first seeded in DMEM medium without antibiotics in a 24-well plate 
overnight before transfection. Ready-to-use siRNA was mixed with 50 μl medium 
containing Lipofectamine 2000 (1 μl/well) to achieve a final concentration of siRNA 
at 10 nM. The mixture was incubated at room temperature for 20 min to allow the 
formation of transfection complexes. The formed mixture was then added into the 
well and incubated for 4 h before it was replaced by fresh DMEM medium. The 
transfected cells were treated with Andro 72 h after transfection, and apoptotic cell 
death was evaluated by DAPI staining.  
2.2.8 Immunofluorescence and confocal microscopy 
HepG2 cells were seeded in 8-well chamber slides 24 h before treatment. At the 
end of treatments, cells were washed with PBS and fixed in 3% paraformaldehyde for 
 58
1 h. After permeablized for 2 min with 0.2% CHAPS in PBS, cells were blocked in 
2% BSA with 0.2% Tween-20 for 30 min and further incubated with anti-Bax 6A7 
antibody overnight at 4°C. After washed with buffer (PBS+0.2% Tween-20) cells 
were incubated with anti-mouse Alexa 633 secondary antibody for another 1 h. Cover 
slips were mounted onto slides using ProLong anti-fade mounting reagent (Molecular 
Probes). Cells were visualized under Olympus FLOVIEW V500 confocal microscope. 
The intensity of Bax 6A7 staining was measured in ten randomly selected fields with 
Image-Pro-Plus (Media Cybernetics) and the relative fluorescence intensity (arbitrary 
unit) were presented as means ± SD. 
2.2.9 Statistical analysis 
All numerical data were presented as mean ± SD from at least 3 independent 
experiments. Student's t test was used to analyze statistical difference. p values less 
than 0.05 were considered significant. 
2.3 Results  
2.3.1 Andro induces apoptosis in human cancer cells 
To explore the anticancer potential of Andro, three types of human cancer cell 
lines (human hepatoma cell HepG2, human cervical cancer cell HeLa and human 
breast cancer cell MDA-MB-231) were treated with different concentrations of Andro. 
After 24 h treatment, the apoptotic cell death induced by Andro was identified by 
typical nuclear condensation visualized with DAPI staining. Fig. 2.1A demonstrated a 
dose-dependent pattern of Andro-induced apoptotic cell death in three cancer cell 
lines. Andro-induced apoptosis was further examined using DNA content analysis. As 
shown in Fig. 2.1B, in HepG2 cells the dose-dependent increase of sub-G1 cells was 
basically consistent with the results in Fig. 2.1A. Furthermore, a typical 87 kD PARP 
cleavage product, a hallmark of apoptosis (D'Amours et al., 1999), was observed in 
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HepG2 cells upon Andro treatment in a time- and dose-dependent manner (Fig. 2.1C). 
However, Andro demonstrated no cytotoxic effect on mouse embryo fibroblasts (MEF) 
(Fig. 2.2), suggesting its specific apoptosis-inducing effect in tumor cells.  
2.3.2 Caspase cascade in Andro-induced apoptosis 
To determine the involvement of caspase cascade in Andro-induced apoptosis, I 
first examined the caspase activation by performing Apo-One™ Caspase-3/7 assay. 
As shown in Fig. 2.3A, around 8 fold increases of caspase-3/7 activity were observed 
after treatment with Andro for 12 h. Cells treated with TNF-α were used as a positive 
control.  
Consistent with this observation, the cleavage of caspase-3 from proform into its 
active form (p17) was detected by western blot after Andro treatments (Fig. 2.3B). In 
order to determine the involvement of the initiator caspases upstream of caspase-3, I 
measured the activation of the two initiator caspases: caspase-8 in the death receptor 
pathway and caspase-9 in the mitochondrial pathway. A dose-dependent cleavage of 
caspase-8 and decrease of proform of caspase-9 were detected (Fig. 2.3B). The 
involvement of the caspase cascade in Andro-induced apoptosis was further studied 
by applying different caspase inhibitors in Andro-treated cells. Both pan-caspase 
inhibitor Z-VAD-FMK and the specific inhibitors for caspases-8, -9 and -3 could 
effectively block the PARP cleavage (Fig. 2.4A) as well as Andro-induced apoptotic 
cell death as detected by DAPI staining (Fig. 2.4B).  
All these findings demonstrated that Andro-induced apoptosis involves key 






Fig 2.1 Andro induces apoptosis in human cancer cell lines.  
 
(A), Human cancer cells were treated with Andro for 24 h. The percentage of cells 
with evident nuclear condensation in 200 randomly selected cells was presented. 
Inserted are representative images of HeLa cells photographed under a normal light 
microscope (upper panel) or cells with DAPI staining under an inverted fluorescence 
microscope (lower panel) (magnification × 200 times). (B), HepG2 cells were treated 
with various concentrations of Andro for 24 h. At the end of treatment, cells were 
collected and fixed with 70% ice ethanol, and flow cytometry analysis was used to 
show the percentage of sub-G1 cells. Inserted images are typical histograms showing 
the sub-G1 peak in cells. Data were presented as mean ± SD from three independent 
experiments (**: p<0.01 when compared to the control group). (C), HepG2 cells were 
treated with designated concentrations of Andro for 6 h, 12 h or 24 h, and the PARP 
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Fig 2.2 Andro shows no cytotoxicity in MEF cells.  
 
(A), MEF cells were treated with various concentrations of Andro for 24 h, and 
apoptotic cell death was evaluated by DAPI staining as described in Fig. 2.1A. 
Representative images of MEF cells photographed under a normal light microscope 
(upper panel) or cells with DAPI staining under an inverted fluorescence microscope 
(lower panel) (magnification × 200 times). (B), Both MEF and HeLa cells were 
treated for 24 h with indicated concentrations of Andro. The percentage of cells with 
evident nuclear condensation in 200 randomly selected cells was presented. Data were 
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Fig 2.3 Andro promotes caspase activation.  
 
(A), Caspase-3/7 like activity was measured by Apo-One™ Caspase-3/7 Assay Kit. 
HepG2 cells were cultured in the 96-well plate and treated with Andro (50 μM) for 12 
h. TNFα (20 ng/mL + CHX 25 ng/mL) for 6 h was used as a positive control. Data 
were presented as mean ± SD from three independent experiments and analyzed by 
using Student’s t-test (**: p<0.01 when compared to the control group). (B), The 
caspase-8, -9 and -3 activation after Andro treatment were detected by Western blot. 
HepG2 cells were treated with Andro at indicated concentrations for 24 h. Treatment 
with CHX + TNFα for 6 h was used as a positive control. Data were representative of 
three independent experiments.  
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Fig 2.4 Andro induced caspase-dependent apoptosis. 
 
(A), HepG2 cells were pretreated with Z-VAD-FMK (25 μM), Z-DEVD-CHO (50 
μM), Z-LETD-FMK (50 μM) or Z-LEHD-CHO (50 μM) for 1 h followed with Andro 
(50 μM) treatment for 24 h. PARP cleavage was detected by Western blot. (B), 
Apoptotic cell death was evaluated by DAPI staining as described in Fig. 2.1A. (**: 
p<0.01 when compared to control group; ##: p<0.01 when compared to the Andro-
treated only group) (magnification × 200 times). Data were representative of three 
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2.3.3 Andro induces Bid cleavage following caspase-8 activation 
It has been well established that Bcl-2 family proteins play pivotal roles in 
regulation of apoptotic pathways (Rupniewska and Bojarska-Junak, 2004). Among 
these proteins, Bid, a pro-apoptotic Bcl-2 family member, provides a critical step 
cross-linking the extrinsic cell death receptor signaling pathway to mitochondria upon 
caspase-8-mediated cleavage (Danial and Korsmeyer, 2004). In this study, activation 
of the two initiator caspase-8 and -9 prompted us to examine the involvement of Bid 
and other Bcl-2 family members in Andro-induced apoptosis. After the treatment with 
Andro, I first observed a dose- and time-dependent decrease of full length Bid protein 
(Fig. 2.5A). More importantly, as shown in the Fig. 2.5B, when cells were pretreated 
with pan-caspase inhibitor (Z-VAD-FMK) or caspase-8 inhibitor (Z-IETD-FMK), the 
decrease of full length of Bid caused by Andro was prevented, suggesting that Bid 
cleavage is mediated by caspase-8 activation.  
2.3.4 Andro induces Bax conformational change  
It has been reported that pro-apoptotic Bax is closely related with Bid and 
undergoes a conformational change and consequent mitochondrial translocation 
during apoptosis (Kuwana et al., 2005). In this study, I examined the Bax changes 
induced by Andro treatment. By using the Bax (6A7) monoclonal antibody, which 
specifically recognizes the Bax protein with conformational change but not the native 
form (Hsu and Youle, 1997), there was a time-dependent increase of Bax staining in 
Andro-treated cells, suggesting the conformational change of Bax (Fig. 2.6A). Being 
consistent with this observation, I also detected the increase of Bax protein with 
conformational changes using immunoprecipitation with the Bax (6A7) antibody (Fig. 
2.6B). Furthermore, as shown in Fig. 2.6C, Bax conformational changes were proven 
to be caspase-8-dependent, as pretreatment with caspase-8 inhibitor (Z-IETD-FMK) 
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almost completely abolished the Andro-induced conformational changes of Bax. 
2.3.5 Andro induces Bax translocation and cytochrome c release 
To further examine the effect of Andro on mitochondria, I studied the 
mitochondrial translocation of Bax (Fig. 2.7A) and the release of cytochrome c from 
the mitochondria (Fig. 2.7B). Starting from 4 h, there was a time-dependent 
progressive increase of Bax in the mitochondrial fraction and the concurrent increase 
of cytochrome c release from mitochondria to the cytosol in the Andro-treated cells. 
Such a finding is consistent with the previous reports that the integration of Bax in the 
outer membrane followed by cytochrome c release is a possible prerequisite for 
mitochondrial apoptotic pathway (Eskes et al., 2000). 
2.3.6 Knockdown of Bid expression protects cell from Andro-induced cell death 
In order to confirm the critical role of Bid in Andro-induced apoptotic cell death, I 
manipulated Bid protein level by using siRNA technology. Transient transfection of 
siRNA duplex specifically targeting human Bid gene resulted in a significant 
reduction of Bid protein level comparing to the negative control siRNA transfection 
(Fig. 2.8A). As a result, there was no pronounced Bax staining (by Bax 6A7 antibody) 
in Bid siRNA transfected cells (Fig. 2.8B), different from the observation on the 
negative control siRNA transfected cells, suggesting that the Bax conformational 
changes were triggered by Bid cleavage following Andro treatment.  
Moreover, knockdown of Bid protein level also offered significant resistance to 
Andro-induced apoptosis (Fig. 2.8C), which supports the notion that Bid-Bax 
signaling plays a critical role in Andro-induced apoptosis. 
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Fig 2.5 Andro-induced Bid cleavage following caspase-8 activation in HepG2 
cells.  
 
(A), Andro-induced Bid cleavage detected by Western blot. HepG2 cells were treated 
with Andro (50 μM) for indicated times (upper panel). In the lower panel, HepG2 
cells were treated with Andro in designated concentrations for 6 h. (B), Andro-
induced Bid cleavage was blocked by caspase inhibitors. HepG2 cells were pretreated 
with caspase-8 inhibitor (Z-IETD-FMK) or pan-caspase inhibitor (Z-VAD-FMK) for 
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Fig 2.6 Bax conformational change following caspase-8 activation in HepG2 cells.  
 
(A), Following treatment with Andro (50 μM) for indicated time, Bax conformational 
changes were determined by immunofluorescence staining using a mouse anti-Bax 
6A7 antibody. The nuclei were counterstained with DAPI. (B), HepG2 cells were 
treated as panel A and subjected to immunoprecipitation with anti-Bax 6A7 antibody 
followed by Western blot analysis with anti-Bax polyclonal antibody. Parthenolide (25 
μM, 8 h) was used as positive control (Zhang et al., 2004). (C), HepG2 cells were 
treated with Andro (50 μM) with/without pretreatment of Z-IETD-FMK. The intensity 
of Bax 6A7 staining was measured in ten randomly selected fields and the relative 
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Fig 2.7 Andro induces Bax mitochondrial translocation and cytochrome c release 
in HepG2 cells.  
 
(A), Mitochondrial translocation of Bax. HepG2 cells were exposed to Andro (50 μM) 
for 0, 4, 8 or 12 h and subjected to subcellular fractionation for mitochondria-rich 
fraction and cytosol. (B), Cytochrome c release upon Andro treatments. HepG2 cells 
were treated with Andro (50 μM) for 4 h, 8 h or 12 h respectively and cytosolic 
fraction was subject to Western blot for detection of cytochrome c release. MnSOD 
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Fig 2.8 Down-regulation of Bid inhibited the Bax conformational changes. 
 
(A), HeLa cells were transfected with various siRNA duplexes for 72 h and Bid 
protein level were evaluated by Western blot. (B), After transfection as described 
above, cells were treated with Andro (50μM) for 12 h. The conformational changes of 
Bax were visualized by immunofluorescence as mentioned in Fig. 2.5. (C), HeLa cells 
were transfected and treated as panel B. Cells under apoptotic cell death were counted 
under an inverted fluorescence microscope after DAPI staining (mean ± SD from at 
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2.3.7 Bcl-2 and CrmA over-expression block Andro-induced apoptosis 
In addition to pro-apoptotic Bcl-2 family proteins, I further examined the 
involvement of the anti-apoptotic Bcl-2 protein. It is known that Bcl-2 is a 
mitochondrial protein that inhibits apoptotic process and promotes cell survival by 
heterodimerization with pro-apoptotic Bcl-2 family members such as Bax (Hengartner, 
2000; Yi et al., 2003). As shown in Fig. 2.9, over-expression of Bcl-2 effectively 
inhibited the Andro-induced apoptotic death. This observation strongly supports the 
notion that Bcl-2 family members including both the anti-apoptotic and pro-apoptotic 
proteins are critical regulators in Andro-induced apoptosis. Finally, in order to 
confirm the initiating function of caspase-8 activation in the mitochondrial apoptotic 
pathway induced by Andro, I overexpressed a specific caspase-8 inhibitor protein 
(CrmA) in HeLa cells. In Fig. 2.9A, those successfully transfected cells were 
visualized in red and the living cells maintained the normal morphology while the 
dead cells appeared rounded and shrinked. It is evident that over-expression of CrmA 
protein remarkably protected the cell from apoptotic death caused by Andro. The 
above data were quantified by counting the percentage of dead cells among the 
transfected cells (Fig. 2.9B). Data from this part of the experiment further 
demonstrate that Andro is capable of utilizing the death receptor pathway in the 




Fig 2.9 Ectopic expression of Bcl-2 and CrmA block Andro-induced apoptosis in 
HeLa cells.  
 
(A), HeLa cells were transiently transfected with pcDNA, CrmA or Bcl-2, together 
with pDsRed as a transfection marker. 48 h after transfection, cells were treated with 
Andro (50 μM) for another 24 h. Cell death was then evaluated by morphological 
changes under a fluorescent microscope and those successfully transfected cells were 
in bright red. (B), Quantification of cell death by counting the percentage of dead cells 
among those transfected cells in total of randomly selected 200 transfected cells. Data 
are presented as mean ± SD from 3 independent transfection experiments (**: p<0.01 









































Although the medicinal herb Andrographis paniculata has been used for centuries 
as an anti-inflammatory medicine, its anticancer property has not been well studied. 
Recently, Andro, the main active component of this herbal medicine, has been found 
to be able to inhibit cancer cell proliferation (Satyanarayana et al., 2004), induce cell 
cycle arrest (Rajagopal et al., 2003; Satyanarayana et al., 2004) and promote 
apoptosis (Cheung et al., 2005; Kim and Milner, 2005) in human cancer cells. 
However, there are a number of important issues regarding the effect of Andro on 
apoptosis remaining to be further elucidated. First, Andro may inhibit or promote 
apoptosis depending on various factors such as the cell type and the nature of the 
apoptotic stimuli. For instance, Andro is capable of protecting endothelial cells 
against apoptosis induced by growth factor deprivation via activation of the PI3K-
AKT pathway (Chen et al., 2004). Second, the molecular mechanism underlying 
Andro-induced apoptosis in cancer cells has not been fully investigated. In this part of 
study, I examined the mechanisms of Andro-induced apoptosis by focusing on the 
caspase cascade and the regulatory role of the Bcl-2 family members. The results 
from this study suggest that Andro-induced apoptotic cell death by the receptor 
apoptotic pathway leads to the apoptotic activation of mitochondria which facilitates 
the release of apoptotic factors and thus amplifies the caspase cascade. More 
importantly, Bid and Bax, two pro-apoptotic Bcl-2 family members are critical 
mediators relaying the death signal from the initiator caspase-8 to caspase-9 and 
eventually the effector caspase-3 and apoptotic cell death in cancer cells. 
One intriguing finding from this chapter is that the apoptotic cell death induced by 
Andro was initiated by the extrinsic death receptor pathway, based on the 
observations that Andro activated caspase-8 and both synthetic caspase-8 inhibitor (z-
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IETD-FMK) (Fig. 2.4B) and CrmA, a viral caspase-8 inhibitory protein (Muzio et al., 
1997), were able to prevent Andro-induced apoptosis (Fig. 2.9). Such a mechanism of 
action by Andro is indeed similar to a number of other natural products that have been 
shown to induce apoptotic via the death receptor apoptotic pathway. For instance, 
ajoene, an extract from garlic, kills HL-60 cells via activation of the initiator caspase-
8 (Dirsch et al., 2002).  Prodelphinidin B-2 3, 3'-di-O-gallate from Myrica rubra 
induces the apoptosis in MCF-7 cells through the Fas/FasL system (Kuo et al., 2004). 
Similarly, the apoptosis triggered by the water extract of Phyllanthus urinaria is also 
mediated through Fas ligand/receptor (Huang et al., 2004). The exact mechanisms by 
which the extrinsic apoptosis pathway is activated by those natural products are 
mostly elusive. One possibility is that Andro may augment caspase-8 activation via its 
inhibitory effect on NF-κB activation, based on an earlier observation that Andro is 
able to inhibit NF-κB by covalent modification of reduced cysteine 62 of p50 in 
immuno cells (Xia et al., 2004). It has been well established that NF-κB is generally 
acting as a powerful anti-apoptotic factor via up-regulation of an array of anti-
apoptotic genes (Micheau et al., 2001). One of such target genes is cellular FLICE-
inhibitory protein (c-FLIP) which is capable of directly inhibiting caspase-8 activation 
(Thome and Tschopp, 2001). Therefore, suppression of NF-κB signaling pathway will 
lead to down-regulation of c-FLIP and increased activation of caspase-8 (Chang et al., 
2006). In this study, Andro did not affect the basal level of NF-κB activation in the 
cancer cells tested (data not shown). Nevertheless, it remains to be further 
investigated whether the inhibitory effect of Andro on NF-κB is involved in apoptosis 
in cells with stimulated NF-κB pathway.  
 An earlier study by Kim et al on Andro provided some preliminary evidence 
showing the activation of caspase-8 and caspase-3, without examining the detailed 
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mechanism contributing to Andro-induced apoptosis (Kim and Milner, 2005). In this 
study, I further examined the apoptotic cell death process following the activation of 
the initiator caspase-8. It was found that the protein level of full length Bid was 
significantly decreased upon Andro treatment (Fig. 2.5A). As expected, such a change 
was prevented by the pretreatment of the caspase-8 inhibitor Z-IETD-FMK and the 
pan-caspase inhibitor Z-VAD-FMK (Fig. 2.5B), suggesting that caspase-8 was 
responsible for Bid cleavage in Andro-treated cells. It has been well established that 
caspase-8-mediated Bid cleavage and subsequent Bid mitochondrial translocation 
mediate mitochondria alteration in response to activation of cell surface death 
receptor (Li et al., 1998; Luo et al., 1998). One of the key molecules in response to 
Bid cleavage and mitochondrial translocation is Bax: Bax undergoes transformation 
and oligomerization to form pores in the outer mitochondrial membrane, leading to 
the release of pro-apoptotic proteins from mitochondria, such as cytochrome c (Cory 
and Adams, 2002; Kuwana et al., 2005). Therefore, I next focused on the involvement 
of Bax in Andro-induced apoptosis, with the following observations: First, there was a 
striking conformational change of Bax detected in Andro-treated cells with the 
conformation-specific antibody 6A7 in both immunohistochemistry staining (Fig. 
2.6A) and immunoprecipitation assay (Fig. 2.6B). Second, in the cell fractionation 
experiments, significant amount of Bax accumulated in mitochondria following 
Andro treatment (Fig. 2.7A). Different from an earlier observation in which Andro 
enhanced Bax protein expression (Cheung et al., 2005), no change of the total Bax 
protein level was found in this study (data not shown) suggesting that Andro-induced 
apoptosis is mainly regulated via Bid cleavage-associated Bax transformational 
alteration, but not via up-regulation of Bax.  
As mentioned above, Bax has been considered as one of the most important pro-
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apoptotic Bcl-2 members promoting mitochondrial apoptotic pathway (Kuwana et al., 
2005). One important underlying mechanism of the pro-apoptotic function of Bax is 
to promote the release of pro-apoptotic factors such as cytochrome c from 
mitochondria (Desagher and Martinou, 2000; Eskes et al., 2000). It has been proposed 
that Bax may stimulate the opening of the permeability transition pore (PTP) through 
interaction with the adenine nucleotide translocator. As a result of PTP opening, 
mitochondria would swell, leading to rupture of the outer mitochondrial membrane 
and release of cytochrome c (Eskes et al., 2000). In this study, Bax mitochondrial 
translocation was accompanied by the concurrent release of cytochrome c in Andro-
treated cells (Fig. 2.7B). Furthermore, it is known that Bax’s proapoptotic activity is 
subject to the regulation by other Bcl-2 family members. For instance, the anti-
apoptotic Bcl-2 protein is able to block apoptosis by binding to Bax to form Bcl-2-
Bax heterodimers (Murphy et al., 2000). In this study, overexpression of Bcl-2 protein 
offered significant protection against Andro-induced apoptosis (Fig. 2.8). Andro has 
been shown to down-regulate the expression of Bcl-2 protein (Cheung et al., 2005). It 
is thus believed that in Andro-treated cells, the pro-apoptotic function of Bid and Bax 
overruns the anti-apoptotic function of Bcl-2, leading to apoptosis. 
In order to further elucidate the role of Bid-Bax in Andro-induced apoptosis, I 
manipulated the Bid protein level by using the siRNA technology. It is clear that the 
knockdown of Bid protein level gave rise to two important consequences: reduction of 
Bax transformation (Fig. 2.8B) and protection from apoptotic cell death (Fig. 2.8C). 
These results thus strengthen our argument that Bid and Bax play key role in the 
apoptotic signaling initiated by Andro. Although our data clearly suggest that Bid is a 
critical upstream regulator of the pro-apoptosis function of Bax, Bax activation and 
translocation also can be initiated by other mechanisms: (i) direct activation of Bax by 
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Bim (Kuwana et al., 2005); (ii) enhanced Bax expression induced by tumor 
suppressor p53 (Miyashita and Reed, 1995). Further studies are required to elucidate 
the role of other Bcl-2 family members in Andro-induced apoptosis.  
Taking together, data from this part of study provide convincing evidence that the 
pro-apoptotic Bcl-2 family members (Bid and Bax) are the key mediators in relaying 
the cell death signaling initiated by Andro from caspase-8 to mitochondria and then to 
downstream effector caspase, and eventually leading to apoptotic cell death. 
Understanding the molecular mechanisms underlying Andro-induced apoptosis in 
cancer cells may provide new insights for further investigation and development of 























ANDRO SENSITIZES CANCER CELLS TO TRAIL-INDUCED APOPTOSIS 


















Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) is a 
member of the TNF subfamily. TRAIL is a promising anticancer agent for its ability 
to selectively induce apoptosis in tumor cells but not in normal cells (Hall and 
Cleveland, 2007; Wang and El-Deiry, 2003). TRAIL-based therapies are now in Phase 
I and II clinical trials (Huang and Sheikh, 2007). TRAIL induces apoptosis through 
recognizing and binding to its cognate death receptors, DR4 and DR5 (also named as 
TRAIL-R1 and TRAIL-R2) on the cell surface (Huang and Sheikh, 2007; Wang and 
El-Deiry, 2003). This ligand binding initiates receptor conformational changes and 
formation of a death-inducing signaling complex (DISC) by further recruiting an 
adaptor molecule Fas-associated death domain (FADD) and caspase-8/10, which 
consequently results in the autoactivation of caspase-8/10 to trigger the caspase 
cascade and eventually leads to apoptosis.  
However, the anticancer application of TRAIL is unfortunately shadowed by the 
fact that some types of cancer cells are resistant to TRAIL-induced cell death (Duiker 
et al., 2006; Dyer et al., 2007). This resistance is generally conferred by a few 
molecular changes, such as lower expression of cell surface death receptors, and/or 
higher expression of anti-apoptotic molecules (e.g. decoy receptors, FLICE-like 
inhibitory protein (FLIP) and X-linked inhibitors of apoptosis proteins (XIAP)) 
(LeBlanc and Ashkenazi, 2003; Shankar and Srivastava, 2004). Thus, identification of 
sensitizing agents capable of overcoming such resistance and establishment of 
TRAIL-based combination regimens may facilitate an improved treatment of TRAIL-
resistant cancers. A number of sensitizing agents have been reported, including 
histone deacetylase inhibitors (Inoue et al., 2004), cyclin-dependent kinase inhibitors 
(Palacios et al., 2006), proteasome inhibitors (Ganten et al., 2005), and Myc 
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oncoprotein and the Raf kinase inhibitor (Ricci et al., 2007). Previous work in our 
laboratory has also identified several phytochemicals to be effective in overcoming 
TRAIL resistance, such as luteolin by degradation of XIAP (Shi et al., 2005) and 3,3’-
diindolylmethane by down-regulation of FLIP (Zhang et al., 2005).  
I previously have reported that Andro is capable of utilizing the death receptor-
mediated apoptotic pathway to induce apoptosis in human cancer cells in chapter 2. In 
the present study, I demonstrate that Andro sensitizes TRAIL-induced apoptosis in 
TRAIL-resistant human cancer cells. Such sensitization effect is achieved through 
p53-dependent transcriptional up-regulation of DR4, a process mediated by a number 
of sequential events including ROS production, JNK activation, p53 phosphorylation 
and stabilization. Results from this study thus present a novel function of Andro as a 
potent sensitizer for TRAIL-induced apoptotic cell death. 
3.2 Materials and Methods  
3.2.1 Chemicals, reagents, and antibodies  
Andro, 4', 6-diamidino-2-phenylindole (DAPI), and other common chemicals 
were all purchased from Sigma-Aldrich (St. Louis, MO). Human recombinant TRAIL 
(carrier free) was from R&D Systems (Minneapolis, MN). Pan-caspase inhibitor Z-
VAD-FMK, caspase-8 inhibitor Z-IETD-CHO and caspase-3 inhibitor Z-DEVD-CHO 
were from Biomol (Plymouth Meeting, PA). JNK inhibitor SP600125 was from 
Calbiochem (San Diego, CA). Trizol RNA extraction kit and LipofectAMINE 2000 
transfection reagent were from Invitrogen (Carlsbad, CA). Anti-p53, anti-
phosphorylated p53 (Thr81 and Ser20), anti-caspase-3, anti-caspase-8, anti-survivin, 
anti-Bcl-2, anti-Bcl-xL and anti-Mcl-1 antibodies were from Cell Signaling (Beverly, 
MA). The anti-XIAP and anti–poly (ADP-ribose) polymerase (PARP) antibody were 
from BD PharMingen (Los Angeles, CA). Anti-DR4, anti-DcR1, anti-DcR2, anti-c-
 80
IAP-1, anti-c-IAP-2 and anti-α-tubulin antibodies were from Santa Cruz 
Biotechnology (Santa Cruz, CA). Anti-DR5 antibody was from Chemicon (Temecula, 
CA). Anti-FLIP antibody, anti-DR4 and anti-DR5 antibodies used for receptor 
blockage were purchased form Alexis (Gruenberg, Germany). Antibodies against DR4 
and DR5 used for flow cytometry were from eBioscience (San Diego, CA). The 
secondary antibodies (horseradish peroxidase–conjugated goat anti-mouse IgG and 
rabbit anti-goat IgG) and the enhanced chemiluminescence substrate were from Pierce 
(Rockford, IL).  
3.2.2 Cell culture and treatments 
Human liver cancer cells HepG2 and Hep3B, human cervical cancer cells HeLa, 
human colorectal cancer cells HCT116 were all obtained from the American Type 
Culture Collection (Manassas, VA). An isogenic pair of HCT116 colon cancer cell 
lines was kindly provided by Dr. Bert Vogelstein (Johns Hopkins University, 
Baltimore, MD) (Bunz et al., 1998). All cell lines were maintained in DMEM (Sigma-
Aldrich) supplemented with 100 U/mL penicillin, 100 μg/mL streptomycin and 10% 
FBS (Hyclone, Logan, UT) under standard incubator condition (37°C, 5% CO2). 
Andro was dissolved in dimethyl sulfoxide (DMSO) at 100 mM as stock solution and 
human recombinant TRAIL was prepared in PBS containing 0.1% bovine serum 
albumin at 50 mg/mL. In all treatments, the control group was treated with the same 
amount of DMSO. 
3.2.3 Detection of apoptosis  
The DAPI staining for morphological changes was carried out as described earlier 
(section 2.2.3). 
3.2.4 RNA interference  
For the RNA interference study, synthetic small interfering RNA (scrambled 
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siRNA and p53 siRNA) were obtained from QIAGEN (Valencia, CA). The cellular 
delivery of siRNA was carried out by using LipofectAMINE 2000 according to the 
manufacture’s recommendations, as described earlier in Chapter 2. 
3.2.5 Immunoblot analysis  
The Western blotting was carried out as described earlier (section 2.2.6). 
3.2.6 Measurement of intracellular ROS  
Production of intracellular ROS was examined by CM-H2DCFDA (Molecular 
Probe) as described previously (Lu et al., 2007). Cells were loaded with 10 μM CM-
H2DCFDA for 30 min in culture medium at 37°C, followed with the treatments as 
indicated. After designated treatments, cells were collected and the fluorescence 
intensity was analyzed using the flow cytometer (BD Biosciences) with excitation at 
488 nm and emission at 525 nm. 
3.2.7 Measurement of cell surface expression of death receptors  
The DR4 and DR5 cell surface expression was determined by flow cytometry as 
described previously with minor modification (Earel et al., 2006). Briefly, after 
designated treatments, cells in 6-well plates were collected with non-enzyme 
dissociation buffer (Sigma–Aldrich), and washed with PBS. 5×105 cells were 
incubated with 100 μl staining buffer containing saturating amounts of anti-DR4 or 
anti-DR5 antibody at room temperature for 30 min. After incubation, cells were 
washed twice with staining buffer and analyzed by flow cytometer with excitation at 
488 nm and emission at 575 nm.  
3.2.8 RNA extraction and reverse transcription-PCR  
RNA extraction was carried out by Trizol extraction using a total RNA extraction 
kit (Invitrogen, Carlsbad, CA) following the instructions from the manufacturer. Total 
RNA (1 μg) from each sample was subjected to reverse transcription using M-MLV 
 82
reverse transcriptase (Promega). For PCR, the amplification reaction was carried out 
with 200 pmol of each primer, 200 μM of each dNTPs, and 0.5 units Taq DNA 
polymerase II (Promega, Madison, WI). The reverse transcription-PCR primers used 
for GAPDH, p53, DR4 and DR5 were based on our previous report (Zhang et al., 
2005). PCR products were size fractionated using 1.0% agarose gel and visualized by 
ethidium bromide staining. 
3.3 Results 
3.3.1 Andro sensitizes TRAIL-induced apoptosis  
I first tested the cytotoxicity of TRAIL in human cancer cells originated from 
various tissues, including human hepatoma cells HepG2, human cervical cancer cells 
HeLa and colorectal cancer cells HCT116. As shown in Fig. 3.1A, these three cell 
lines show different sensitivity to TRAIL-induced cell death. HeLa and HCT116 cells 
are sensitive to as low as 2.5 ng/mL of TRAIL. In contrast, HepG2 cells are rather 
resistant to TRAIL-induced apoptosis even at a much higher concentration (20 
ng/mL). In contrast, Andro alone exhibits a similar dose-dependent cytotoxicity in 
both TRAIL-resistant cells and TRAIL-sensitive cells (with a IC50 approximately at 
60 μM, Fig. 3.1B).  
To evaluate whether Andro could sensitize TRAIL-induced cell death, I treated 
three cell lines with the combination of Andro and TRAIL. As shown in Fig. 3.2, 
when the cells were pretreated with Andro (7.5-30 μM) for 2 h followed by a low-
cytotoxic concentration of TRAIL for 12 h, all these three cell lines tested underwent 
dramatic apoptotic cell death as evidenced by the typical apoptotic morphological 
changes detected by DAPI staining (Fig. 3.2A), and decreased cell viability as shown 
by MTT assay (Fig. 3.2B).  
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Fig 3.1 TRAIL or Andro induces apoptosis in human cancer cells.  
(A), TRAIL-induced apoptosis in human cancer cells. HepG2, HCT116 and HeLa 
cells were treated with indicated concentrations of TRAIL for 24 h. (B), Andro-
induced apoptosis in human cancer cells. Cancer cells were treated with indicated 
doses of Andro for 24 h. The percentage of apoptosis was determined using DAPI 
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Fig 3.2 Andro sensitizes human cancer cells to TRAIL-induced apoptosis.  
 
(A), HepG2, HCT116 and HeLa were pretreated with the indicated concentration of 
Andro for 2 h, followed by treatment with a subtoxic concentration of TRAIL (10 
ng/mL for HepG2, 1 ng/mL for HCT116 and HeLa) for another 12 h. Representative 
images of HepG2 cells with various treatments were photographed using a normal 
light microscope and an inverted fluorescence microscope (magnification × 200 
times). The percentage of apoptosis was determined using DAPI staining and data 
were presented as mean ± SD from three independent experiments. (B), HepG2 cells 
was treated as panel A. The cell viability was evaluated by MTT assay and expressed 
by relative cell viability compared with untreated control group. 
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3.3.2 Andro promotes TRAIL-induced caspase activation 
It is well known that TRAIL-induced apoptosis is mainly executed by the extrinsic 
cell death receptor pathway, involving caspase-8 as the initiator and caspase-3 as the 
executor caspase (LeBlanc and Ashkenazi, 2003). Here I first examined the effect of 
Andro on TRAIL-initiated caspase cascade. As shown in Fig. 3.3, subtoxic dose of 
Andro or TRAIL alone has no evident effect on the cleavage of caspase-8 and 
caspase-3. Notably, pretreatment with Andro significantly augmented TRAIL-induced 
cleavage/activation of caspase-8 and caspase-3, as well as the cleavage of one of the 
caspase-3 substrates poly (ADP-ribose) polymerase (PARP) (Fig. 3.3).  
I next utilized various caspase inhibitors to confirm the role of caspase cascade in 
apoptotic cell death induced by Andro and TRAIL. As shown in Fig. 3.4A and 3.4B, 
the general caspase inhibitor (Z-VAD-FMK), caspase-8 inhibitor (Z-IETD-CHO) or 
caspase-3 inhibitor (Z-DEVD-CHO) are able to prevent PARP cleavage and apoptosis 
induced by the combined treatment of Andro and TRAIL. In order to further confirm 
the initiating function of caspase-8 activation in the apoptosis sensitized by Andro, I 
over-expressed a specific caspase-8 inhibitor protein (CrmA) in HepG2 cells. The 
over-expression of CrmA protein almost completely protected the cells from apoptotic 
cell death caused by Andro and TRAIL (Fig. 3.6). Therefore, it is believed that Andro 















Fig 3.3 Andro enhances the caspase cascade triggered by TRAIL.  
 
HepG2 cells were pretreated with 15 μM Andro for 2 h, followed by treatment with 
TRAIL (10 ng/mL) for indicated periods of time. Cell lysates were collected and 
subjected to Western blot for detecting the cleavage of caspase-8, caspase-3 and PARP. 
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Fig 3.4 Caspase inhibitors block PARP cleavage and apoptosis induced by Andro 
and TRAIL.  
 
HepG2 cells were pretreated with Z-IETD-CHO (25 μM), Z-DEVD -CHO (25 μM) or 
Z-VAD-FMK (25 μM) for 30 min, followed by combined treatment of Andro (15 μM) 
and TRAIL (10 ng/mL). Cells were collected for measurement of PARP cleavage by 
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3.3.3 Andro promotes FLIP-L cleavage and XIAP down-regulation as a result 
of enhanced caspase activation  
In order to understand the underlying mechanism responsible for the sensitization 
effect of Andro on TRAIL-induced apoptosis, I systematically examined the 
involvement of various apoptosis regulatory proteins. Re-establishment of TRAIL-
induced cell death in TRAIL-resistant cells is usually conveyed by the down-
regulation of anti-apoptotic molecules, including FLIP, inhibitor of apoptosis proteins 
(XIAP, c-IAP-1 and c-IAP-2), Bcl-2, Bcl-xL and Mcl-1 (Ji et al., 2005; Mirandola et 
al., 2006; Ricci et al., 2007; Shi et al., 2005; Taniai et al., 2004; Zhang et al., 2005).  
As shown in Fig. 3.5, Andro significantly enhances TRAIL-induced cleavage of 
FLIP-L and reduction of XIAP protein level in HepG2 cells, while no evident changes 
are found for other apoptosis regulatory proteins. Moreover, ectopic expression of 
either FLIP-L or XIAP protected Andro-sensitized apoptosis (Fig. 3.6A), indicating 
that FLIP-L or XIAP plays an important role in the sensitization effect of Andro on 
TRAIL-induced apoptosis. Interestingly, the pan-caspase inhibitor Z-VAD-FMK 
almost completely reversed the effect of Andro on FLIP-L cleavage and XIAP down-
regulation (Fig. 3.6B). It is thus believed that the enhanced FLIP-L cleavage and 
XIAP protein down-regulation lie downstream of the increased caspase activation, as 













Fig 3.5 Andro promotes FLIP-L cleavage and XIAP down-regulation in TRAIL-
treated HepG2 cells. 
 
Changes of apoptosis regulatory proteins in cells treated with Andro and TRAIL. 
HepG2 cells were treated with Andro (15 μM) for 2 h, followed by TRAIL (10 ng/mL) 
for indicated periods of time. At the end of treatment, cell lysates were collected and 
subjected to Western blot.  
 
+ + - + + - + + - - Andro  
- TRAIL  - + + - + - + + + 













Bcl-2 28 kD 
55 kD 
survivin 16 kD 
 90
 
Fig 3.6 Down-regulation of FLIP-L and XIAP protein lie downstream of the 
increased caspase activation.  
 
(A), Suppression of cell death by overexpression of FLIP-L and XIAP. HepG2 cells 
were transiently transfected with pcDNA, FLIP-L or XIAP expression vectors 
together with GFP vector as a transfection indicator. 24 h after transfection, cells were 
treated with Andro (15 μM) for 2 h, followed by TRAIL (10 ng/mL) for another 12 h. 
Under a fluorescent microscope, the successfully transfected cells were in green and 
the morphologic changes of apoptotic cells were evaluated, and data were presented 
as mean ± SD from three independent experiments. (B), Effects of Z-VAD-FMK on 
FLIP-L cleavage and XIAP down-regulation. HepG2 cells were pretreated with Z-
VAD-FMK (25 μM) for 30 min, followed by the treatment of Andro and TRAIL. At 
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3.3.4 Andro sensitizes TRAIL-induced apoptosis via DR4 up-regulation  
It has been well-established that the decreased expression of TRAIL receptors 
DR4, DR5 and/or up-regulation of the decoy receptors, DcR1 and DcR2 account for 
TRAIL-resistance in certain cancer cell lines (LeBlanc and Ashkenazi, 2003; Takeda 
et al., 2007; Wang and El-Deiry, 2003). To determine the possible role of TRAIL 
receptors in Andro-sensitized apoptosis, I first detected the protein levels of various 
TRAIL receptors in cells treated with Andro and TRAIL. As shown in Fig. 3.7A, 
Andro treatment markedly increases the expression of DR4 in HepG2 cells from 6 h 
onwards as detected by Western blot, while no evident changes were found for DR5, 
DcR1 and DcR2. To confirm the effect of Andro on DR4, I further detected the DR4 
expression level at cell surface using flow cytometry. Consistently, Andro markedly 
increased the cell surface expression of DR4, but not DR5 (Fig. 3.7B). Similar to a 
previous report (Galligan et al., 2005), it is noted that the basal level of DR5 is much 
higher than that of DR4, detected by either Western blot or flow cytometry (Fig. 3.7A 
and B).  
3.3.5 DR4 up-regulation is critical for the sensitization effect of Andro  
In order to further elucidate the critical role of DR4 in Andro-induced sensitization 
effects, I neutralized the function of TRAIL receptors by using DR4 or DR5 blocking 
antibody, as reported previously (Sprick et al., 2002). It is evident that DR4 blocking 
antibody is able to suppress caspase-8 cleavage (Fig. 3.8A) and protect against 
apoptotic cell death induced by the combined treatment of Andro and TRAIL (Fig. 
3.8B). On the contrary, these effects could not be detected after neutralization with the 
DR5 blocking antibody. These results thus strengthen our argument that DR4 but not 







Fig 3.7 Andro up-regulates DR4 transcription.  
 
(A), Time-dependent up-regulation of DR4 protein level by Andro. HepG2 cells were 
treated with Andro (15 μM) for 2 h, followed by TRAIL (10 ng/mL) for indicated 
periods of time. Cell lysates were collected for Western blot to detect protein 
expression level of various TRAIL death receptors. (B), Effects of Andro on the cell 
surface expression of DR4 and DR5. HepG2 cells were incubated with Andro (15 μM) 
for 6 h and the cell surface expression of DR4 and DR5 proteins was analyzed by 
flow cytometry. X axis, fluorescence intensity; Y axis, relative number of cells. Data 
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Fig 3.8 DR4 blocking antibody suppresses the cleavage of caspase-8 and PARP 
induced by Andro and TRAIL. 
 
HepG2 cells were pretreated with DR4 or DR5 blocking antibodies (10 μg/mL) for 30 
min, followed by pretreatment with Andro (15 μM × 2 h) and then TRAIL (10 ng/mL) 
for another 12 h. At the end of treatment, cells were collected for Western blot (A) and 









































3.3.6 p53 is required for the DR4 up-regulation and enhanced apoptosis 
induced by Andro  
In order to determine whether the increased DR4 protein level is due to enhanced 
gene transcription, I next measured the mRNA level of both DR4 and DR5 using RT-
PCR (Fig. 3.9A). Consistent with the changes of the protein level, significant increase 
of DR4 mRNA level was observed from 3 h onwards, preceding the increase of DR4 
protein level. Taken together, it is clear that Andro treatment selectively up-regulates 
DR4 expression at transcriptional level.  
It has been well documented that p53 tumor suppressor is one of the main 
transcription factors regulating the expression of both DR4 and DR5 (El-Deiry, 2001; 
Guan et al., 2001; Liu et al., 2004). Here I tested whether Andro-mediated DR4 
transcriptional up-regulation is p53-dependent. I first demonstrated that Andro 
treatment increases p53 protein level, which is coincident with the temporal change of 
DR4 protein level (Fig. 3.9B). Next, I manipulated the p53 expression by using 
specific siRNA against p53. As expected, knockdown of p53 resulted in the 
suppression of Andro-induced DR4 up-regulation (Fig. 3.10A) and consequently 
prevented Andro-sensitized apoptosis (Fig. 3.10B). These observations thus establish 
that p53 is required for Andro-induced DR4 up-regulation and sensitization to 






Fig 3.9 p53 is responsible for the DR4 transcriptional up-regulation.  
 
(A), Effects of Andro and TRAIL on DR4 and DR5 mRNA level. HepG2 cells were 
treated with Andro (15 μM) for 2 h, followed by TRAIL (10 ng/mL) for indicated 
periods of time. The mRNA levels of DR4 and DR5 were measured by reverse 
transcription-PCR. GAPDH was used as an internal control. (B), Andro promotes p53 
protein accumulation. HepG2 cells were treated with Andro (15 μM) for 2 h, followed 
by TRAIL (10 ng/mL) for indicated periods of time. The p53 and DR4 protein levels 
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Fig 3.10 p53 is required for DR4 up-regulation and enhanced apoptosis by Andro.  
(A), p53 knockdown prevents Andro-induced DR4 up-regulation. HepG2 cells were 
transfected with scrambled siRNA or p53 siRNA for 24 h. Then cells were treated 
with Andro (15 μM) for 6 h. At the end of treatment, cells were collected for detection 
of p53 and DR4 by Western blot. (B), p53 knockdown suppresses apoptosis induced 
by Andro and TRAIL. After p53 knockdown, HepG2 cells were treated with Andro 
(15 μM) for 2 h, followed by TRAIL (10 ng/mL) for 12 h. Cells were assessed using 
DAPI staining and images were representatives of 3 independent experiments.  
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To further confirm the critical role of p53 in Andro-sensitized apoptosis in 
TRAIL-treated cells, I selected two pairs of cancer cell lines with different genetic 
features of p53: p53 wild-type HepG2 vs. p53 mutant Hep3B cells (Bressac et al., 
1990), and p53-wild type HCT116 vs. p53- knockout HCT116 cells (Bunz et al., 
1998). As shown in Fig. 3.11A, Andro plus TRAIL induce significant apoptosis in 
HepG2 cells, but not in Hep3B cells. Similarly, the combined treatment causes 
obvious apoptotic death in HCT116 p53-wild type cells but shows no effect in 
HCT116 p53-knockout cells (Fig. 3.11B). I next examined the DR4 and p21 
expression levels in HCT116 cells treated with Andro. As expected, upon Andro 
treatment, the dramatic enhancement of DR4 could be detected in HCT116 p53-wild 
type but only slight increase in HCT116 p53-knockout cells (Fig. 3.11C), which is 
consistent to the change of p21, a well-established p53 target protein.  
Although p53 is a well-known transcriptional regulator of DR4 (Guan et al., 2001; 
Liu et al., 2004), NF-κB (Jin et al., 2005) and c-myc (Sussman et al., 2007) also have 
been reported to be able to regulate the expression of DR4. Therefore, it is possible 
that other regulatory mechanisms may contribute to the slight up-regulation of DR4 in 
HCT116 p53-knockout cells. However, this slight up-regulation of DR4 is not 
sufficient to enhance the sensitivity of HCT116 p53 knockdown cells to TRAIL and 
Andro induced apoptosis (Fig. 3.11C). Therefore, it is believed that up-regulation of 
DR4 and sensitization of TRAIL-induced apoptosis by Andro are dependent on the 





Fig 3.11 Andro sensitizes TRAIL-induced apoptosis in p53-wild type but not in 
p53-deficient cancer cells.  
 
(A), HepG2 and Hep3B cells were pretreated with Andro (15 μM) for 2 h, followed 
by TRAIL (10 ng/mL) for another 12 h. The percentage of apoptosis was determined 
using DAPI staining and data were presented as mean ± SD from three independent 
experiments. (B, C), HCT116 p53-wild type cells and HCT116 p53-knockout cells 
were pretreated with Andro (15 μM) for 2 h, followed by TRAIL (1 ng/mL) for 
another 12 h. At the end of treatment, the cells were collected for DAPI staining (B) 
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3.3.7 Andro elevates p53 expression through JNK-mediated p53 Thr81 
phosphorylation  
Activation of p53 may result from either the increased transcriptional level or 
post-translational modification and stabilization (Ashcroft and Vousden, 1999). In this 
study, Andro did not affect the mRNA level of p53 (Fig. 3.12A). Consistently, it was 
found that in the presence of cycloheximide, a protein synthesis inhibitor, Andro 
significantly prolongs the half-life of p53 from 30 min to more than 2 h (Fig. 3.12B), 
suggesting that accumulation of p53 protein by Andro is most probably due to its 
post-transcriptional regulation. 
It has been well established that p53 protein level is mainly regulated via the 
ubiquitination and proteasome pathway, a process closely associated with the 
phosphorylation status of p53 (Ashcroft and Vousden, 1999; Brooks and Gu, 2006). I 
next examined the pattern of p53 phosphorylation in response to Andro treatment. 
Notably, dramatic p53 phosphorylation at Thr81 site was detected upon Andro 
treatment, with concurrent increase of p53 and DR4 protein levels (Fig. 3.12C). On 
the contrary, I failed to detect any significant changes at the other phosphorylation 
sites, such as Ser20, in Andro-treated cells, in contrast to the effect of etoposide, a 
DNA damaging agent (Fig. 3.12C). It has been documented that p53 Thr81 is 
specifically phosphorylated by JNK in response to DNA damage and stress-inducing 
agents (Wu, 2004). More importantly, JNK phosphorylation of p53 on Thr81 is 
important for p53 stabilization and transcriptional activities as a stress response 
(Buschmann et al., 2001). To assess the involvement of JNK in the activation of p53 
by Andro, I determined the activation of JNK in Andro-treated cells. As shown in Fig. 
3.12D, Andro promotes JNK phosphorylation in a temporal pattern consistent with 
that of p53 phosphorylation and stabilization, and subsequent DR4 up-regulation.  
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JNK is readily activated by ROS (Shen and Liu, 2006) and separate reports 
showed that Andro triggers cellular accumulation of ROS as well as JNK activation 
(Ji et al., 2007; Li et al., 2007b). I thus examined whether ROS plays a role in Andro-
induced JNK activation. The DCF assay revealed that the intracellular ROS level 
increased significantly following the treatment with Andro in both time-dependent 
and dose-dependent patterns (Fig. 3.13A), a process that could be completely blocked 
by an antioxidant N-acetyl cysteine (NAC) (Fig. 3.13B). Next, I attempted to 
determine the role of Andro-induced ROS in the sequential events of JNK activation, 
p53 protein phosphorylation/stabilization and DR4 up-regulation. Pretreatment with 
NAC or JNK inhibitor (SP600125) led to significant inhibition of JNK activation and 
p53 phosphorylation (Fig. 3.14A). Moreover, pretreatments with NAC or SP600125 
also completely blocked the up-regulation of DR4 mRNA and protein level (Fig. 
3.14A and B). As a result, both reagents effectively abolished the sensitization effect 
of Andro on TRAIL-induced apoptosis in HepG2 cells (Fig. 3.14C). Taken together, 
the above results indicate that ROS-mediated JNK activation by Andro accounts for 
the sensitization effect of Andro on TRAIL-induced apoptosis via sequential events 





Fig 3.12 Andro enhances p53 accumulation and phosphorylation.  
 
(A), Andro shows no effect on p53 mRNA level. HepG2 cells were treated with 
Andro (15 μM) as indicated. The mRNA level of p53 was measured by RT-PCR. 
GAPDH was used as an internal control. (B), Andro enhances p53 stabilization. 
HepG2 cells were treated with Andro (15 μM) or DMSO for 30 min followed by 
cycloheximide (CHX, 1 μg/mL) as indicated. Cells were collected for detection of 
p53. (C), Andro enhances p53 phosphorylation at Thr81. HepG2 cells were treated 
with Andro (15 μM) or etoposide (5 μM) for 6 h. Cell lysates were then subjected to 
Western blot. (D), Andro induces JNK activation. HepG2 cells were treated with 
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Fig 3.13 Andro promotes intracellular ROS formation.  
 
(A), Andro enhances ROS intracellular accumulation in time- and dose-response 
manners. In time-course study, HepG2 cells were treated with Andro (15 μM) for up 
to 2 h (upper panel). In dose-response study, cells were treated with indicated 
concentrations of Andro for 1 h (lower panel). (B), NAC abrogates Andro-induced 
ROS formation. HepG2 cells were pretreated with NAC (2.5 mM for 30 min), 
followed by Andro (15 μM for 1 h). In Panel A and B, the intracellular ROS level was 
detected using DCFH-DA as the fluorescence probe and data were presented as mean 
± SD from three independent experiments. The embedded histograms represent the 









































































120 60 30 0 Andro (min) 































+ - - 




Fig 3.14 NAC and SP600125 abrogate Andro-induced p53 phosphorylation DR4 
up-regulation and apoptosis.  
 
(A), HepG2 cells were pretreated with NAC (2.5 mM for 30 min) or SP600125 (20 
μM for 30 min), followed by the treatment of Andro (15 μM × 2 h) and then TRAIL 
(10 ng/mL) for another 3 h (for detection of DR4 mRNA level) or 6 h (for detection of 
DR4 protein level). (B), HepG2 cells were pretreated with NAC as described above, 
followed by Andro (15 μM) for 6 h. The cell surface expression of DR4 was measured 
using flow cytometry as described above. (C), After pretreatment as indicated in panel 
A, HepG2 cells were treated with Andro (15 μM × 2 h), followed by TRAIL (10 
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The unique property of triggering apoptosis in a variety of human cancer cells, 
whereas sparing normal cells makes TRAIL a highly promising cancer therapeutic 
agent. However, TRAIL resistance is a major limitation in its clinical application as a 
cancer therapeutic agent. One effective strategy to overcome this obstacle is to 
combine TRAIL with other anticancer agents (Zhang and Fang, 2005). A number of 
chemical compounds have been identified as effective sensitizing agents to TRAIL-
induced apoptosis, including some natural products (Ganten et al., 2005; Inoue et al., 
2004; Palacios et al., 2006; Shi et al., 2005; Zhang et al., 2005). Results from this 
study provide substantial evidence that Andro, a diterpenoid lactone isolated from a 
traditional medicinal herb, is capable of sensitizing TRAIL–induced apoptosis in 
TRAIL-resistant cancer cells. Thus this study presents a novel anticancer effect of 
Andro, and supports its potential application in cancer therapy.  
Andro sensitizes TRAIL-induced apoptosis by up-regulation of DR4  
The expression level of death receptors (DR4 and DR5) plays a critical role in 
determining the cell fate in response to TRAIL (LeBlanc and Ashkenazi, 2003; 
Takeda et al., 2007; Wang and El-Deiry, 2003). Numerous literatures have shown 
convincing data that the up-regulation of DR4 and DR5 could sensitize TRAIL-
resistant cells to TRAIL-induced cell death (Galligan et al., 2005; Jin et al., 2004). In 
this study, it is believed that Andro-induced sensitization on TRAIL-induced 
apoptosis is mainly executed via modulation of DR4, but not DR5, based on the 
following observations. First, Andro selectively enhanced the expression level of DR4 
in HepG2 cells (Fig. 3.7). Second, the administration of blocking antibody of DR4, 
but not DR5, effectively protected the cell death induced by combination of Andro 
and TRAIL (Fig. 3.8), further confirming that up-regulation of DR4 is functionally 
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important in Andro-sensitized apoptosis.  
At present, there are inconsistent reports whether DR4 or DR5 is the main 
mediator for TRAIL-mediated apoptosis in cancer cells. It has been well reported that 
in chronic lymphocytic leukaemia cells, DR4 seems to be the principal receptor in 
response to TRAIL in the presence of histone deacetylase inhibitors (MacFarlane et 
al., 2005a; MacFarlane et al., 2005b; Natoni et al., 2007). Suppression of DR4 
expression or function by homozygous deletion or epigenetic silencing led to TRAIL 
resistance (Horak et al., 2005; Ozoren et al., 2000). Recently, Kurbanov et al. utilized 
an established cell culture model for TRAIL resistance and regained TRAIL 
sensitivity, and indicated that significant down-regulation of initiator caspase and 
DR4 was characteristic for TRAIL-resistant melanoma cells (Kurbanov et al., 2007). 
Additionally, another recent report suggested that reactivation of DR4 expression 
contributed to restore sensitivity of melanoma cells to IFN-β or Apo2L/TRAIL 
(Meyer et al., 1993). Moreover, Aza-Blanc et al. reported that a small interfering 
RNA targeting DR4 was effective in blocking TRAIL-induced apoptosis whereas 
knockdown of DR5 failed to confer any protection (Aza-Blanc et al., 2003). In this 
regard, DR4 represents the major determinant of TRAIL sensitivity in certain cancer 
cells. On the other hand, there is evidence that DR5 may play a more prominent role 
than DR4 in mediating apoptotic signals emanating from TRAIL in cells expressing 
both death receptors (Foyouzi-Youssefi et al., 2000); and TRAIL binds with a higher 
affinity to DR5 than to DR4 in some cells (Truneh et al., 2000). One possible 
explanation for such inconsistent results might be the different expression levels of 
these two receptors in different types of cancer cells. In line with some previous 
studies (Galligan et al., 2005), I found that in HepG2 cells DR5 is expressed in a 
much higher basal level but is more insensitive to regulatory mechanisms. In contrast, 
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DR4 with a very low basal level is susceptible of being up-regulated by p53. Such a 
difference may well explain the fact that it is DR4 that is responsible for the 
sensitization effect of Andro to TRAIL-induced apoptosis.   
Andro up-regulates DR4 via p53-dependent transcriptional regulation  
The tumor suppressor gene p53 is a key apoptosis regulator in cancer cells and 
one of its pro-apoptosis functions is achieved via transcriptional activation of death 
receptors (Guan et al., 2001; Liu et al., 2004). In the present study, I found that p53 
played a critical role in Andro-sensitized apoptosis through up-regulation of DR4, 
owing to the following findings. First, RNA interference of p53 could effectively 
inhibit Andro-induced DR4 up-regulation (Fig. 3.10A) and abolish the apoptotic cell 
death induced by the combined treatment of Andro and TRAIL (Fig. 3.10B). Second, 
evident apoptotic cell death and DR4 up-regulation were only observed in p53 wild-
type cancer cells, but not in p53 deficient cells (Fig. 3.11C). It is thus believed that 
Andro is capable of enhancing TRAIL-mediated cancer cell apoptosis via activating 
p53-dependent DR4 transcription.  
The involvement of p53 in control of DR4 and DR5 transcription remains 
contradictory. Original work mainly by El-Deiry’s group identified DR5 as the main 
target of p53 as the molecular link between the apoptotic pathways mediated by DNA 
damage and cell death receptors (Takimoto and El-Deiry, 2000; Wu et al., 2000). On 
the other hand, there is convincing evidence showing that DNA damage-induced p53 
activation also leads to DR4 up-regulation (Guan et al., 2001; Liu et al., 2004). It is 
likely that p53 is important for both DR4 and DR5 depending on the context including 
the nature of stimuli and the cell type. It remains to be further tested whether p53-
mediated DR4 up-regulation is also applicable to other TRAIL-resistant cancer cells. 
One implication of such findings is that the therapeutic value of TRAIL is at least 
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partly dependent on functional p53 in cancer cells and the sensitization effect of 
Andro may only be achievable in p53-wild type cancer cells. 
Andro stabilizes p53 protein via oxidative stress and JNK activation  
It has been well established that p53 activity is mainly regulated through complex 
networks of posttranslational modifications, including phosphorylation, ubiquitination 
and proteasome degradation (Ashcroft and Vousden, 1999; Brooks and Gu, 2006). 
The phosphorylation status of p53 directly affects MDM2 binding and subsequent 
ubiquitination and proteasome degradation. At present, more than a dozen 
phosphorylation sites have been mapped on p53, but only a few have been 
characterized with respect to the phosphorylating kinase and the relevance to p53 
activities (Brooks and Gu, 2006). Among them, activation of JNK has been linked 
with p53Thr81 phosphorylation in response to DNA damage and stress-inducing 
agents (Wu, 2004). Consistently, I observed p53 phosphorylation at Thr81, but not 
Ser20 in response to Andro treatment, in contrast to the effect of etoposide, a DNA 
damaging agent. Meanwhile, it is intriguing to note that no up-regulation of DR4 was 
found in cells treated with etoposide, despite the equally enhanced total p53 protein 
level (Fig. 3.12C). The mechanism underlying such a discrepancy remains to be 
further investigated. More importantly, pretreatment of SP600125, a specific JNK 
inhibitor, suppressed Andro-induced JNK activation and thus abrogated p53 
phosphorylation, total p53 protein accumulation, DR4 up-regulation and subsequent 
cell death induced by combined treatment of Andro and TRAIL (Fig. 3.14). 
Collectively, our data reveal a sequence of events elicited by Andro, from ROS 
production to JNK activation, p53 phosphorylation and stabilization to DR4 up-
regulation and eventually enhanced cell death. 
In conclusion, this study demonstrates a novel anticancer effect of Andro: Andro is 
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capable of activating p53 function via ROS-dependent JNK activation, leading to 
DR4 up-regulation and sensitization to TRAIL-induced apoptosis in TRAIL-resistant 
cancer cells. Data from this study support the further development of Andro as a 
chemosensitizer in combined therapy with TRAIL to overcome TRAIL resistance in 













INHIBITION OF CONSTITUTIVE STAT3 ACTIVITY BY ANDRO ENHANCES 














Signal transducers and activators of transcription (STAT) proteins are a family of 
seven proteins (STATs 1, 2, 3, 4, 5a, 5b, and 6) that mediate signal transduction from 
extracellular signals to transcription of target genes. Among the STATs, STAT3 is the 
most intimately linked to tumorigenesis (Bromberg et al., 1999; Hirano et al., 2000). 
Numerous studies have shown a constitutive activation of the STAT3 pathway in a 
variety of human cancers, including breast carcinoma, colon cancer, cervical cancer, 
prostate cancer, melanoma, multiple myeloma, and leukemia (Hirano et al., 2000; Yu 
et al., 2007b). 
STAT3 and its upstream Janus-activated kinase (JAK) signaling were originally 
identified as the signaling pathway for interferon (IFN). It mediates the immune 
responses of various cytokines as well as many growth factors and hormones, and 
thus participates in inflammation, cell growth and metastasis (Bromberg et al., 1999; 
Darnell, 1997).  STAT3 can be activated by a number of different cytokines, including 
interleukin-6 (IL-6), IL-11, ciliary neurotrophic factor, oncostatin M, and leukemia 
inhibitory factor, which all signal through a shared gp130 signal transducer receptor 
subunit (Hirano et al., 2000). IL-6–induced STAT3 activation involves a series of 
reactions: initial binding of cytokine molecules to a membrane-bound IL-6 receptor 
(IL-6R), recruition of gp130 on IL-6R, and trans-phosphorylation of JAK. The 
association between gp130 and JAK subsequently phosphorylates tyrosine residues of 
gp130. These phosphotyrosine side chains serve as docking sites for latent 
transcription factors of the STAT3. Phosphorylation of STAT3 on Tyr705 results in 
homodimerization or heterodimerization of STAT3, enabling its nuclear localization 
and DNA binding (Darnell, 1997). Besides regulation by tyrosine phosphorylation, 
the duration and degree of STATs activation can be augmented by serine-
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phosphorylation. STAT3 Ser727 phosphorylation is mediated by several 
serine/threonine kinases, including extracellular signal-regulated kinases (ERK) and 
c-Jun-NH2-kinase (JNK) (Chung et al., 1997; Lim and Cao, 1999). Fully activated 
STAT3 regulates specific transcription of target genes. These target genes include 
anti-apoptotic proteins (Bcl-xL, Mcl-1) (Catlett-Falcone et al., 1999; Epling-Burnette 
et al., 2001) and proliferation regulatory proteins (cyclinD1, Myc and survivin) 
(Bowman et al., 2001; Niu et al., 2002; Sinibaldi et al., 2000).  
STAT3 signaling pathway has recently been shown to confer resistance to 
chemotherapy-induced apoptosis in human tumors, due to its involvement in the 
proliferation, angiogenesis, immune evasion and anti-apoptosis of cancer cells and its 
aberrant activation in various tumor cells (Darnell, 1997; Levy and Darnell, 2002; 
Schindler and Darnell, 1995). Thus, abrogation of STAT3 activation with effective 
therapeutic agents has been confirmed for rendering tumor cells susceptible to 
classical anticancer drugs.  
STAT3 and another important transcription factor NF-κB play major roles in 
inflammatory pathways and tumorigenesis (Aggarwal et al., 2009; Lin and Karin, 
2007). Modulation of these two pathways had been suggested as effective approaches 
in the treatment of inflammation and cancer. Interestingly, some inhibitors of NF-κB 
pathway, such as phytochemicals including curcumin, resveratrol, ursolic acid, 
capsaicin, and plumbagin, could also suppress the STAT3 pathway (Bhardwaj et al., 
2007; Bharti et al., 2003; Bhutani et al., 2007; Pathak et al., 2007), suggesting an 
inherent link between these two pathways. Andro was previously reported to possess 
powerful anti-inflammatory activity through the inhibition of NF-κB activity (Xia et 
al., 2004), but to date, there is no report of Andro on STAT3 signaling pathway. 
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In previous chapters, I demonstrated that Andro possess potent anticancer 
property through promoting apoptosis in cancer cells. Andro alone or combined with 
TRAIL could induce both mitochondria-involved and death receptor-involved cell 
death. However, whether Andro could inactivate other survival signaling pathways to 
achieve its anti-tumor effect remains unclear. In the present study, I sought to 
examine the effect of Andro on JAK/STAT3 pathway and evaluate whether 
suppression of STAT3 activity by Andro could sensitize cancer cells to a common 
chemotherapeutic drug doxorubicin. This set of results show that Andro could be an 
inhibitor of JAK/STAT3 signaling pathway and such inhibitory effect sensitizes 
cancer cells to doxorubicin-induced apoptosis. 
4.2 Material and methods 
4.2.1 Cell culture and reagents  
Human cancer cells, HCT116, MDA-MB-231, HepG2 and HeLa, were purchased 
from ATCC and maintained in Dulbecco's Modified Eagle's Medium containing 10% 
fetal bovine serum. Andro, 4', 6-diamidino-2-phenylindole (DAPI), anti-Flag antibody 
and other common chemicals were all purchased from Sigma-Aldrich (St. Louis, MO). 
A JAK specific inhibitor, P6, anti-human phospho-(Tyr1007/1008)-JAK2 antibody, 
and recombinant human IL-6 were purchased from Merck (San Diego, CA). pSTAT3 
luciferase vector was obtained from Panomics (Redwood City, CA). Anti-human 
phospho-(Tyr705)-STAT3, phospho-(Ser727)-STAT3, STAT3, Bcl-xL, caspase-3 and 
PARP antibodies were from Cell Signaling (Beverly, MA). Anti-human Mcl-1, 
cyclinD1, phosphor-(Tyr1022)-JAK1, gp130 (C20) were from Santa Cruz (Santa Cruz, 
CA).  
4.2.2 Luciferase assay 
The transient transfection of pSTAT3 luciferase vector was done in MDA-MB-231 
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cells using LipofectMINE plus transfection reagent according to the manufacturer’s 
protocols. Renilla luciferase vector, which acts as a transfection control, was also 
cotransfected with the above vector. The luciferase activity was measured in the 
cellular extracts using a Dual-Luciferase Reporter Assay System (Promega) based on 
the protocol provides by the manufacturer. Briefly, following the treatments, the cell 
lysate was collected from each well after the addition of cell lysis reagent. After 
adding the luciferase assay substrate, the firefly luciferase activity was determined 
using a luminometer (Promega) and the Renilla luciferase activity was then measured 
by adding the Stop&Glo substrate. 
4.2.3 Preparation of nuclear and cytosolic extracts 
Nuclear extracts and cytosolic extracts were prepared by NE-PER® nuclear and 
cytoplasmic extraction reagents (Pierce) according to the manufacturer’s protocol. 
Briefly, after being washed with PBS, cell pellets were collected by centrifugation at 
500g for 3 min. Cell pellets were incubated with cytoplasmic extract reagent I for 10 
min then added with ice-cold cytoplasmic extract reagent II. After 5 min 
centrifugation at maximum speed, supernatant was collected and considered as 
cytoplasmic extract. The insoluble fraction were resuspended with ice-cold nuclear 
extract reagent and incubated for a total of 40 min, and centrifuged at maximum speed 
for 10 min. The supernatant were collected immediately as nuclear extract. Protein 
concentration was determined using Bio-Rad Protein Assay reagent. 
4.2.4 Immunofluorescence and confocal microscopy 
Subcellular localization of STAT3 was imaged by immunofluorescence and 
confocal microscopy. Cells were grown on 4-well chamber and starved overnight and 
then treated with Andro for 3 h before stimulation with IL-6 for another 30 min. The 
following steps for immunofluorescence and confocal microscopy were carried out as 
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described earlier (section 2.2.8). 
4.2.5 DNA transfection and immunoprecipitation 
HCT116 cells were transfected with flag-STAT3 vector using LipofectAMINE 
PLUS (Invitrogen), following the manufacturer’s instructions. Cells were treated as 
indicated for 24 h after transfection. Immunoprecipitation were performed essentially 
by following the instructions of the manufacturers of the respective antibodies. In 
brief, the cell were washed three times with cold PBS and lysed in 1 mL RIPA buffer 
(150 mM NaCl, 50 mM Tris-HCl [pH 7.2], 1% Triton X-100, 0.1% SDS, 0.25 mM 
EDTA [pH 8.0]) containing protease inhibitor cocktails (Roche). Cell lysates 
containing 3 mg of protein were incubated with appropriate antibody at 4°C overnight 
or 50 μl ANTI-FLAG® M1 Monoclonal Antibody-Agarose Affinity Gel (Sigma). 
Immune complexes were captured by adding 50 μl of protein A/G agarose beads and 
rotated as 4°C for 3 h (this step was omitted when ANTI-FLAG® M1 Monoclonal 
Antibody-Agarose Affinity Gel was used). After 5 times washing of protein A/G 
agarose beads with ice-cold TBS, the immunoprecipitates were fractionated by SDS-
PAGE. 
4.2.6 Colony formation assay 
Cancer cells (HCT116, MDA-MB-231, HeLa, and HepG2) were treated as 
indicated for 12 h before reseeded in six-well plates (5,000 cells/well) respectively. 
After 3 weeks, the survival clones were stained by 0.5% crystal violet for 1h and 
photos were taken using digital camera. 
4.3 Results 
4.3.1 Andro suppresses constitutive STAT3 activation in human cancer cells  
STAT3 is an important pro-survival factor in regulation of apoptosis (Levy and 
Darnell, 2002). Here I sought to determine whether Andro suppresses STAT3 
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phosphorylation and activation. First I tested the effect of Andro on the constitutively 
activated STAT3 in MDA-MB-231 cells, a cell line known to possess high basal level 
of STAT3 (Sasser et al., 2007). As shown in Fig. 4.1A, Andro inhibited the 
constitutive phosphorylation of STAT3 on both Tyr705 and Ser727 in a dose- and 
time-dependent manner, but Andro treatment did not alter the overall expression of 
STAT3 proteins. Next, to further validate the inhibitory effect of Andro on STAT3 
activity, the luciferase reporter assay was carried out using a pSTAT3-TA-Luc vector. 
After normalization with Renilla, the relative luciferase activities in cells treated with 
different concentrations of Andro were compared with that of control. As shown in 
Fig. 4.1B, addition of Andro dose-dependently repressed STAT3 activity in MDA-
MB-231 cells (Fig. 4.1B). These data consistently demonstrate that Andro possesses a 
remarkable inhibitory effect on STAT3 activity. 
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Fig.4.1 Andro inhibits constitutive STAT3 activity in MDA-MB-231 cells in a 
dose- and time-dependent manner.  
 
(A), Andro inhibits STAT3 phosphorylation in dose- and time-dependent manners. 
MDA-MB-231 were treated either with increasing concentrations of Andro for 3 h, or 
with 15 μM Andro for the indicated durations. The levels of phosphorylated STAT3 
(Tyr705 and Ser727) and overall STAT3 were examined in whole cell lysate by 
Western blot. (B), Effect of Andro on STAT3 luciferase activity. MDA-MB-231 cells 
were transiently transfected with a STAT3 luciferase report vector together with 
Renilla luciferase vector as a transfection control. 24h after transfection, cells were 
treated with indicated concentrations of Andro for 12 h. Columns represent the mean 
of three independent transfection experiments. Andro-treated cells were normalized to 
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4.3.2 Andro inhibits IL-6-inducible STAT3 phosphorylation and nuclear 
translocation in human cancer cells   
As IL-6 is a growth factor which plays an important role in cell proliferation and 
IL-6-induced signals are mediated mainly through STAT3 phosphorylation and 
nucleus translocation (Darnell et al., 1994), I examined whether Andro could inhibit 
IL-6-induced STAT3 phosphorylation in human cancer cells. In this context, IL-6 
stimulation on HCT116 cells was associated with increases of phospho-STAT3 levels, 
as shown in Fig. 4.2A. Exposure of cells to Andro for 3h was sufficient to abolish IL-
6-induced STAT3 tyrosine phosphorylation (Fig. 4.2A). Under resting conditions, 
STAT3 is retained in the cytoplasm, and after phosphorylation it translocates to the 
nucleus. Nuclear translocation of activated STAT3 is a crucial event for its 
transcriptional function (Darnell, 1997). Therefore, I analyzed the effect of Andro on 
STAT3 translocation to the nucleus. HCT116 cells were processed to obtain 
cytoplasmic and nuclear fractions, respectively. In resting condition, STAT3 resided 
predominantly in cytoplasm and phospho-STAT3 was barely detectable (Fig. 4.2B). 
But upon IL-6 stimulation, phospho-STAT3 level substantially increased in both 
cytoplasmic and nuclear fractions, especially the nuclear fraction. Interestingly, 
pretreatment of Andro almost abolished the increase of active form of STAT3 nuclear 
translocation, regardless of the presence of IL-6.  
Next, I further tested Andro’s inhibitory effect on STAT3 nuclear translocation by 
immunofluorescence study. As shown in Fig. 4.3, STAT3 in the un-stimulated MDA-
MB-231 cells were mainly detected in the cytoplasm but not in the nuclei. In response 
to IL-6 stimulation, STAT3 rapidly translocated to the nuclei, however, pretreatment 
of Andro effectively blocked the IL-6-stimulated nuclear translocation of STAT3, a 








Fig.4.2 Andro blocks IL-6-induced STAT3 phosphorylation and nucleus 
translocation.  
 
HCT116 cells were pretreated with Andro (15 μM) for 3 h and then stimulated with 
IL-6 (20 ng/mL) for 30 min. whole cell lysate were immunoblotted with the indicated 
antibodies (A). Subfraction of cytoplasm and nucleus was conducted according to 
manufacturer’s protocol, as indicated in Material and Methods section. Cytosolic and 
nuclear lysates were immunoblotted with the indicated antibodies. Tubulin and Lamin 
A/C were used as loading controls for cytosol and nucleus subfraction, respectively 
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Fig.4.3 Andro blocks IL-6-induced STAT3 nucleus translocation 
 
Immunofulorescence confocal microcopy was used to detect inhibitory effect of Andro 
on IL-6-induced STAT3 nucleus translocation. MDA-MB-231 cells were seeded in 
chamber, and after 24 h cells were starved overnight. Cells were exposed to 20 ng/mL 
IL-6 for 30 min with or without pretreatment of Andro (15 μM) for 3 h. Following 
fixation and permeabilization, cells were immunostained with antibodies against 
STAT3 (green), nuclei were stained by propidium iodide (red), as described in the 
Materials and Methods section. Results were shown in confocal immunofluorescent 









4.3.3 Andro inhibits STAT phosphorylation through JAK1/2 suppression 
As shown above, Andro suppresses STAT3 activity by inhibiting its tyrosine 
phosphorylation. It has been reported that the phosphorylation of STAT3 on Tyr705 is 
mainly regulated by JAKs, the tyrosine kinase of growth factor receptors (Darnell et 
al., 1994; Yu et al., 1995). Therefore, I examined the effect of Andro on JAK 
activation in terms of JAK phosphorylation. As shown in Fig 4.4A, tyrosine 
phosphorylation of JAK1 and JAK2 were markedly suppressed by Andro. The effect 
of Andro for JAK kinases was compared with Pyridone 6, a well-established pan-JAK 
inhibitor (Gao et al., 2007; Pedranzini et al., 2006), by examining JAK1, JAK2 and 
STAT3 phosphorylation in MDA-MB-231 cells. The inhibitory effect of Andro on 
JAK1 and JAK2 phosphorylation is comparable to that of Pyridone 6 (Fig. 4.4A). 
The active JAK1 and JAK2 phosphorylation contribute to gp130 phosphorylation, 
which subsequently serves as docking sites for STAT3 recruitment to gp130 upon 
cellular stimulation (Bromberg and Wang, 2009; Novotny-Diermayr et al., 2002; Shin 
et al., 2009). To investigate the possibility that Andro could alter the association of 
STAT3 and gp130 following the inhibitory effect of Andro on JAK1 and JAK2 
phosphorylation, I transfected Flag-STAT3 into MDA-MB-231 cells, and examined 
their interaction with the endogenous gp130 by immunoprecipitation and western blot 
experiments. When the cell lysates were pulled down with anti-Flag antibodies, an 
evident association of STAT3 with the endogenous gp130 was detected in the 
presence of IL-6 induction (Fig. 4.4B). Interestingly, the presence of Andro strongly 
blocked the binding of STAT3 to the gp130 after IL-6 stimulation (Fig. 4.4B). To 
confirm this result, I also used anti-gp130 antibody to pull down its associated-protein 
from cell lysates. As expected, the interaction between STAT3 and gp130 was 
disrupted in the presence of Andro (Fig. 4.4C), consistent to the result in panel B. 
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Taken together, these data suggested that Andro suppresses the JAK phosphorylation 
and subsequently impairs the recruitment of STAT3 to gp130, which may contribute 











Fig.4.4 Andro disrupts the interaction between STAT3 and gp130 via 
JAK1/JAK2 inhibition. 
 
(A), Andro inhibits JAK1/JAK2 phosphorylation. MDA-MB-231 cells were treated 
with Andro (15 μM) or Pyridone 6 (5 μM) for 3h, and cell lysates were collected and 
subjected to Western blot for detecting phospho-JAK1 and phospho-JAK2. (B) and (C) 
MDA-MB-231 cells were transfected with Flag-STAT3 vector and treated with IL-6 
(20 ng/mL),  Andro (15 μM) or their combination as indicated on top. Subsequently, 3 
mg of cell lysates were immunoprecipitated with Anti-FLAG Agarose Affinity Gel (B) 
or 5 μg of gp130 antibody (C), and the bound proteins were fractionated on SDS-
PAGE gel, then analyzed by Western blot with the antibodies indicated on the left. 
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4.3.4 Constitutively active STAT3 confers resistance to doxorubicin-induced 
cell death in cancer cells 
The abnormal activation of STAT3 implicated STAT3 not only as a factor in 
tumorigenesis, but also as a regulator in the resistance to chemotherapeutic drug 
treatment (Catlett-Falcone et al., 1999). Whereas some previous reports have utilized 
STAT3 inhibition as a means to sensitize cytotoxicity, in combination with 
chemotherapeutic drug regimens (Alas and Bonavida, 2001, 2003; Gariboldi et al., 
2007; Rebbaa et al., 2001), I hypothesized that abrogation of this signaling pathway 
and its dependent anti-apoptotic proteins by Andro would lower the apoptotic threshold 
and increase chemotherapy sensitivity. To investigate this, several cancer cell lines 
(HCT116, MDA-MB-231, HepG2 and HeLa) were selected to evaluate the constitutive 
activation of STAT3 in these cell lines. Notably, both the total STAT3 protein level, 
and more strikingly the pSTAT3 level were found to be different in these four cell lines 
(Fig. 4.5A). Among them, MDA-MB-231, HepG2 and HCT116 cells, HeLa cells in 
particular, possess high level of pSTAT3, while the pSTAT3 level in HCT116 cells 
was hardly detectable.   
To confirm the effect of STAT3 in chemo-resistance, I tested the relationship 
between STAT3 activation level and cellular resistance to doxorubicin. All four cell 
lines were treated with increasing doses of doxorubicin for 24 h or 48 h, and the cell 
viability was scored using the MTT assay. As showed in Fig. 4.5B, these four cell lines 
show different sensitivity to doxorubicin, especially in longer treatment. HCT116 cells 
are more sensitive to as low as 0.1 μM of doxorubicin. In contrast, the other three cell 
lines are rather resistant to doxorubicin-induced cytotoxicity. Interestingly, this 
tendency is correlated to the different activation level of STAT3 in these cell lines (Fig. 
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4.5), implying that the activated STAT3 may contribute to the survival advantage of 
human cancer cells. 
To directly investigate the role of activation of STAT3 signaling in doxorubicin-
resistant cells, a dominant negative mutant (STAT3-Y705F) that is incapable of being 
phosphorylated and binding to DNA was introduced into HeLa cells, the cell line 
harboring constitutively activated STAT3. As shown in Fig. 4.6A, STAT3 
phosphorylation in the cells transfected with STAT3-Y705F was significantly 
abrogated compared to cells transfected with empty vector. To test the effect of 
inactivation of STAT3 on the cellular response of HeLa cells to doxorubicin, the cell 
viability was examined after transfection. As shown in Fig. 4.6B, in the HeLa cells 
transfected with STAT3-Y705F, doxorubicin treatment significantly decreased the cell 
viability compared to that of the control transfection, indicating abrogation of STAT3 
signaling pathway by Andro would increase sensitivity of cancer cells to doxorubicin-
induced cell death. 
 








Fig. 4.5 The chemoresistance of tumor cells to doxorubicin-induced cytotoxicity 
is correlated to STAT3 activity.  
 
(A), Western blot was used to detect the pSTAT3 and STAT3 level in HCT116, MDA-
MB-231, HepG2 and HeLa cells. (B), HCT116, MDA-MB-231, HepG2 and HeLa cells 
were treated with indicated concentrations of doxorubicin for 24 h or 48 h, then cell 
viability was evaluated by MTT assay. Data were presented as mean ± SD from three 
independent experiments. 






























































Fig.4.6 Constitutively active STAT3 plays a crucial role in chemoresistance of 
tumor cells to doxorubicin. 
(A), HeLa cells were transiently transfected with STAT3-Y705F or pcDNA which was 
used as transfection control, then Western blot was used to detect STAT3 tyrosine 
phosphorylation. (B), After transfection with pcDNA or STAT3-Y705F, HeLa cells 
were treated with doxorubicin (0.5 μM) for 24 h, and cell viability was evaluated by 
MTT assay and represented by relative cell viability compared with untreated control 



































4.3.5 Andro enhances doxorubicin-induced apoptosis in human cancer cells 
Since STAT3 activation is responsible for the resistance of cancer cells to 
doxorubicin-induced cytotoxicity, I hypothesized that Andro inhibitory effect on 
STAT3 activation could provide synergistic effect to doxorubicin cytotoxicity in 
cancer cells. To determine whether Andro could be used as a STAT3 inhibitor to 
enhance the sensitivity of tumor cells to doxorubicin, I treated all cell lines with the 
combination of Andro and doxorubicin. As shown in Fig. 4.7A, when the cells were 
pretreated with Andro for 2 h following by a low-cytotoxic concentration of 
doxorubicin for 24 h, the cell viability of all these cell lines were reduced 
dramatically, comparing to the Andro alone and doxorubicin alone treatment. 
Additionally, to test the long-term effect of Andro and doxorubicin on cancer cell 
growth, the colony formation assay was done on these cell lines. As showed in Fig. 
4.7B, either Andro alone or doxorubicin alone could reduce the number of HCT116 
colony formation, comparing to control. However, a combination of Andro and 
doxorubicin completely suppressed HCT116 cell growth and colony formation. 
These data provide clear evidence for a causal relationship between STAT3 inhibition 
by Andro and increased inhibition of cell growth in response to doxorubicin. 
Because doxorubicin-mediated cytotoxicity is mainly executed by inducing 
apoptotic cell death, here I examined whether Andro could enhance the apoptotic cell 
death in doxorubicin-treated cells. As shown in Fig. 4.8A, only upon the combined 
treatment of Andro and doxorubicin, the HeLa cells underwent dramatic apoptotic cell 
death as evidenced by chromatin condensation, a typical apoptotic morphological 
change detected by DAPI staining, accompanied by evident cleavage of caspase-3 and 
its downstream substrate PARP (Fig. 4.8B). I next utilized Z-VAD-FMK, a pan-
caspase inhibitor to further confirm the role of caspase cleavage in cell death induced 
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by Andro and doxorubicin. As shown in Fig. 4.8, the pan-caspase inhibitor, Z-VAD-
FMK is able to prevent PARP cleavage and apoptosis induced by the combined 
treatment of Andro and doxorubicin. Therefore, it is believed that Andro enhances 




Fig.4.7 Andro enhances doxorubicin-induced cytotoxicity in cancer cells.  
 
(A), HCT116, MDA-MB-231, HepG2 and HeLa cells were pretreated with Andro (15 
µM) for 2 h, followed by treatment with a subtoxic concentration of doxorubicin (0.5 
µM) for another 24 h. The cell viability was evaluated by MTT assay and expressed 
by relative cell viability compared with untreated control group. (B), cells were 
treated as indicated for 12h before reseeded in six-well plates (5,000 cells/well) 
respectively. After 3 weeks, the survival colonies were stained by 0.5% crystal violet 
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Fig. 4.8 Andro sensitizes human cancer cells to doxorubicin-induced apoptosis.  
 
(A), HCT116, MDA-MB-231, HepG2 and HeLa were pretreated with the indicated 
concentration of Andro for 2 h, followed by treatment with a subtoxic concentration 
of doxorubicin (0.5 μM) for another 24 h with or without the pretreatment of Z-VAD-
FMK (25 μM). Representative images of HeLa cells with various treatments were 
photographed using a normal light microscope and an inverted fluorescence 
microscope. (B), HeLa cells were treated as indicated in panel (A) for various periods. 
Cell lysates were collected and subjected to Western blot for detecting the cleavage of 








24 24 18 12 24 24 - Time  (h) 
+ + + + + - - Doxo 





4.3.6 Andro sensitizes doxorubicin-induced apoptosis via suppression of STAT3  
It is well documented that Mcl-1 and Bcl-xL are transcriptionally regulated by 
STAT3 (Darnell, 1997; Epling-Burnette et al., 2001). These Bcl-2 proteins are 
apparently the predominant endogenous anti-apoptotic factors in cancer cells, and up-
regulation of these proteins is reported to be responsible for cell resistance to 
doxorubicin (Chanan-Khan, 2004; Ravizza et al., 2008; Wei et al., 2001). In order to 
elucidate the underlying mechanism responsible for the sensitization effect induced by 
Andro, I detected several downstream proteins of STAT3 signaling, including Bcl-xL, 
Mcl-1 and cyclinD1. As expected, Andro treatment markedly decreased the activation 
of pSTAT3 as detected by Western blot, followed by the concomitant reduction of 
Bcl-xL, Mcl-1 and cyclinD1 at later time point (Fig. 4.9).  
To confirm the pivotal effect of STAT3 suppression in Andro-enhanced chemo-
sensitivity, HCT116 cells, which harbor less activated STAT3, were transient 
transfected with wild-type STAT3 and evaluated for cell viability. As shown in Fig. 
4.10A and B, Andro plus doxorubicin caused up to 70% reduction of cell viability in 
pcDNA-transfected cells. On the contrast, STAT3-overexpressing cells exhibited more 
resistance to the treatment of Andro plus doxorubicin. The above experimental results 
suggest that recovery of STAT3 activation in Andro-treated cells could confer a 
marked resistance to doxorubicin. Therefore, it is believed that Andro enhances 
doxorubicin-induced cell death mainly via blocking STAT3 activation.  
Taken together, the above results indicate that Andro possesses significant 
inhibitory effect on JAK-STAT3 pathway and this effect accounts for the sensitization 








Fig. 4.9 Andro suppresses STAT3-mediated Bcl-xL, Mcl-1 and cyclinD1 
expression 
MDA-MB-231 cells were treated with Andro, doxorubicin or the combination of 
Andro and doxorubicin for indicated periods. Cell lysates were subjected to Western 
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Fig. 4.10 Overexpression of STAT3 could reverse Andro-mediated chemo-
sensiticity. 
 
(A), HCT116 cells were transiently transfected with wild-type STAT3 or pcDNA 
vector. After 24 h, cells were treated with the combination of Andro and doxorubicin 
for indicated periods. At the end of treatment, cell lysates were collected and 
subjected to Western blot. (B), HCT116 cells were transfected and treated as indicated 
in panel (A), and measured the cell viability with MTT assay. Data were presented as 
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As discussed in Chapter 2 and 3, Andro has demonstrated the potent anticancer 
effect via inducing apoptosis in cancer cells and enhancing TRAIL cytotoxicity. 
Results from this part of our study provide substantial evidences that Andro is capable 
of blocking STAT3 activation by inhibition of JAK1/2. More importantly, since 
constitutively active STAT3 plays a crucial role in chemo-resistance of tumor cells to 
doxorubicin treatment, inhibition of STAT3 by Andro resulted in the enhanced 
chemo‑sensitivity of cancer cells to doxorubicin treatment.  
Constitutive activation of STAT3 has been implicated in tumorigenesis by 
promoting proliferation and inhibiting apoptosis (Darnell, 1997; Levy and Darnell, 
2002; Schindler and Darnell, 1995). On the basis of the importance of STAT3 in 
tumor progression and survival, STAT3 recently has been considered as a molecular 
target for cancer chemotherapeutics. Studies with antisense, gene therapy, and RNA 
interference (siRNA) have demonstrated that inhibition of STAT3 signaling 
suppresses tumor growth and induces apoptosis in vitro and in vivo (Deng et al., 
2007).  In this study, it is found that Andro could be a potent inhibitor of STAT3 
activation, based on the following observations. First, Andro suppressed constitutive 
STAT3 tyrosine phosphorylation in time- and dose-dependent manners (Fig. 4.1). 
Second, Andro abrogated IL-6-induced phosphorylation and nuclear translocation of 
STAT3 in tumor cells (Fig. 4.2 and Fig. 4.3).  
STAT3 is typically maintained in the cytoplasm as an inactive monomer. In 
response to some inflammatory stimuli, such as ligation of IL-6 to its receptor, 
heterodimerization of the gp130 leading to JAK1/JAK2 phosphorylation, which 
induces STAT3 phosphorylation and subsequent translocation to the nucleus, 
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therefore initiating a transcriptional program (Darnell, 1997; Zhong et al., 1994). In 
this study, Andro treatment led to the reduction of STAT3 tyrosine phosphorylation 
and less STAT3 nuclear translocation (Fig. 4.2 and Fig. 4.3).  As documented 
previously, several different approaches can be taken for the inhibition of the STAT3 
phosphorylation: (i) inhibition of upstream STAT3-activating receptor tyrosine 
kinases (Ahmad et al., 2008; Kim et al., 2003); (ii) activation of the upstream 
phosphotyrosine phosphotases (Nicholson et al., 2000); and (iii) inhibition of STAT 
dimerization, nuclear translocation or DNA binding and transcription (Turkson et al., 
2005). According to the present data, the effect of Andro on STAT3 activity was 
resulted from the suppression of JAK1 and JAK2 phosphorylation, two key tyrosine 
kinases known for STAT3 phosphorylation (Pedranzini et al., 2006), and this 
inhibitory effect was comparable to that of pan-JAK inhibitor P6 (Fig. 4.4A). 
Furthermore, Andro disrupted the association between gp130 and STAT3 (Fig. 4.4B), 
which is the direct consequence of reduced JAK1/2 phosphorylation (Bromberg and 
Wang, 2009; Novotny-Diermayr et al., 2002). All these results clearly suggest that 
Andro’s inhibitory effect on STAT3 activation is mainly executed via inhibition of 
upstream STAT3-activating tyrosine kinase JAK1/JAK2. Such effect of Andro is 
indeed similar to a number of other natural products that have been reported to inhibit 
JAK/STAT3 pathway, such as curcumin, ursolic acid, and capsaicin (Bhutani et al., 
2007; Pathak et al., 2007; Rajasingh et al., 2006). At present, the exact mechanisms 
by which JAK1/2 phosphorylation is abrogated by Andro are still elusive and remain 
to be further investigated.  
Doxorubicin is one of the most commonly used anticancer drugs, but its 
application has been limited by the development of cellular resistance (Hortobagyi, 
1997). Recent studies on human cancer have established STAT3 as a major regulator 
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of cell proliferation and survival to protect the cells from various therapeutic agents 
including doxorubicin (Alas and Bonavida, 2003; Real et al., 2002; Salem et al., 
2000). Numerous literatures have shown convincing data that the inhibition of STAT3 
could sensitize tumor cells to doxorubicin-induced cell death (Alas and Bonavida, 
2003; Bourguignon et al., 2008; Gariboldi et al., 2007; Rebbaa et al., 2001; Vigneron 
et al., 2005), which prompted us to analyze the correlation between STAT3 activity 
and sensitivity of cancer cell lines to doxorubicin, and whether Andro could enhance 
the chemosensitivity of cancer cells to doxorubicin. 
In this study, STAT3 was found to be expressed differently in four cancer cell lines. 
Interestingly, higher basal activity of STAT3 was found to confer higher resistance to 
doxorubicin-induced cytotoxicity in HeLa cells, while HCT116 cells with lower basal 
level of STAT3 were more sensitive to doxorubicin-induced cell death (Fig. 4.5). 
More interestingly, when activated STAT3 was blocked by ectopic expression of a 
dominant negative mutant form of STAT3, a significant decrease of cell viability was 
detected in HeLa cells with doxorubicin treatment (Fig. 4.6). In this regard, 
constitutively activated STAT3 represents the major determinant of doxorubicin 
sensitivity in certain cancer cells. Therefore, here I postulate that Andro may enhance 
chemo-sensitivity of tumor cells to doxorubicin through inhibition of STAT3 activity. 
As expected, combination of Andro and doxorubicin apparently induced cell death 
and suppressed the cell proliferation in a number of cancer cell lines (Fig. 4.7).  
An important downstream effect of STAT3 activation is the STAT3-dependent 
regulation of several anti-apoptotic genes including Bcl-xL and Mcl-1 (Catlett-
Falcone et al., 1999; Epling-Burnette et al., 2001). The anti-apoptotic Bcl-2 proteins 
play important role in preventing tumor cells from apoptosis induction. Treatment 
with Andro induced apoptosis with corresponding decrease in STAT3 activation, 
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accompanied by the reduction of Bcl-xL and Mcl-1, two transcriptional targets of 
STAT3 (Fig.4.9). The down-regulation of the expression of Bcl-xL and Mcl-1 is likely 
to provide a link between STAT3 suppression and ability of Andro to enhance 
apoptosis in tumor cells. In this study, ectopic expression of wild-type STAT3 offered 
significant protection against the synergistic effects of Andro and doxorubicin (Fig. 
4.10A and B). These results thus strengthened our argument that the suppression of 
STAT3 activation plays an important role in the sensitization effect of Andro on 
doxorubicin-induced apoptosis. Additionally, in view of the reported role of STAT3 in 
repressing p53 expression and function (Niu et al., 2005), it remains to be further 
tested whether inhibition of constitutive STAT3 activity by Andro could partially 
explain the p53 accumulation in Andro-treated cells, as shown in Chapter 3.  
In conclusion, these observations collectively suggest that Andro could be a 
promising anticancer agent via its potent inhibitory effect on STAT3. Inhibition of 
STAT3 activity by Andro enhanced chemosensitivity of tumor cells to doxorubicin, 
suggesting a potential therapeutic strategy using Andro in combination with 


















 Andrographis paniculata, the mother plant of Andro, has been popularly used as 
an anti-inflammation herbal medicine for the treatment of numerous ailments and 
diseases, including respiratory infection, bacterial dysentery, diarrhea, and fever 
(Iruretagoyena et al., 2005; Poolsup et al., 2004). As the major active component 
contained in Andrographis paniculata, Andro has been shown to be responsible for 
the anti-inflammatory (Gabrielian et al., 2002; Xia et al., 2004), anti--human 
immunodeficiency virus (HIV) (Reddy et al., 2005), hepatoprotective (Visen et al., 
1993) and cardiovascular protective effect (Thisoda et al., 2006). Recently, Andro was 
demonstrated to work as a potent anticancer agent, based on the following 
observations: (i) Andro was found to induce either G0/G1 cell-cycle arrest through 
induction of p27 and decreased expression of cyclin-dependent kinase (CDK) 4 in 
some human cancer cells (Rajagopal et al., 2003; Satyanarayana et al., 2004); (ii) 
Andro was able to induce caspase-dependent apoptosis in human prostatic 
adenocarcinoma PC-3 cells (Kim and Milner, 2005) and human leukemic HL60 cells 
(Cheung et al., 2005); and (iii) Andro was found to inhibit tumor growth by using in 
vivo B16F0 melanoma syngenic and HT-29 xenograft models (Rajagopal et al., 2003). 
Despite the fact that Andro’s anticancer properties have been proposed, the molecular 
mechanisms are largely unknown. Therefore, it was of interest to investigate the 
possible mechanisms responsible for the anticancer effect of Andro. 
Apoptosis is a cell death process characterized by a well-defined sequence of 
morphological and biochemical changes (Hengartner, 2000). Apoptosis plays a critical 
role in development, tissue homeostasis and cancer (Danial and Korsmeyer, 2004; 
Kaufmann and Hengartner, 2001). Lack of apoptotic induction has been implicated in 
tumor development and progression, as well as chemo-resistance (Evan and Vousden, 
2001). Thus induction of apoptosis in cancer cells has been an established strategy in 
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cancer therapy. Two main apoptosis signaling pathways (the extrinsic death receptor 
pathway and intrinsic mitochondrial pathway) have been characterized. The extrinsic 
pathway starts with ligation of cell surface receptors termed “death receptor” (DRs), 
such as DR4 and DR5, which could be triggered by TRAIL, leading to the recruitment 
of the adaptor molecules which results in the activation of caspase cascade 
(Ashkenazi and Dixit, 1999). The intrinsic mitochondrial pathway of caspase 
activation involves the loss of mitochondrial membrane potential and release of 
cytochrome c, which in turn activates caspase-9-involved cascade (Kaufmann and 
Hengartner, 2001). The role of mitochondria in apoptosis is mainly mediated by the 
Bcl-2 members in response to a range of cell death stimuli, including conventional 
anticancer agents such as doxorubicin.  
The challenge limiting the efficacy of cancer therapy is that cancer cells often 
evolve resistance to the drugs against them. This resistance is generally conferred by a 
few molecular changes. For example, deficient expression of cell surface death 
receptors fails to relay signal from cell surface to its downstream cascade (LeBlanc 
and Ashkenazi, 2003; Shankar and Srivastava, 2004). The expression level of death 
receptors has been suggested to play an important role in determining the sensitivity 
of cancer cells to TRAIL, and up-regulation of DR4 and DR5 contributed to 
sensitization of TRAIL-resistant cells to TRAIL-induced apoptosis (Galligan et al., 
2005; Jin et al., 2004). On the other hand, chemo-resistance could be developed in the 
cells with constitutive activation of survival signaling pathways. STAT3 pathway, 
which is constitutively activated in a wide range of tumor cells, has been shown to 
confer resistance to chemotherapy-induced apoptosis (Duan et al., 2006; Rebbaa et al., 
2001). It is known that STAT3 activation triggers high expression of a number of anti-
apoptotic molecules (e.g. Bcl-xL, Mcl-1 and survivin, etc) (Darnell, 1997; Epling-
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Burnette et al., 2001). These anti-apoptotic proteins are apparently the predominant 
endogenous anti-apoptotic factors in cancer cells, and up-regulation of these proteins 
is reported to be responsible for cell resistance to classical anticancer agents, such as 
doxorubicin (Duan et al., 2006; Rebbaa et al., 2001). Thus, it was important to seek 
effective and specific strategies to overcome the resistance in cancer therapy. 
Currently, combined therapies have been explored in clinical trials, and are definitely 
more effective to overcome chemo-resistance than single administration (Nieboer et 
al., 2005; Zhang and Fang, 2005).  
Although emerging evidences in recent years have suggested the anticancer 
potential of Andro, the underlying molecular mechanisms are poorly understood. 
Moreover, no study has been carried out to examine the anticancer potential of Andro 
in combination with other cancer therapeutic agents. Therefore, the objective of this 
study was to systematically investigate the anticancer effect of Andro through the 
following studies: (i) the molecular mechanism responsible for Andro-induced 
apoptosis (Chapter 2); (ii) sensitization effect of Andro on TRAIL-induced apoptosis 
(Chapter 3); (iii) inhibitory effect of Andro on STAT3 pathway and its combined 
effect with doxorubicin (Chapter 4). 
5.1 Pro-apoptotic Bcl-2 members play a critical role in Andro-induced apoptosis  
Apoptosis is a type of programmed cell death characterized by typical 
morphological and biochemical changes, and insufficient apoptosis is one of main 
reasons for tumor formation and development (Hengartner, 2000). It was found in the 
present study that Andro could induce caspase-dependent apoptosis in various cancer 
cells, which is consistent with two previous reports (Cheung et al., 2005; Kim and 
Milner, 2005). 
In the search of the molecular mechanisms involved in the Andro-induced 
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apoptosis, the role of pro-apoptotic Bcl-2 members became the focus of this part of 
study. As I have discussed earlier, there are two major highly regulated apoptotic 
pathways: the death receptor pathway starting with ligation of cell surface receptors; 
and the mitochondrial pathway which involves the loss of mitochondrial dysfunction 
and release of pro-apoptotic substances. Bid (one BH3 only protein) is believed to 
provide a connection between these two apoptotic signaling pathways, relaying the 
cell death signaling from caspase-8 to mitochondria and then to downstream caspases 
(Li et al., 1998; Luo et al., 1998). Our data demonstrated that full-length Bid was 
cleaved progressively upon Andro treatment (Fig. 2.5A) and this cleavage could be 
prevented by caspase-8 inhibitor (Fig. 2.5B), confirming that caspase-8 is the initiator 
of Bid cleavage (tBid), which provides a link between caspase-8 activation and 
mitochondria in Andro-induced apoptosis.  
There are two possible mechanisms of tBid-induced mitochondrial dysfunction: (1) 
translocation and oligomerization of tBid on mitochondrial membranes cause the 
release of cytochrome c (Luo et al., 1998); and (2) tBid induces Bax conformational 
change and mitochondrial translocation (Korsmeyer et al., 2000). Bax has been 
considered as one of the most important pro-apoptotic Bcl-2 members promoting 
mitochondrial apoptotic pathway (Kuwana et al., 2005). In this study, there was no 
evidence of Bid translocation, however, I did detect a striking conformational change 
of Bax in Andro-treated cells in both immunofluorescent staining (Fig. 2.6A) and 
immunoprecipitation assay (Fig. 2.6B). Furthermore, significant amount of Bax 
accumulated in mitochondria fraction following Andro treatment (Fig. 2.7A). One 
important underlying mechanism of the pro-apoptotic function of Bax is to promote 
the release of pro-apoptotic factors such as cytochrome c from mitochondria 
(Desagher and Martinou, 2000; Eskes et al., 2000). Consistently, in Andro-treated 
 143
cells, Bax mitochondrial translocation was accompanied by the concurrent release of 
cytochrome c (Fig. 2.7B). It thus believed that Andro treatment resulted in Bid 
cleavage-associated Bax translocation.  
The next question needed to be answered is whether the Bid cleavage and 
subsequent Bax translocation are critical for Andro-induced apoptosis. The crucial 
role of Bid cleavage on promoting Bax translocation was confirmed by the Bid 
knockdown experiment, decreased level of Bid gave rise to two important 
consequences: reduction of Bax transformation (Fig. 2.8B) and protection from 
apoptotic cell death (Fig. 2.8C). On the other hand, it is known that Bax’s pro-
apoptotic activity is subject to the regulation by other Bcl-2 family members. For 
instance, the anti-apoptotic Bcl-2 protein is able to block apoptosis by binding to Bax 
to form Bcl-2-Bax heterodimers (Murphy et al., 2000). In this study, overexpression 
of Bcl-2 protein offered significant protection against Andro-induced apoptosis (Fig. 
2.9). Andro’s regulatory effect on Bcl-2 proteins was further investigated in Chapter 4. 
Andro was demonstrated to be able to suppressed STAT3 activity, which is 
responsible for the transcriptional regulation of anti-apoptotic Bcl-2 members Bcl-2, 
Bcl-xL and Mcl-1. It is likely that Andro may further promote Bax pro-apoptotic 
function via blocking the expression of anti-apoptotic Bcl-2 proteins. These results 
thus strengthen our argument that Bid and Bax play key role in the apoptotic signaling 
initiated by Andro. 
Collectively, this part of study explored the molecular mechanism responsible for 
Andro’s action on apoptosis induction, demonstrating the key role of pro-apoptotic 
Bcl-2 proteins (Bid and Bax) in relaying the cell death signaling initiated by Andro 
from caspase-8 to mitochondria and then to downstream caspase cascade, and 
eventually leading to apoptotic cell death in tumor cells. 
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5.2 Andro sensitizes TRAIL-induced apoptosis in human cancer cells 
TRAIL, a newly identified member of the TNF subfamily, is a promising 
anticancer agent for its unique property to selectively induce apoptosis in tumor cells 
but not in normal cells (Wang and El-Deiry, 2003). However, the anticancer 
application of TRAIL is unfortunately shadowed by the fact that some types of cancer 
cells are resistant to TRAIL-induced cell death (Duiker et al., 2006; Dyer et al., 2007). 
This resistance is generally conferred by a few molecular changes, such as lower 
expression of cell surface death receptors, and/or higher expression of anti-apoptotic 
molecules (e.g. DcRs, FLIP and XIAP) (LeBlanc and Ashkenazi, 2003; Shankar and 
Srivastava, 2004). Thus, combination TRAIL with other agents capable of 
overcoming such resistance has been a promising strategy to potentiate the 
cytotoxicity of TRAIL and its therapeutic application. In Chapter 3, the anticancer 
potential of Andro has been further studied by exploring the synergistic effect of 
Andro in combination with TRAIL. 
In Chapter 3, I first tested TRAIL-induced apoptosis in a panel of human cancer 
cells and found that some were resistant to TRAIL-idnuced apoptosis (Fig 3.1). 
Interestingly, in the presence of low-toxic concentration of Andro, TRAIL could 
induce apoptosis rapidly in cancer cells (Fig. 3.2). More importantly, Andro is capable 
of sensitizing TRAIL-induced apoptosis in TRAIL-resistant cancer cells (Fig. 3.2). 
This striking synergistic effect suggests that Andro can be an effective chemo-
sensitizer to overcome TRAIL resistance. In searching for the molecular mechanisms 
involved in the sensitization, I systematically examined the involvement of various 
apoptosis regulatory signaling pathways (Fig. 3.5 and Fig. 3.6). I demonstrated that 
the p53-dependent DR4 up-regulation may account for the sensitization effect of 
Andro on TRAIL-induced apoptosis. And this action was initiated by sequential 
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events including ROS induction, JNK activation, and p53 
phosphorylation/stabilization.  
In this study, Andro was capable of prolonging p53 half life (Fig. 3.12B) and 
promoting p53 accumulation (Fig. 3.9B) in cancer cells. More importantly, Andro’s 
sensitization effect on TRAIL-induced apoptosis is confirmed to be dependent on the 
functional p53, based on the following observations: (i) Andro-sensitized apoptotic 
cell death were only observed in p53 wild-type cancer cells, but not in p53 deficient 
cells (Fig. 3.11C); (ii) RNA interference of p53 could effectively abolish the apoptotic 
cell death induced by the combined treatment of Andro and TRAIL (Fig. 3.10B). 
The tumor suppressor gene p53 is a key apoptosis regulator in cancer cells and 
loss of p53 function promotes malignant transformation which is required for cancer 
progression (Hainaut and Hollstein, 2000). In normal cells, p53 remains at low 
expression level in the absence of stresses. In response to stress signals, however, p53 
becomes functionally active and triggers either cell cycle arrest or apoptotic cell death 
(Vogelstein et al., 2000). The amount of p53 protein in cells is determined mainly by 
the posttranscriptional regulation rather than the regulation at transcriptional level 
(Vogelstein et al., 2000). The regulation of p53 function by phosphorylation and 
dephosphorylation could occur through many sites. At present, more than a dozen 
phosphorylation sites have been mapped on p53, but only a few have been 
characterized with respect to the phosphorylating kinase and the relevance to p53 
activities (Bode and Dong, 2004; Olsson et al., 2007; Shieh et al., 1997). Among 
various kinases responsible for p53 phosphorylation, the regulatory effects of 
mitogen-activated protein kinases (MAPKs) on p53 phosphorylation have been 
discovered. It is noteworthy that MEKK1/JNK signaling plays an important role in 
p53 stability and transcriptional activities (Fuchs et al., 1998). Activation of JNK has 
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been specifically linked with p53 Thr81 phosphorylation in response to DNA damage 
and stress-inducing agents, and Thr81 phosphorylation confers p53 transcriptional 
activities and the ability to elicit apoptosis (Buschmann et al., 2001; Wu, 2004). 
Andro is likely to stabilize p53 via JNK-mediated protein phosphorylation, owing 
to the following observations: first, Andro increases the p53 phosphorylation at Thr81 
(a specific phosphorylation site of JNK) (Wu, 2004), but not at other phosphorylated 
sites (Fig. 3.12C); second, Andro promotes JNK phosphorylation in a temporal pattern 
consistent with that of p53 phosphorylation and stabilization, and Andro-induced JNK 
activation and p53 accumulation could be suppressed by SP600125, a specific JNK 
inhibitor (Fig. 3.14). It is reported that JNK could be activated by a variety of stress 
factors, and activated JNK subsequently phosphorylates p53 (Fuchs et al., 1998), As I 
known, JNK is readily activated by ROS (Shen and Liu, 2006) and a couple of studies 
showed that Andro triggers cellular accumulation of ROS as well as JNK activation 
(Ji et al., 2007; Li et al., 2007b). The DCF assay revealed that the intracellular ROS 
level increased significantly following the treatment with Andro (Fig. 3.13A), a 
process that could be completely blocked by an antioxidant N-acetyl cysteine (NAC) 
(Fig. 3.13B), indicating the initiating effect of Andro-induced ROS accumulation in 
Andro-mediated p53 stabilization and apoptotic cell death. 
Although p53 is believed to exert its pro-apoptotic effect though both 
transcriptional-dependent and transcriptional-independent manners (Haupt et al., 1995; 
Kokontis et al., 2001), it is widely accepted that p53 regulates apoptosis mainly via 
transcriptional activation of a broad spectrum of pro-apoptotic proteins, including Bax 
(Miyashita and Reed, 1995), Noxa (Oda et al., 2000), PUMA (Nakano and Vousden, 
2001), DR4 (Liu et al., 2004) and DR5 (Sheikh et al., 1998; Wu et al., 1997). In this 
part of study, data demonstrated that p53 plays a critical role in Andro-sensitized 
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apoptosis through up-regulation of DR4. 
TRAIL elicits its function through recognizing and binding to its receptors (DR4 
and DR5) on the cell surface. This ligand binding initiates receptor conformational 
changes and recruitment of FADD. Subsequently, FADD further recruits caspase-8/10 
and leads to the formation of a death-inducing signaling complex (DISC), which 
consequently results in the auto-activation of caspase-8/10 or cleavage of Bid, which 
then cross-talks with mitochondria to trigger the caspase-9 and caspase-3 and 
eventually leads to apoptosis (Ashkenazi, 2002; Wang and El-Deiry, 2003). Strategies 
that target death receptors up-regulation in combination with TRAIL-based therapy 
have been tested in several models successfully (Jin et al., 2007; Singh et al., 2005). 
Therefore, it is proposed that the expression level of DR4 and DR5 plays a critical 
role in determining the cell fate in response to TRAIL (LeBlanc and Ashkenazi, 2003; 
Takeda et al., 2007; Wang and El-Deiry, 2003). In this study, I not only observed the 
increases of total protein level of DR4 (Fig. 3.7A), but also the cell surface expression 
level of DR4 was markedly elevated in Andro-treated cells (Fig. 3.7B), suggesting the 
increase of functional DR4 in the presence of Andro.  
The expression level of DR4 could be regulated at both transcriptional and post-
transcriptional levels. I found significant increase of DR4 mRNA level in Andro-
treated cells, preceding the increase of DR4 protein level (Fig. 3.9A), suggesting 
Andro enhances DR4 expression at transcriptional level. In this part of study, data 
demonstrated that p53 plays a critical role in Andro-sensitized apoptosis through up-
regulation of DR4, because Andro-induced apoptotic cell death and DR4 up-
regulation were only observed in p53 wild-type cancer cells, but not in p53 deficient 
cells (Fig. 3.11C). Furthermore, RNA interference of p53 could effectively inhibit 
Andro-induced DR4 up-regulation (Fig. 3.10A) and abolish the apoptotic cell death 
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induced by the combined treatment of Andro and TRAIL (Fig. 3.10B). It is thus 
believed that Andro is capable of enhancing DR4 transcription via promoting p53 
accumulation.  
It is noted that another death receptor of TRAIL, DR5 is also known as one of the 
target genes of p53 transcriptional regulation. However, in Andro-treated cells, DR5 
was not affected in the presence of activated p53. The involvement of p53 in control 
of DR4 and DR5 transcription remains contradictory. There is convincing evidence 
showing that DNA damage-induced p53 activation also leads to DR4 up-regulation 
(Guan et al., 2001; Liu et al., 2004; Tomasetti et al., 2006). On the other hand, 
original works mainly by El-Deiry’s group identified DR5 as the main target of p53 as 
the molecular link between the apoptotic pathways mediated by DNA damage and cell 
death receptors (Takimoto and El-Deiry, 2000; Wu et al., 1997; Wu et al., 2000). It is 
likely that p53 is important for both DR4 and DR5 regulation depending on the 
context including the nature of stimuli and the cell type. In a given stimuli only 
certain genes will be chosen from the broad spectrum of p53-responsive targets to 
mediate a specific event. In line with some previous studies (Galligan et al., 2005), I 
found that in HepG2 cells DR5 is expressed in a much higher basal level thereby it is 
more insensitive to regulatory mechanisms. In contrast, the basal level of DR4 is very 
low in HepG2 cells, which may be one explanation why DR4 is more susceptible to 
be up-regulated by p53. In addition, the administration of blocking antibody of DR4, 
but not DR5, effectively protected the cell death induced by combination of Andro 
and TRAIL (Fig. 3.8). Such a difference may well explain the fact that DR4 could be 
major determinant that is responsible for the sensitization effect of Andro to TRAIL-
induced apoptosis. It remains to be further tested whether p53-mediated DR4 up-
regulation is also applicable to other TRAIL-resistant cancer cells. 
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Taken together, data from this part of study demonstrated a novel anticancer effect 
of Andro: sensitization of human cancer cells to TRAIL-induced apoptosis via p53-
mediated DR4 up-regulation, supporting the further development of Andro as a 
chemo-sensitizer in combined therapy with TRAIL to overcome TRAIL resistance in 
p53 wild type cancers. 
5.3 Andro inhibits STAT3 activation and sensitizes doxorubicin-induced cell 
death in human cancer cells  
 Doxorubicin is considered to be one of the most effective agents in the treatment 
of bladder, breast, lung, ovarian, cervical and other cancers (Hortobagyi, 1997).  
However, the application of doxorubicin in cancer therapy has been limited by its 
cytotoxicity to normal cells and the development of cellular resistance in tumor cells 
(Bunz et al., 1999; Muller et al., 1998). Similar to TRAIL application, it will be more 
attractive to use a lower dosage of doxorubicin in combination with other drugs, 
which may overcome the cellular resistance to doxorubicin by reducing or altering 
pathways associated with cell survival. On the other hand, STAT3 signaling pathway 
has been shown to confer resistance to chemotherapy-induced apoptosis in human 
tumors, and convincing data demonstrated that inhibition of STAT3 could sensitize 
tumor cells to doxorubicin-induced cell death (Alas and Bonavida, 2003; 
Bourguignon et al., 2008; Gariboldi et al., 2007; Rebbaa et al., 2001; Vigneron et al., 
2005). In this part of study, I focused on the inhibitory effect of Andro on STAT3 and 
its synergistic function in doxorubicin-induced cell death.  
One significant finding in this part of study is that Andro could inhibit both 
endogenous STAT3 and IL-6-induced STAT3 activation in tumor cells via the 
upstream tyrosine kinase, JAK1 and JAK2. STAT3 signaling pathway has recently 
been considered as a valid molecular target for therapeutic intervention, due to its 
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aberrant activation in various tumor cells and its intimate involvement in the tumor 
survival and malignant transformation through transcriptional regulation on a range of 
target genes in cancer cells (Darnell, 1997; Levy and Darnell, 2002; Schindler and 
Darnell, 1995). Many studies have shown that tumor cells harboring with 
constitutively active STAT3 are more sensitive to STAT3 inhibitors than normal cells 
(Yu and Jove, 2004). This is likely due to an increased dependence of this kind of 
tumor cells on persistent STAT3 activity. A variety of STAT3 inhibitors have been 
identified. Plant extracts, such as curcumin, resveratrol and capsaicin also have been 
shown to inhibit STAT3 function, and thereby impede tumor growth (Bhutani et al., 
2007; Pathak et al., 2007; Rajasingh et al., 2006). Due to the strikingly inhibitory 
effect of Andro on STAT3 activity, Andro could be developed as one promising 
anticancer agent especially for tumor cells with constitutively activated STAT3. 
Another significant finding in this part of work is that constitutively activated 
STAT3 contributes to the survival advantage of cancer cells to doxorubicin. 
Numerous studies have indicated the constitutive activation of the STAT3 pathway in 
a variety of human cancers, including breast carcinoma, colon cancer, cervical cancer, 
prostate cancer, melanoma, multiple myeloma, and leukemia (Hirano et al., 2000; Yu 
et al., 2007b). In Chapter 4, four kinds of cancer cells were selected to detect the basal 
level of STAT3 activation and their response to doxorubicin treatment. These cell 
lines were found to response differently to doxorubicin-induced cell death (Fig. 4.5). 
Interestingly, this tendency is correlated to the activation level of STAT3 in these cell 
lines. HeLa cells, which harbor a higher basal level of STAT3, showed higher 
resistance to doxorubicin-induced cell death. However, when I introduced the 
dominant negative form of STAT3 vector into HeLa cells, the STAT3 
phosphorylation was blocked and resulted in enhanced sensitivity of this cell line to 
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doxorubicin (Fig. 4.6), confirming that activated STAT3 contribute to the survival 
advantage of cancer cells to doxorubicin. In this regard, constitutively activated 
STAT3 represents the major determinant of doxorubicin sensitivity in certain cancer 
cells. 
Because of the inhibitory effect of Andro on STAT3 activity and the causal 
correlation between STAT3 constitutive activation and doxorubicin sensitivity, these 
results implied that suppression of STAT3 activation by Andro, as described above, 
could provide synergistic effect to doxorubicin-induced cytotoxicity in cancer cells. 
As expected, combination of Andro and doxorubicin apparently induced cell death 
and suppressed the cell proliferation in a number of cancer cell lines (Fig. 4.7). The 
molecular mechanisms underlying STAT3’s involvement in cell survival and anti-
apoptosis are demonstrated by regulation of its target genes which include anti-
apoptotic proteins (Bcl-xL, Mcl-1) (Catlett-Falcone et al., 1999; Epling-Burnette et al., 
2001) and proliferation regulatory proteins (cyclinD1, Myc and survivin) (Bowman et 
al., 2001; Niu et al., 2002; Sinibaldi et al., 2000). Furthermore, suppression of the 
expression of Bcl-xL and Mcl-1 proved to be useful in cancer therapy by inducing cell 
apoptosis (Catlett-Falcone et al., 1999; Epling-Burnette et al., 2001).  The inhibitory 
effect of Andro on STAT3 activation correlated with a concurrent inhibition of Bcl-xL 
and Mcl-1 expression and increased apoptosis (Fig. 4.9), suggesting that inhibition of 
STAT pathway by Andro down-regulates the expression of anti-apoptotic genes that 
influence cellular response to chemotherapeutic drugs. Notably, suppression of 
STAT3 activation and its downstream proteins appear to be essential for rendering 
tumor cells susceptible to doxorubicin, because over-expression of STAT3 inhibited 
the synergistic effects of Andro and doxorubicin in inducing cell death (Fig. 4.10). 
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These findings thus collectively indicate that abrogation of constitutive activation 
of STAT3 by Andro greatly enhanced the anti-tumor activity of doxorubicin against 
cancer cells. This part of study further confirmed that Andro is valuable as a chemo-
sensitizer to improve the efficacy of doxorubicin in the treatment of human cancers.   
5.4 The interlinks among molecular mechanisms involved in Andro  anticancer 
property 
In the summary of the molecular pathways through which Andro induces 
apoptosis and sensitizes TRAIL and doxorubicin-induced apoptosis in cancer cells, 
Andro is capable of utilizing distinct mechanisms dependent on the nature of the cell 
death stimuli. In first part of this study, I focused on the ability of Andro on Bid 
cleavage, Bax mitochondrial translocation and release of cytochrome c which finally 
lead to apoptosis; in the presence of TRAIL, Andro enhances DR4 expression level 
through the JNK-dependent p53 transcriptional activation; in doxorubicin-treated cells, 
Andro inhibits STAT3 activation and thereby overcome the chemo-resistance of tumor 
cells in response to doxorubicin.  
Although distinct mechanisms are involved in different parts of this study, it is 
worth mentioning that some of the above mechanisms may act synergistically in 
response to Andro treatment. For instance, Andro could promote p53 accumulation 
via JNK-mediated p53 phosphorylation, as discussed in Chapter 3. As I know, p53 is 
not only an important transcriptional regulator for apoptosis (Miyashita and Reed, 
1995), in the presence of cellular stimuli, p53 could rapidly translocate to the 
mitochondria, where p53 interacts with the anti-apoptotic Bcl-2 proteins Bcl-xL and 
Bcl-2 and thereby antagonizes their anti-apoptotic ability; or cytosolic p53 can 
directly promotes Bax mitochondrial translocation (Chipuk et al., 2004; Marchenko et 
al., 2000; Mihara et al., 2003). It is thus possible that treatment with Andro may then 
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offer multiple regulations on pro-apoptotic Bcl-2 proteins: Bax mitochondrial 
translocation via Bid cleavage; or elevation of Bax level through p53 transcriptional 
activity; or Bax mitochondrial translocation promoted by cytosolic p53 in the 
presence of cellular stimuli. On the other hand, anti-apoptotic Bcl-2 proteins, Bcl-xL 
and Mcl-1 were documented to be transcriptional target genes of STAT3 activation 
(Bowman et al., 2000; Bromberg et al., 1999; Hirano et al., 2000). Bax-mediated 
apoptotic process can be prevented by the Bcl-2 or Bcl-xL via forming inhibitory 
heterodimers with Bax or Bak then preventing cytochrome c release. In Chapter 4, 
Andro was demonstrated to possess potent inhibitory effect on STAT3 activation, 
accompanied by decreased level of Bcl-xL and Mcl-1, suggesting that Andro-
mediated down-regulation of Bcl-xL and Mcl-1 via STAT3 inhibition may further 
promote the Bax-dependent apoptotic signaling. 
The functional interlinks demonstrate the importance of understanding the 
complexity and cellular context of signal transduction pathways. This understanding 
has important implications for the design and development of anticancer agents that 
regulate molecular targets in cancer cells.  
5.5 Conclusions  
The anticancer property of Andro, a major component extracted from 
Andrographis paniculata, has been systematically investigated in this study. The 
whole study can be divided into three parts, which have been summarized in Fig. 5.1: 
①  Andro exerts its anti-tumor effect by inducing caspase-dependent apoptosis 
through Bid-mediated mitochondrial pathway; ② Andro sensitizes TRAIL-induced 
apoptosis in cancer cells by p53-dependent DR4 up-regulation via ROS accumulation; 
③ Andro enhances the anticancer activity of doxorubicin by down-regulating anti-
apoptotic proteins via suppression of STAT3 activation (Fig. 5.1).  
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In summary, data from this study demonstrate that Andro could be a potent 
anticancer agent through inducing apoptosis in various cancer cells. More importantly, 
this study provides evidence showing that Andro is highly capable of sensitizing 
TRAIL and doxorubicin-induced cancer cell apoptosis. Such findings support the 
potential application of Andro as a potent apoptosis inducer and chemo-sensitizer in 
cancer therapy.  
However, tumor formation is a highly complicated series of intertwined events, 
and apoptosis induction also could be limited by the cellular response and in vivo 
environment. Therefore, in vivo studies, including the use of animal models, will be 
necessary to verify the effects of Andro as a therapeutic agent for the prevention and 
treatment of tumor growth. Such studies will eventually contribute to a more complete 





Fig. 5.1 Mechanisms involved in Andro-induced apoptosis 
 
Andro is capable of either directly inducing apoptosis or sensitizing cancer cells to 
apoptosis via the following pathways: ① Andro enhances caspase 8 activation and 
Bid-mediated Bax mitochondrial translocation, then directly induces apoptosis 
through mitochondrial apoptosis pathway; ② Andro activates p53 function via ROS-
dependent JNK activation, leading to DR4 up-regulation and sensitization to TRAIL-
induced apoptosis; ③ Andro suppresses JAK-STAT3 pathway and its target proteins 
expression, and thereby overcomes the resistance of cancer cells to chemotherapeutic 
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